10-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K/A

(Amendment No.1)

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended March 31, 2021

OR

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from April 1, 2020 to March 31, 2021

Commission File Number: 000-53723

TAURIGA SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Florida	30-0791746
(State or other jurisdiction of	(IRS Employee
incorporation or organization)	Identification No.)

4 Nancy Court Suite #4
Wappingers Falls, NY	12590
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (917) 796-9926

Securities registered under Section 12(b) of the Exchange Act:

None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, $0.00001 Par Value

(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. [  ] Yes [X] No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. [  ] Yes [X] No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] Yes [  ] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [  ] Yes [X] No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [X]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or, an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company”, in Rule 12b-2 of the Exchange Act.

Large accelerated filer [  ]	Accelerated filer [  ]
Non-accelerated filer [  ]	Smaller reporting company [X]
(Do not check if smaller reporting company)	Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [  ] Yes [X] No

On September 30, 2020, the last business day of the registrant’s most recently completed second quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was $5,660,617 based upon the closing price on that date of the Common Stock of the registrant on the OTC Bulletin Board system of $0.0324. For purposes of this response, the registrant has assumed that its directors, executive officers and beneficial owners of 5% or more of its Common Stock are deemed affiliates of the registrant.

As of as of August 13, 2021, the registrant had 287,871,214 shares of its Common Stock, $0.00001 par value (the “Common Stock”), outstanding.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	TAUG	OTCQB

EXPLANATORY NOTE

This Amendment No. 1 on Form 10-K/A (this “Amendment”) of Tauriga Sciences, Inc. (the “Company”) amends the Company’s Annual Report on Form 10-K for the year ended March 31, 2021 (the “Original Report”), originally filed with the Securities and Exchange Commission on June 29, 2021 (the “Original Filing Date”). This Amendment is being filed solely for the purpose of indicating on Scrivener’s Error in the published financial statements. In this amendment the Company is represent the Consolidated Balance Sheet and the Consolidated Statement of Cash Flows for the year ended March 31, 2021 and 2020. The Consolidated Statement of Operations and the Consolidated Statement of Stockholders’ Equity (Deficit) remain unchanged from the Original Report.

The numbers affected in this amendment relate to Inventory, Prepaid Inventory and Prepaid Expenses. The amount on the Original Report correctly listed Current Assets as $2,396,567. This total for Current assets is correct and remains unchanged. The amount listed for Inventory was transcribed incorrectly from our records and was not noticed prior to the publication of this report. The sum of the Current assets was different than the total presented. The total of inventory on hand of $201,372 instead of the previously reported $647,013. This change reflected in the below presented financial statements had no effect on the Cash Used in Operating Activities, Current Assets or Total Assets.

As a result of the Scrivener’s Error, there were also changes necessary in the presentation of the Consolidated Cash Flow Statement. The Original Report indicated an increase in Prepaid Assets in the amount of $1,348 which was represented as a decrease of $20,544. The Original Report indicated an increase in Inventory (including deposits on inventory not received) of $518,302 which was represented as an increase of $495,861. Additionally, the Original Report indicated an increase in Accounts Payable of $296,892 which was represented to an increase of $314,892. As a result of these figures not summing correctly, the Cash used in Operating Activities was not impacted.

The last effect of the Scrivener’s Error was the duplication of the repayment of a loan from an officer. The Original Report indicated Cash Used by Investing Activities in the amount of $50,159. This amount was already as Cash Used in Financing Activities. This report represents Cash Used in Financing Activities as $369,854 compared to the Original Report stating $420,013.

Other than as expressly set forth above, no other changes have been made to the Original Report. This Amendment speaks as of the Original Filing Date of the Original Report, does not reflect events that may have occurred subsequent to the Original Filing Date, and does not modify or update in any way disclosures made in the Original Report. Accordingly, this Amendment should be read in conjunction with the Original Report and the Company’s other filings with the Securities and Exchange Commission.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

Consolidated Balance Sheets	F-1
Consolidated Statements of Cash Flows	F-2

TAURIGA SCIENCES, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

(IN US$)

	March 31, 2021			March 31, 2020
ASSETS
Current assets:
Cash	$	49,826		$	5,348
Accounts receivable, net allowance for doubtful accounts		32,227			42,580
Investment - trading securities		1,246,050			101,200
Investment - other		312,481			178,100
Inventory asset		201,372			128,711
Prepaid inventory		423,200			-
Prepaid expenses and other current assets		131,411			151,955
Total current assets		2,396,567			607,894
Lease right of use asset		64,301			22,090
Assets held for resale		11,084			-
Property and equipment, net		12,063			13,478
Leasehold improvements, net of amortization		4,688			-
Total assets	$	2,488,703		$	643,462
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Notes payable, net of discounts	$	504,819		$	585,134
Accounts payable		390,947			76,055
Accrued interest		14,722			39,384
Accrued expenses		68,442			46,719
Loan Payable to office		-			50,159
Liability for common stock to be issued		174,000			131,000
Lease liability - current portion		14,426			13,891
Deferred revenue		-			384
Total current liabilities		1,167,356			942,726
Lease liability - net of current portion		50,100			8,933
Total liabilities		1,217,456			951,659
Stockholders’ equity (deficit):
Common stock, par value $0.00001; 400,000,000 shares authorized, 275,858,714 and 107,039,107 outstanding at March 31, 2021 and 2020, respectively		2,760			1,070
Additional paid-in capital		63,417,565			58,213,365
Accumulated deficit		(62,149,078	)		(58,522,632	)
Accumulated other comprehensive income		-			-
Total stockholders’ equity (deficit)		1,271,247			(308,197	)
Total liabilities and stockholders’ equity (deficit)	$	2,488,703		$	643,462

The accompanying notes are an integral part of the consolidated financial statements.

F-1

TAURIGA SCIENCES, INC. AND SUBSDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN US$)

	For the Years Ended
	March 31,
	2021			2020
Cash flows from operating activities
Net loss attributable to controlling interest	$	(3,626,446	)	$	(3,033,290	)
Adjustments to reconcile net loss to cash used in operating activities:
Bad debt expense		29,404			64,146
Amortization of original issue discount		100,543			67,044
Non-cash lease operating lease expense		327			331
Depreciation and amortization		1,737			914
Loss on disposal of fixed assets		-			1,230
Non-cash interest		253,869			75,960
Loss (gain) on extinguishment of debt		-			(113,468	)
Gain on lease termination		(836	)		-
Amortization of debt discount		645,832			687,486
Common stock issued and issuable for services (including stock-based compensation)		1,019,814			569,636
Gain on disposal of discontinued operation		244,706			(4,941	)
Legal fees deducted from proceeds of notes payable		17,700			24,900
(Gain) loss on the sale of trading securities		(146,577	)		(10,000	)
Unrealized loss (gain) on trading securities		(1,023,600	)		219,200
(Increase) decrease in assets
Prepaid expenses		20,544			(24,435	)
Inventory (including deposits on inventory not received)		(495,861	)		(117,839	)
Proceeds (purchase) of trading securities, net		-			40,000
Accounts receivable		(19,051	)		(106,726	)
Increase (decrease) in liabilities
Accounts payable		314,892			41,352
Deferred revenue		(384	)		384
Accrued expenses		21,722			46,720
Accrued interest		87,087			60,834
Cash used in operating activities		(2,554,578	)		(1,510,562	)
Cash flows from investing activities
Investment in VTGN warrants		-			(37,500	)
Exercise of unregistered warrants for common stock		(240,000	)		-
Sales proceeds from trading securities		302,827			-
Investment - other		(416,587	)		(68,100	)
Purchase of property and equipment		(16,094	)		(2,612	)
Cash used in investing activities		(369,854	)		(108,212	)
Cash flows from financing activities
Loan from Officer		(50,159	)		50,159
Repayment of principal on notes payable to individuals and companies		(221,457	)		(27,500	)
Proceeds from the sale of common stock (including to be issued)		1,665,211			244,420
Proceeds from notes payable to individuals and companies		482,000			971,100
Proceeds from sale of registered shares - Tangiers Investment Agreement		400,515			-
Proceeds from convertible notes		692,800			-
Cash provided by financing activities		2,968,910			1,238,179
Net decrease in cash		44,478			(380,595	)
Cash, beginning of year		5,348			385,943
Cash, end of year	$	49,826		$	5,348
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest Paid	$	78,542		$	43,819
Taxes Paid	$	-		$	-
NON-CASH ITEMS
Recognition of lease liability and right of use asset at inception	$	67,938		$	12,066
Recognition of lease liability and right of use asset lease modification	$	-			23,177
Conversion of notes payable and accrued interest for common stock	$	1,700,675		$	496,262
Original issue discount on notes payable and debentures	$	68,333		$	10,000
Recognition of debt discount	$	208,806		$	794,272

The accompanying notes are an integral part of the consolidated financial statements.

F-2

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.

The following exhibits are filed herewith as a part of this Amendment.

Exhibit Number	Description
31.1	Certification of Chief Executive Officer of Tauriga Sciences, Inc. Required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Accounting Officer of Tauriga Sciences, Inc. Required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Principal Executive Officer of Tauriga Sciences, Inc. Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 Of 18 U.S.C. 63
32.2	Certification of Principal Accounting Officer of Tauriga Sciences, Inc. Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 Of 18 U.S.C. 63

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

/s/ Seth M. Shaw	August 16, 2021
Seth M. Shaw, Principal Executive Officer	Date
/s/ Kevin P. Lacey	August 16, 2021
Kevin P. Lacey, Principal Accounting Officer	Date

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

/s/ Seth M. Shaw	August 16, 2021
Seth M. Shaw, Director	Date
/s/ Dr. David L. Wolitzky	August 16, 2021
Dr. David L. Wolitzky, Director	Date
/s/ Thomas J. Graham	August 16, 2021
Thomas J. Graham, Director	Date
/s/ Chris Sferruzzo	August 16, 2021
Chris Sferruzzo, Director	Date
/s/ James V. Rosati	August 16, 2021
James V. Rosati, Director	Date

EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

REQUIRED BY RULE 13A-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 AS AMENDED,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Seth M. Shaw, certify that:

1. I have reviewed this annual report on Form 10-K/A of Tauriga Sciences, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 16, 2021	By:	/s/ Seth M. Shaw
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

REQUIRED BY RULE 13A-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 AS AMENDED,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kevin Lacey, certify that:

1. I have reviewed this annual report on Form 10-K/A of Tauriga Sciences, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 16, 2021	By:	/s/ Kevin P. Lacey
		Chief Financial Officer
		(Principal Accounting Officer)

EX-32.1

Exhibit 32.1

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

I, Seth M. Shaw, Chief Executive Officer of Tauriga Sciences, Inc. (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Annual Report on Form 10-K/A of the Company for the year ended March 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 16, 2021	By:	/s/ Seth M. Shaw
		Chief Executive Officer
		(Principal Executive Officer)

EX-32.2

Exhibit 32.2

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

I, Kevin P. Lacey, Chief Financial Officer of Tauriga Sciences, Inc. (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Annual Report on Form 10-K/A of the Company for the year ended March 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 16, 2021	By:	/s/ Kevin P Lacey
		Chief Financial Officer
		(Principal Accounting Officer)

XML

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2021	Aug. 01, 2021	Sep. 30, 2020
Cover [Abstract]
Entity Registrant Name	TAURIGA SCIENCES, INC.
Entity Central Index Key	0001142790
Document Type	10-K/A
Document Period End Date	Mar. 31, 2021
Amendment Flag	true
Amendment Description	This Amendment No. 1 on Form 10-K/A (this "Amendment") of Tauriga Sciences, Inc. (the "Company") amends the Company's Annual Report on Form 10-K for the year ended March 31, 2021 (the "Original Report"), originally filed with the Securities and Exchange Commission on June 29, 2021 (the "Original Filing Date"). This Amendment is being filed solely for the purpose of indicating on Scrivener's Error in the published financial statements. In this amendment the Company is represent the Consolidated Balance Sheet and the Consolidated Statement of Cash Flows for the year ended March 31, 2021 and 2020. The Consolidated Statement of Operations and the Consolidated Statement of Stockholders' Equity (Deficit) remain unchanged from the Original Report. The numbers affected in this amendment relate to Inventory, Prepaid Inventory and Prepaid Expenses. The amount on the Original Report correctly listed Current Assets as $2,396,567. This total for Current assets is correct and remains unchanged. The amount listed for Inventory was transcribed incorrectly from our records and was not noticed prior to the publication of this report. The sum of the Current assets was different than the total presented. The total of inventory on hand of $201,372 instead of the previously reported $647,013. This change reflected in the below presented financial statements had no effect on the Cash Used in Operating Activities, Current Assets or Total Assets. As a result of the Scrivener's Error, there were also changes necessary in the presentation of the Consolidated Cash Flow Statement. The Original Report indicated an increase in Prepaid Assets in the amount of $1,348 which was represented as a decrease of $20,544. The Original Report indicated an increase in Inventory (including deposits on inventory not received) of $518,302 which was represented as an increase of $495,861. Additionally, the Original Report indicated an increase in Accounts Payable of $296,892 which was represented to an increase of $314,892. As a result of these figures not summing correctly, the Cash used in Operating Activities was not impacted. The last effect of the Scrivener's Error was the duplication of the repayment of a loan from an officer. The Original Report indicated Cash Used by Investing Activities in the amount of $50,159. This amount was already as Cash Used in Financing Activities. This report represents Cash Used in Financing Activities as $369,854 compared to the Original Report stating $420,013. Other than as expressly set forth above, no other changes have been made to the Original Report. This Amendment speaks as of the Original Filing Date of the Original Report, does not reflect events that may have occurred subsequent to the Original Filing Date, and does not modify or update in any way disclosures made in the Original Report. Accordingly, this Amendment should be read in conjunction with the Original Report and the Company's other filings with the Securities and Exchange Commission.
Current Fiscal Year End Date	--03-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Reporting Status Current	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 5,660,617
Entity Common Stock, Shares Outstanding		287,871,214
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021

XML

Consolidated Balance Sheets - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Current assets:
Cash	$ 49,826	$ 5,348
Accounts receivable, net allowance for doubtful accounts	32,227	42,580
Investment - trading securities	1,246,050	101,200
Investment - other	312,481	178,100
Inventory asset	201,372	128,711
Prepaid inventory	423,200
Prepaid expenses and other current assets	131,411	151,955
Total current assets	2,396,567	607,894
Lease right of use asset	64,301	22,090
Assets held for resale	11,084
Property and equipment, net	12,063	13,478
Leasehold improvements, net of amortization	4,688
Total assets	2,488,703	643,462
Current liabilities:
Notes payable, net of discounts	504,819	585,134
Accounts payable	390,947	76,055
Accrued interest	14,722	39,384
Accrued expenses	68,442	46,719
Loan Payable to office		50,159
Liability for common stock to be issued	174,000	131,000
Lease liability - current portion	14,426	13,891
Deferred revenue		384
Total current liabilities	1,167,356	942,726
Lease liability - net of current portion	50,100	8,933
Total liabilities	1,217,456	951,659
Stockholders' equity (deficit):
Common stock, par value $0.00001; 400,000,000 shares authorized, 275,858,714 and 107,039,107 outstanding at March 31, 2021 and 2020, respectively	2,760	1,070
Additional paid-in capital	63,417,565	58,213,365
Accumulated deficit	(62,149,078)	(58,522,632)
Accumulated other comprehensive income
Total stockholders' equity (deficit)	1,271,247	(308,197)
Total liabilities and stockholders' equity (deficit)	$ 2,488,703	$ 643,462

XML

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 28, 2021	Mar. 31, 2021	Mar. 31, 2020
Statement of Financial Position [Abstract]
Common stock, par value		$ 0.00001	$ 0.00001
Common stock, shares authorized		400,000,000	400,000,000
Common stock, shares outstanding	283,496,214	275,858,714	107,039,107

XML

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Gross revenue	$ 354,667	$ 239,388
Sales Discounts	(63,973)	(4,999)
Sales returns	(5,375)
Net Revenue	285,319	234,389
Cost of goods sold	162,627	180,154
Gross profit	122,692	54,235
Operating expenses
Marketing and advertising	273,305	188,129
Research and development	273,385	6,923
Fulfilment services	106,519	42,050
General and administrative	2,857,220	1,855,229
Depreciation and amortization expense	1,737	914
Total operating expenses	3,512,166	2,093,245
Loss from operations	(3,389,474)	(2,039,010)
Other income (expense)
Interest expense	(1,093,071)	(902,228)
Unrealized gain (loss) on trading securities	1,023,600	(219,200)
Gain (Loss) on conversion of debt	(70,208)	113,466
Loss on asset disposal		(1,230)
Gain on lease termination	836
Gain on sale of trading securities	146,577	10,000
Loss on impairment of investment	(244,706)
Gain on disposal of discontinued operations		4,941
Foreign exchange		(29)
Total other income (expense)	(236,972)	(994,280)
LOSS FROM CONTINUING OPERATIONS BEFORE PROVISION FOR INCOME TAXES	(3,626,446)	(3,033,290)
PROVISION FOR INCOME TAXES
Net loss	(3,626,446)	(3,033,290)
Net loss attributable to common shareholders	$ (3,626,446)	$ (3,033,290)
Loss per share - basic and diluted - Continuing operations	$ (0.019)	$ (0.037)
Loss per share - basic and diluted - Discontinuing operations
Weighted average number of shares outstanding - basic and full diluted	193,622,141	80,949,849

XML

Consolidated Statement of Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Subscription Receivable [Member]	Non-Controlling Interest [Member]	Total
Balance at Mar. 31, 2019	$ 681	$ 55,991,704	$ (55,488,939)				$ 503,446
Balance, shares at Mar. 31, 2019	68,123,326
Issuance of shares via private placement	$ 54	143,366					143,420
Issuance of shares via private placement, shares	5,470,286
Issuance of commitment shares - debt financing	$ 25	218,435					218,460
Issuance of commitment shares - debt financing, shares	2,350,000
Shares issued for note conversion	$ 212	496,050					496,262
Shares issued for note conversion, shares	21,295,495
Stock-based compensation vesting		569,636					569,636
Stock-based compensation vesting, shares
Stock issued for services	$ 73	(73)
Stock issued for services, shares	7,350,000
Issuance of shares for distribution agreements	$ 25	(25)
Issuance of shares for distribution agreements, shares	2,450,000
Recognition of beneficial conversion feature of convertible notes			794,272				794,272
Cumulative effect of adoption of Lease standard ASC 842				(403)			(403)
Net loss				(3,033,290)			(3,033,290)
Balance at Mar. 31, 2020	$ 1,070	58,213,365	(58,522,632)				(308,197)
Balance, shares at Mar. 31, 2020	107,039,107
Issuance of shares via private placement	$ 401	1,586,811					1,587,212
Issuance of shares via private placement, shares	40,084,998
Issuance of commitment shares - debt financing	$ 58	253,810					253,868
Issuance of commitment shares - debt financing, shares	5,740,000
Shares issued for note conversion	$ 932	1,699,744					1,700,676
Shares issued for note conversion, shares	93,197,109
Stock-based compensation vesting		1,019,814					1,019,814
Stock-based compensation vesting, shares
Stock issued for services	$ 152	(152)
Stock issued for services, shares	15,187,500
Recognition of beneficial conversion feature of convertible notes		208,806					208,806
Cumulative effect of adoption of Lease standard ASC 842
Issuance of shares to CEO for cash	$ 7	34,993					35,000
Issuance of shares to CEO for cash, shares	700,000
Issuance of unrestricted shares - Tangiers Investment agreement at $0.02614 to $0.02754	$ 140	400,374					400,514
Issuance of unrestricted shares - Tangiers Investment agreement at $0.02614 to $0.02754, shares	13,910,000
Net loss			(3,626,446)				(3,626,446)
Balance at Mar. 31, 2021	$ 2,760	$ 63,417,565	$ (62,149,078)				$ 1,271,247
Balance, shares at Mar. 31, 2021	275,858,714

XML

Consolidated Statement of Stockholders' Equity (Deficit) (Parenthetical) - $ / shares	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Minimum [Member]
Equity issuance price to private placement	$ 0.024	$ 0.02
Equity issuance of commitment shares for debt financing	0.028	0.039
Equity issuance price of note conversion	0.01242	0.01412
Equity issuance price to services	0.0306	0.0174
Equity issuance for distribution agreements	0.02614	0.08
Maximum [Member]
Equity issuance price to private placement	0.09	0.07
Equity issuance of commitment shares for debt financing	0.092	0.19
Equity issuance price of note conversion	0.03	0.04725
Equity issuance price to services	0.05	0.2092
Equity issuance for distribution agreements	$ 0.03344	$ 0.2092

XML

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities
Net loss attributable to controlling interest	$ (3,626,446)	$ (3,033,290)
Adjustments to reconcile net loss to cash used in operating activities:
Bad debt expense	29,404	64,146
Amortization of original issue discount	100,543	67,044
Non-cash lease operating lease expense	327	331
Depreciation and amortization	1,737	914
Loss on disposal of fixed assets		1,230
Non-cash interest	253,869	75,960
Loss (gain) on extinguishment of debt		(113,468)
Gain on lease termination	(836)
Amortization of debt discount	645,832	687,486
Common stock issued and issuable for services (including stock-based compensation)	1,019,814	569,636
Gain on disposal of discontinued operation	244,706	(4,941)
Legal fees deducted from proceeds of notes payable	17,700	24,900
(Gain) loss on the sale of trading securities	(146,577)	(10,000)
Unrealized loss (gain) on trading securities	(1,023,600)	219,200
(Increase) decrease in assets
Prepaid expenses	20,544	(24,435)
Inventory (including deposits on inventory not received)	(495,861)	(117,839)
Proceeds (purchase) of trading securities, net		40,000
Accounts receivable	(19,051)	(106,726)
Increase (decrease) in liabilities
Accounts payable	314,892	41,352
Deferred revenue	(384)	384
Accrued expenses	21,722	46,720
Accrued interest	87,087	60,834
Cash used in operating activities	(2,554,578)	(1,510,562)
Cash flows from investing activities
Investment in VTGN warrants		(37,500)
Exercise of unregistered warrants for common stock	(240,000)
Sales proceeds from trading securities	302,827
Investment - other	(416,587)	(68,100)
Purchase of property and equipment	(16,094)	(2,612)
Cash used in investing activities	(369,854)	(108,212)
Cash flows from financing activities
Loan from Officer	(50,159)	50,159
Repayment of principal on notes payable to individuals and companies	(221,457)	(27,500)
Proceeds from the sale of common stock (including to be issued)	1,665,211	244,420
Proceeds from notes payable to individuals and companies	482,000	971,100
Proceeds from sale of registered shares - Tangiers Investment Agreement	400,515
Proceeds from convertible notes	692,800
Cash provided by financing activities	2,968,910	1,238,179
Net decrease in cash	44,478	(380,595)
Cash, beginning of year	5,348	385,943
Cash, end of year	49,826	5,348
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest Paid	78,542	43,819
Taxes Paid
NON-CASH ITEMS
Recognition of lease liability and right of use asset at inception	67,938	12,066
Recognition of lease liability and right of use asset lease modification		23,177
Conversion of notes payable and accrued interest for common stock	1,700,675	496,262
Original issue discount on notes payable and debentures	68,333	10,000
Recognition of debt discount	$ 208,806	$ 794,272

XML

Basis of Operations and Going Concern

12 Months Ended

Mar. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Operations and Going Concern

NOTE 1 – BASIS OF OPERATIONS AND GOING CONCERN AND GOING CONCERN

NATURE OF BUSINESS

These consolidated financial statements reflect all adjustments, including normal recurring adjustments which, in the opinion of management, are necessary to present fairly the operations and cash flows for the periods presented.

Tauriga Sciences, Inc. (the “Company”) is a Florida corporation, with its principal place of business located at 4 Nancy Court, Suite 4, Wappingers Falls, NY 12590. During October 2020, the Company terminated its primary lease in New York City and established its new corporate headquarters in Wappingers Falls New York, effective January 6, 2021. The Company has, over time, moved into a diversified life sciences technology and consumer products company, with its mission to operate a revenue generating business, while continuing to evaluate potential acquisition candidates operating in the life sciences technology and consumer products spaces.

Tauriga Pharma Corp.

On January 4, 2018, the Company announced the formation of a wholly owned subsidiary in Delaware initially named Tauriga IP Acquisition Corp., which changed its name to Tauriga Biz Dev Corp. on March 25, 2018.

Effective January 2020, the Company amended the certificate of incorporation of Tauriga Business Development Corp. in relevant part to effectuate a name change of this subsidiary to Tauriga Pharma Corp. The principal reason for the name change is to concentrate this subsidiary’s focus on the development of a pharmaceutical product line that is synergistic with the Company’s primary CBD product line. Currently, the plan is to initially create a pharmaceutical line of products to address nausea symptoms related to chemotherapy treatment in patients, which we will submit for clinical trials and to regulatory agencies for approval.

On March 18, 2020, the Company filed a Provisional U.S. Patent Application covering its pharmaceutical grade version of Tauri-Gum™. This patent application, filed with the United States Patent & Trademark Office (“U.S.P.T.O.”), is titled: “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT.” The Company’s proposed pharmaceutical grade version of Tauri-Gum™ is being developed for nausea regulation, intended specifically to target patients subjected to ongoing chemotherapy treatment(s) (the “Indication”). The delivery system for this pharmaceutical product is an improved version of the existing “Tauri-Gum™” chewing gum formulation based on continued research and development.

On March 17, 2021, the Company converted its U.S. Provisional Patent Application (filed on March 17, 2020) to a U.S. Non-Provisional Patent Application.  This non-provisional patent application relates to the Company’s proposed pharmaceutical cannabinoid chewing gum delivery system for treatment of nausea derived from active chemotherapy treatment.

Also on March 17, 2021, the Company filed an additional U.S. Provisional Patent Application relating to alternative pharmaceutical cannabinoid delivery systems.

On March 17, 2021, the Company filed an International Patent Application under the Patent Cooperation Treaty (“PCT”), a cooperative agreement entered into by more than 130 countries with the purpose of bringing international conformity to the filing and preliminary evaluation of patent applications. This application relates to the Company’s proposed pharmaceutical cannabinoid chewing gum delivery system being developed to treat nausea derived from active chemotherapy treatment.

The PCT application is published by the International Bureau at the World Intellectual Property Organization (“WIPO”), based in Geneva, Switzerland, in one of the ten “languages of publication”: Arabic, Chinese, English, French, German, Japanese, Korean, Portuguese, Russian, and Spanish.

Currently, the pharmaceutical grade version of Tauri-Gum^TM is in the pre-IND stage of development. The development team is working on several parallel workstreams, including:

● formulation development;

● non-clinical in vivo and in vitro studies to inform the effective clinical dose and safety margin;

● regulatory strategy and regulatory documentation preparation;

● confirmation of the active pharmaceutical ingredient (API); and

● Identifying pharma-grade API suppliers.

Tauriga Sciences Limited

On June 10, 2019, the Company formed a wholly owned subsidiary, Tauriga Sciences Limited, with the Registrar of Companies for Northern Ireland. Tauriga Sciences Limited is a private limited Company. The entity was established in conjunction with e-commerce merchant services. In conjunction to this new entity the Company entered into a two-year lease commencing on June 11, 2019. The office is located at Regus World Trade Centre Muelle de Barcelona, edif. Sur, 2a Planta Barcelona Cataluña 08039 Spain. The Company terminated this lease during October 2020. The Company no longer maintains an office in this region.

Collaboration Agreement with Aegea Biotechnologies Inc.

On April 3, 2020, Tauriga Sciences, Inc. entered into a collaboration agreement (“Collaboration Agreement”) with Aegea Biotechnologies Inc. (“Aegea”), for the purpose of developing a Rapid, Multiplexed Novel Coronavirus (COVID-19) Point of Care Test with Superior Sensitivity and Selectivity (the “SARS-Col 2 Test”). The parties believed that the benefits of the SARS-CoV-2 Test were the following: a Rapid SARS-CoV-2 test with the sensitivity and specificity to eliminate false negatives and false positives, and with the ability to detect and measure viral shed, even in patients who are asymptomatic. This SARS-CoV-2 test would use Aegea’s patented technologies, to take coronavirus testing to the next level by differentiating different strains of SARS-CoV-2. The test, if successful, would be adaptable to additional SARS-CoV-2 strain types as necessary and as the virus mutates. It also has the possibility to be rapidly be customized to provide similarly sensitive and specific assays for other viruses. The Company committed to raise funding for the purposes set forth in under the Collaboration Agreement from its $5,000,000 Equity Line of Credit (“ELOC”) with Tangiers Global, LLC, which became effective on March 16, 2020. Seventy percent (70%) of the net proceeds from the sale of the initial 10,000,000 shares of stock of Tauriga under the ELOC were invested in Aegea for the development of the Covid Test and used to purchase shares of common stock of Aegea, at a purchase price of $4.00 per share. The $4.00 stock price corresponds to a current pre-money valuation of Aegea of $25,000,000 for each tranche of cash, up to the first $2,000,000 of our investment in Aegea. Additionally, as part of our agreement with Aegea, on May 26, 2020, Tauriga issued to Aegea 5,000,000 unregistered common shares of Tauriga common stock. On August 10, 2020, the Company and Aegea amended their Collaboration Agreement. Under the terms of the amendment, having invested 70% of the proceeds from the sale of the initial 10,000,000 shares of Tauriga stock under the ELOC with Tangiers, the Company increased the percentage of proceeds it invested in Aegea on the sale of the remaining shares available under the ELOC agreement from 20% to 40%.

On January 6, 2021, however, the Company determined to terminate its ELOC by terminating each of the Investment Agreement and Registration Rights Agreement, and on January 8, 2021 filed a Post-Effective Amendment to its Form S-1 Registration Statement (333-236923) which removed from registration all shares not previously sold thereunder. This effectively also eliminates our obligation to any additional funding to Aegea under the Collaboration Agreement. As of March 31, 2021, the Company had invested $278,212 in Aegea for 69,553 shares, representing an ownership percentage of 1.03%. As of March 31, 2021, resultant delays of project milestones have led the Company to determined that full recovery of its investment in Aegea is in doubt and has recorded a 50% impairment loss on its consolidated Statement of Operations in the amount of $139,106. Aegea is still moving forward on this project and the Company will continue to monitor the progress.

On February 26, 2021, as part of a settlement agreement concluding the Collaboration Agreement, the Company acquired an additional 69,552 common shares of Aegea, increasing the Company’s total holdings to 139,104 Aegea shares (representing a 2.04% stake in Aegea as of March 31, 2021).

Chief Medical Officer

On July 15, 2020, the Company appointed Dr. Keith Aqua (“Dr. Aqua”) as an independent contractor to the position of Chief Medical Officer (“CMO”) and entered into a consulting agreement with Dr. Aqua which carries a term of 12 months from inception, expiring on July 15, 2021. In his CMO capacity, Dr. Aqua will help the Company progress in the development of the Company’s proposed pharmaceutical grade version of Tauri-Gum™. In addition, Dr. Aqua will help establish a distribution network for the Company to market its Tauri-Gum™ brand to a variety of physicians and medical practices in southern Florida. In consideration of the services being provided by Dr. Aqua, and pursuant to the terms of the Agreement, the Company has agreed to issue Dr. Aqua (i) upon entry into the Agreement 750,000 shares of restricted common stock, (ii) agreed to 750,000 shares of restricted common stock which will be issued in equal monthly instalments of 62,500 shares beginning August 15, 2020 and (iii) agreed to $4,000 cash per quarter during the term of the Agreement, payable following the completion of each such quarter. As of March 31, 2021, the Company issued 1,187,500 restricted shares of its common stock to Dr. Aqua valued at $46,906 ($0.0395 per share). Subsequent to March 31, 2021, Dr. Aqua was issued 187,500 restricted shares of its common stock valued at $7,406 ($0.0395 per share).

Master Services Agreement

On December 16, 2020, we entered into a Master Services Agreement with North Carolina based Clinical Strategies & Tactics, Inc. (“CSTI”) to resume the clinical development of its proposed anti-nausea pharmaceutical grade version of Tauri-Gum™. CSTI will primarily focus its efforts on (i) Pharmaceutical Development Strategy, (ii) Commercialization Strategy, and (iii) Funding Strategy. The Company will with work with CSTI’s founder and chief executive officer, JoAnn C. Giannone, who has over 25 years’ experience effectively leading companies through the drug and medical device development process. On December 23, 2020, the Company funded the costs associated with this Agreement, which total consulting fees were $67,500, exclusive of out-of-pocket reimbursable expenses. The Company has paid additional fees, effected through change orders to the original contract, in the amount of $85,000. These additional fees were for pharmaceutical testing and market research. Under the terms of the Agreement and related statement of work, CTSI will provide a high-level assessment and documentation of the development efforts required to commercialize the proposed pharmaceutical product globally, a commercial assessment, and a review of potential funding strategies and funding sources and potential business partners. The delivery system for this proposed pharmaceutical version is a modified version (with higher concentration of CBD) of the existing Tauri-Gum™” chewing gum formulation based on continued research and development.

COMPANY PRODUCTS

Tauri-Gum^TM

In October 2018, the Company’s management, along with its board of directors, began to explore the possibility of launching a cannabidiol (“CBD”) infused gum product line into the commercial marketplace.

To begin this process, during the quarter ended December 31, 2018, the Company began discussions with a Maryland based chewing gum manufacturer - Per Os Biosciences LLC (“Per Os Bio”), which consummated in a manufacturing agreement in late December 2018 to launch and bring to market a white label line of CBD infused chewing gum under the brand name Tauri-Gum^TM. In October 2019, we also filed trademark applications for the above-referenced marks in each of the European Union and Canada. On February 18, 2020, the Company received a notice of allowance from the European Union Intellectual Property Office granting the Company its trademark registration for Tauri-Gum™ (E.U. Trademark # 018138334).

Under the terms of the agreement, Per Os Bio produces Tauri-Gum^TM based on the following criteria:

A.	By composition, the CBD Gum will contain 10 mg of CBD isolate;
B.	The initial production run will be mint flavor;
C.	This proprietary CBD Gum will be manufactured under U.S. Patent # 9,744,128 (“Method for manufacturing medicated chewing gum without cooling”);
D.	Each Production Batch, including the initial production run, is estimated to yield 70,000 gum tablets or 8,700 Units (each Unit contains 8 gum tablets);
E.	Integrated Quality Control Procedures: Each production batch will be tested by a 3rd Party for CBD label content, THC content (0%), and clear for microbiology;
F.	The packaging, for retail marketplace, will consist of 8 count (gum tablet count) blister card labeled (the “Pack(s)”) with Lot # as well as Expiration Date.;
G.	Outer sleeve in the Company’s artwork and graphic design(s) and label copy; and
H.	Shipping System: Bulk packed 266 Packs per master case (“Palletized”).

Under terms of the agreement with Per Os Bio:

A.	Each product order will consist of 8,700 Packs (unless otherwise agreed upon by both parties);
B.	½ of initial production invoice due within 3 days of execution of Manufacturing Agreement;
C.	We will provide graphic design artwork, logo, and label design to Per Os Bio;
D.	We implement Kosher Certification Process;
E.	We procure appropriate Product & Liability insurance policy (as of this report date the Company has in effect an $8,000,000 product liability policy); and
F.	We acquire legal opinion with respect to the confirmation of the legality to sell this CBD Gum on the Federal Statute Level.

The Company’s gum formulation includes distinctive features: allergen free, gluten free, vegan, kosher (K-Star certification), Halal (Etimad certification), Vegan Formulation and incorporates a proprietary manufacturing process. See our “Risk Factors” contained in our Annual Report dated March 31, 2020 filed with the Securities and Exchange Commission on June 29, 2020, including with respect, but not limited, to Federal laws and regulations that govern CBD and cannabis.

The Company’s E-commerce website is www.taurigum.com.

During the fiscal year 2020, the Company added two additional flavors: Blood Orange and Pomegranate.

On August 31, 2020, the Company announced that it has obtained HALAL Certification (Authority: Etimad) for the entirety of its flagship brand Tauri-Gum™. A HALAL Certification is a guarantee that the products comply with the Islamic dietary requirements or Islamic lifestyle.

During the year ended March 31, 2021, the Company received and commenced sales of Peach-Lemon and Black Currant CBG Gum.

During its 4th Fiscal Quarter of 2021, the Company made a strategic decision to enhance its original Tauri-Gum™ formulation, by increasing the infusion concentrations of both its Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Tauri-Gum™ products to 25mg per piece of chewing gum (previous concentration was 10mg for the Pomegranate, Blood Orange, Mint, and Peach-Lemon flavors and 15mg for the Black Currant flavor).  Additionally, the Company increased its Tauri-Gum™ product offerings to 9 SKUs. The new offerings being introduced are Cherry-Lime Rickey flavored Caffeine infused chewing gum, an 8-piece blister pack of containing 50mg of caffeine per piece and Golden Raspberry flavored Vitamin D3 infused chewing gum, containing 2,000 IU (50 micrograms) of Vitamin D3 per piece.  Through its October 2020 partnership with Think Big LLC (the Company founded by the son of late iconic U.S. rap artist, NOTORIOUS BIG aka “Frank White”), the Company is also offering 2 limited edition Licensed Tauri-Gum™/Frank White products: Honey-Lemon flavored chewing gum (containing: 15mg CBD, 15mg CBG, 5mg Vitamin C, 10mg Zinc per piece) and Mint flavor (25mg CBD per piece).  For a full list of our currently available products please visit our E-Commerce Website at https://taurigum.com/.

Tauri-Gummies™

On November 25, 2019, the Company announced that it has finalized the formulation for its Vegan 25 mg CBD (Isolate) Infused Gummies product to be branded Tauri-Gummies™ for which a trademark was filed in Switzerland and the European Union. The company has received a Notice of Allowance from the European Union Intellectual Property Office (“E.U.I.P.O.”) granting the Company its trademark Registration for: Tauri-Gummies™ (E.U. Trademark # 018138348). The effective registration date, granting this Tauri-Gummies™ trademark to the Company, was June 24, 2020. This product contains no gelatin in the formulation, as the Company has utilized plant-based alternatives in completion of this product. Each bottle contains 4 flavors – cherry, orange, lemon and lime.

Each gummy package contains 24 gummies in a jar, 6 of each flavor, containing 25mg of CBD isolate per individual gummy, or 600 mg of CBD isolate per jar. These Gum Drops have been manufactured in the “Nostalgic” 1950s confectionary style and are both plant-based (Vegan Formulated) and Kosher Certified. The Company commenced sales of Tauri-Gummies™ in January 2020.

In addition, we also received a Notice of Allowance to our Tauri-Gummies^TM registered trademark application from the European Union Intellectual Property Office. The trademark application was registered on June 24, 2020 under Serial No. 018138351, which extends our protective period for this mark until October 2029, and which may be extended thereafter for ten-year intervals.

Cannabigerol “CBG” Isolate Infused Version of Tauri-Gum™

On December 30, 2019, the Company announced it had commenced development of a Cannabigerol (“CBG”) Isolate Infused version of its Tauri-Gum™ brand. This initial production run had been completed in its Peach-Lemon flavor (and each piece of Chewing Gum contains 10mg CBG isolate). This initial production run yielded roughly 8,300 blister packs. The product is Kosher Certified, Vegan Formulated, Lab Tested, NON-GMO, Allergen Free, Gluten Free, containing no THC, and 100% Made in the USA. MSRP has been established at $19.99 per Blister Pack.

The Company has also commenced production of its second version of CBG Infused Tauri-Gum - Black Currant Flavor (each piece of Chewing Gum contains 15mg of CBG isolate). The Company’s Black Currant Flavor - CBG Infused Tauri-Gum™: Kosher Certified, Vegan, Halal, Lab-Tested, NON-GMO, Allergen Free, Gluten Free, 15mg CBG/Piece of Chewing Gum, 100% Made in the USA.

During the year ended March 31, 2021, the Company received and commenced sales of Peach-Lemon and Black Currant CBG Gum.

Immune Booster Version of Tauri-Gum™

On May 29, 2020, the Company announced that it has commenced development of an Immune Booster version of Tauri-Gum™, which commenced sales during the three months ended September 30, 2020. This product contains 60mg of Vitamin C and 10mg of Elemental Zinc (“Zinc”) in each piece of chewing gum. This product does not contain any phytocannabinoids (i.e., CBD or CBG). The Company’s Immune Booster Tauri-Gum™ product, is: Kosher certified, Halal Vegan, Lab-Tested, non-GMO, allergen free, gluten free, infused with 60mg Vitamin C & 10mg Elemental Zinc/per each piece of gum, no phytocannabinoids, and 100% made in the United States of America. This product was developed for general usage and as with respect to the entirety of the Company’s retail Tauri-Gum™ product line, there are no “treatment claims” made.

Rainbow Deluxe Sampler Pack

On June 15, 2020, the Company, introduced its Rainbow Deluxe Sampler Pack (“Rainbow Pack”). The Rainbow Pack is comprised of one blister pack of each Tauri-Gum’s™ flavors (6 blister packs in total) and will be available exclusively on the Company’s E-Commerce website (www.taurigum.com). The Rainbow Pack is comprised of three Tauri-Gum™ flavors of Cannabidiol (“CBD”) infused (Mint, Blood Orange, Pomegranate), two of the Tauri-Gum™ flavors are Cannabigerol (“CBG”) infused (Peach-Lemon, Black Currant), and one Tauri-Gum™ flavor is Vitamin C + Zinc (“Immune Booster”) infused (Pear Bellini). The introductory price of the Rainbow Pack is $99.99 per pack. The Rainbow pack commercially launched in late September 2020.

Other Products

The Company, from time to time, will offer various formats of CBD product through its e-commerce website. As of this report date the Company is currently offering a 70% dark chocolate 20mg CBD non-GMO dietary supplement and 100mg CBD scented bath bombs (Mint, Pomegranate and Blood Orange). The Company’s current offering includes a line of skin care products sold on its ecommerce website under the product line name of Uncle Bud’s. The skin care products include three different 4.2mg CBD facemasks (collagen, detoxifying and tightening masks), 100mg CBD daily moisturizer, 30mg CBD anti-wrinkle dream, hand and foot cream with hemp seed oil, 120mg CBD massage and body oil, 240mg CBD body revive roll-on, 35mg CBD transdermal patch and 120mg CBD body spray. Additionally, on December 1, 2020 the Company announced the commencement of development of a Caffeine infused version of Tauri-Gum™. When production run is complete, this will represent the 7th SKU of the Tauri-Gum™ product line.

Delta 8 Version of Tauri-Gum™

During March 2021, the Company developed a Delta-8-Tetrahydrocannabinol (“Delta-8-THC” or “Delta-8”) infused version of Tauri-Gum™.  Delta-8-THC infused products are legal when the ingredient has been derived from the industrial hemp plant (“Cannabis Sativa”) and does not contain more than 0.3% (1/333^rd by dry weight composition) THC.  The Company is focused on expanding both its product offerings and revenue opportunities, in a manner that is ethical, innovative, and fully compliant with Federal laws & regulations.  Due to strong indications of demand, the Company has completed a double production run of its Evergreen Mint flavor, Delta 8 THC infused (10mg per piece of chewing gum), Version of Tauri-Gum™.

DISTRIBUTION OF THE COMPANY’S PRODUCTS

E&M Distribution Agreement

On April 1, 2019, the Company entered into a distribution agreement with E&M Ice Cream Company (“E&M”) to establish Tauri-Gum^TM in the greater New York City marketplace (the “E&M Distribution Agreement”), with substantial levels of both financial resources and marketing support. The Company had both received payment for and completed an initial delivery of $54,000 of Company product to E&M in March 2019, and re-orders in the first quarter of fiscal 2020. In connection with the E&M Distribution Agreement, the Company issued 1,000,000 restricted shares of the Company’s common stock and tendered a one-time cash payment of $125,000 to E&M for early-stage marketing and distribution support services. This $125,000 cash component was paid in full to E&M on April 1, 2019, and the value of the shares is reflected in stock-based compensation based on the grant date of April 1, 2019. These shares were issued on December 26, 2019.

South Florida Region Distribution Agreement

On April 8, 2019, the Company entered into a non-exclusive distribution agreement with IRM Management Corporation (“IRM”), an established medical practice management firm (the “IRM Distribution Agreement”). The purpose of the IRM Distribution Agreement is to target our Tauri-Gum^TM product to the South Florida based medical market, including chiropractors, orthopedists, as well as prospective retail customers in this geographic area. In connection with this IRM Distribution Agreement, the Company has also agreed to a one-time issuance of 450,000 shares of the Company’s restricted common stock and a cash stipend of $10,000 to IRM. As of the date of this report, $6,000 of the $10,000 cash stipend has been paid. The value of the shares were reflected as stock-based compensation based on the grant date of April 8, 2019.

Northeastern United States Distribution Agreement

On April 30, 2019, the Company, entered into a non-exclusive comprehensive distribution agreement with Sai Krishna LLC (“SKL”), a New Jersey based distributor, with relationships in the Northeast region of the United States and Asia. In connection with the SKL Agreement, the Company had issued 1,000,000 restricted common shares the Company’s stock in accordance with a further division of such shares as previously disclosed by us in previous periodic reports. The SKL distribution agreement expired on April 30, 2020 and was not renewed. Further, in connection with this agreement, on May 11, 2019, we also entered into a consulting agreement with Ms. Neelima Lekkala, who was appointed Vice President of Distribution & Marketing. This consulting agreement had a one-year term and expired on May 11, 2020 and was not renewed by us. As of March 31, 2021, Ms. Lekkala earned commission in the amount of $1,143.

Windmill Health Distribution Agreement

On June 28, 2019, the Company entered into a distribution agreement with Windmill Health Products, LLC (“Windmill Health”), a New Jersey based distributor, with the intention of increasing and accelerating market penetration of the Company’s Tauri-Gum^TM product line. The Company did not contribute any capital or issue any equity to Windmill Health in connection with the Windmill Health distribution agreement.

Mr. Checkout Distribution Agreement

On June 29, 2020, the Company entered into a “Go-To-Market” distribution agreement with Mr. Checkout Distributors (“Mr. Checkout”), a marketing and consulting company located in Oviedo, Florida. The Mr. Checkout agreement enables the Company to launch its flagship brand Tauri-Gum™ through Mr. Checkout’s network of independent direct store distributors that service approximately 150,000 stores and retail locations across the United States. These stores include well-known convenience stores, gas station marts and supermarket chains. Under the terms of this agreement, on July 7, 2020, the Company paid a one-time $5,000 retainer on commission against the first $100,000 in sales. Subsequent commissions shall be paid to Mr. Checkout during the first thirty (30) days of the subsequent quarter once retainer has been met and exceeded. Commission will not be paid until the retainer has been met. As of March 31, 2021, the Company has recognized no sales via this agreement.

Think BIG, LLC License Agreement

On September 24, 2020, we entered into (i) a License Agreement (“License”) with Think BIG, LLC, a Los Angeles based company (“Think BIG”), (ii) a Professional Services Agreement (the “PSA”) with Willie C. Mack, Jr., CEO of Think BIG and (iii) a Professional Services Agreement (“PSA 2”) with Christopher J. Wallace, a co-founder of Think BIG (each of Willie C. Mack, Jr. and Christopher J. Wallace referred to herein as a “Brand Ambassador”), with the collective intent to enhance sales and marketing of the Company’s product lines, including its proprietary Rainbow Deluxe Sampler Pack (“Rainbow Pack”), and any co-branded products created by the parties to the License and each of the PSAs (the “Co-Branded Products”).

The term of this license is for a period of two years from September 24, 2020 (the “Effective Date”), unless earlier terminated by either party pursuant to the terms thereunder. The term of each of the PSA and the PSA 2 shall commence on the Effective Date and end on the earlier of (i) the two-year anniversary thereof; (ii) the termination for any reason of the License; or (iii) the earlier termination of the PSA Agreement pursuant to the terms thereunder.

The licensing arrangement permits for cross licensing, brand building, e-commerce customer acquisition efforts, retail customer acquisition efforts, enhanced social media presence, public relations & visibility strategies, as well as potential outreach to celebrities, and various other types of in-kind services in order to increase both Company revenue and customer acquisition efforts. The License will also allow for future joint development projects that will leverage the iconic “Frank White” brand and likeness/intellectual property (to which Think Big has the intellectual property rights). The Companies further agreed to a 50/50 gross profit split on sales of specially branded product, payable on or before the 15th day of each calendar month for the immediately preceding calendar month. In addition, the Company originally agreed to pay Think BIG, via a quarterly marketing fee for a period of twelve months in the amount $15,000 per quarter (for an aggregate total of $60,000), the first payment of which was paid by the Company within 10 days of the entry into the License. Subsequently, the parties agreed that the remaining payments would no longer be paid to Think BIG in exchange for the Company funding specially branded inventory printing and product as well as other marketing initiatives.

Under each of the PSA and the PSA 2, each Brand Ambassador shall provide promotional and marketing services (“Services”) to the Company during the term of the respective PSAs, subject to the terms and conditions set forth therein, in connection with the Co-Branded Products and any co-developed products; and perform their individual marketing and promotional services set forth under the PSA and the PSA 2, respectively, and each of the exhibits annexed thereto.

As consideration for each Brand Ambassador’s Services set forth under their respective PSAs, the Company agreed to issue each Brand Ambassador 1,500,000 restricted shares of the Company’s common stock, upon execution of the PSA and PSA 2. These shares were issued on December 17,2020. In the event that the applicable PSA has not previously been terminated, following the one-year anniversary of the Effective Date, an additional 1,500,000 restricted shares of Company’s common stock shall be issued to each Brand Ambassador, subject to the satisfaction of the terms of such additional services and/or criteria to be mutually agreed upon by the parties to the PSA and/or the PSA 2, as the case may be. In total, all shares issued and to be issued had a value of $183,600 that will be recognized over the term of the contract.

Stock Up Express Agreement

Effective February 1, 2021, the Company entered into a distribution agreement with Connecticut based Stock Up Express, a division of Bozzuto’s Inc., a distributor that generates more than $3 Billion in annual sales. The agreement shall remain in effect for a period of two (2) years, with automatic renewal for additional successive one (1) year terms. Under terms of this distribution agreement, Stock Up Express will market and resell the Company’s flagship brand, Tauri-Gum™, to its customer base of wholesale and retail customers in the mainland United States. The two companies will jointly market Tauri-Gum™ to Stock Up Express’ customer base. The Agreement allows for modification of product offerings, and the Company expects to offer additional product items over the course of calendar year 2021. Either party may terminate this Agreement for convenience by giving a sixty (60) day written notice to the other party or either party has the right to terminate this agreement if the other party breaches or is in default of any obligation hereunder, including the failure to make any payment when due, which default is incapable of cure or which, being capable of cure, has not been cured within thirty (30) days after receipt of written notice from the non-defaulting party or within such additional cure period as the non-defaulting party may authorize in writing.

These arrangements are more fully described in our periodic and current reports that we have filed with the Securities and Exchange Commission and included in these agreements filed by reference as exhibits thereto.

REGULATORY MATTERS

Food and Drug Administration

On May 31, 2019, the U. S. Food and Drug Administration (“FDA”) held public hearings to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds, including CBD. The hearing came approximately five months after the Agricultural Improvement Act of 2018 (more commonly known as the Farm Bill), went into effect and removed industrial hemp from the Schedule I prohibition under the Controlled Substances Act (CSA) (industrial hemp means cannabis plants and derivatives that contain no more than 0.3 percent tetrahydrocannabinol, or THC, on a dry weight basis).

Though the Farm Bill removed industrial hemp from the Schedule I list, the Farm Bill preserved the regulatory authority of the FDA over cannabis and cannabis-derived compounds used in food and pharmaceutical products under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and section 351 of the Public Health Service Act. The FDA has been clear that it intends to use this authority to regulate cannabis and cannabis-derived products, including CBD, in the same manner as any other food or drug ingredient. In addition to holding the hearing, the agency had requested comments by July 2, 2019 regarding any health and safety risks of CBD use, and how products containing CBD are currently produced and marketed, which comment period was concluded on July 16, 2019. As of the date hereof, the FDA has taken the position that it is unlawful to put into interstate commerce food products containing hemp derived CBD, or to market CBD as, or in, a dietary supplement. Furthermore, since the closure of the FDA hearings on this issue, some state and local agencies have issued a ban on the sale of any food or beverages containing CBD. There have been legislative efforts at the federal level, which seek to provide clear guidance to industry stakeholders regarding how to comply with applicable FDA law with respect to CBD and other hemp derived cannabinoids. However, such legislative efforts have been limited and as of this date, these legislative efforts require extensive further approvals, including approval from both houses of Congress and the President of the United States, before being enacted into law, if at all.

Furthermore, with respect to Company’s developing CBG and additional cannabinoid product lines, the FDA has provided no guidance as to how cannabinoids other than CBD (such as CBG) shall be regulated under the FD&C Act, and it is unclear at this time how such potential regulation could affect the results of the operations or prospects of the Company or this product line.

FDA Clinical Trial Process – United States Drug Development

In the United States, the FDA regulates drugs, medical devices and combinations of drugs and devices, or combination products, under the FDCA and its implementing regulations. Drugs are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA’s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, requests for voluntary product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.

The process required by the FDA before a drug may be marketed in the United States generally involves the following:

● completion of extensive pre-clinical in vitro and animal studies to evaluate safety and pharmacodynamic effects , formulation development, analytical method development, and manufacturing of the active pharmaceutical ingredient (API) and drug product for clinical trials in accordance with applicable regulations, including the FDA’s Current Good Laboratory Practice (cGLP) regulations and Current Good Manufacturing Practice (cGMP) regulations;

● submission to the FDA of an Investigational New Drug (IND) application, which must become effective before human clinical trials may begin;

● performance of adequate and well-controlled human clinical trials in accordance with an applicable IND and other clinical study related regulations, sometimes referred to as Current Good Clinical Practice (cGCPs), to establish the safety and efficacy of the proposed drug for its proposed indication, and API and drug product scale-up for registration batch production and stability;

● submission to the FDA of a New Drug Application (NDA);

● satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with the FDA’s cGMP requirements;

● potential FDA audit of the clinical trial sites that generated the data in support of the NDA; and

● FDA review and approval of the NDA prior to any commercial marketing or sale.

Once a pharmaceutical product candidate is identified for development, it enters the pre-clinical testing stage. Pre-clinical tests include laboratory evaluations of product characterization, drug product formulation development and stability, as well as pharmacology and toxicology animal studies. An IND Sponsor must submit the results of the pre-clinical tests, together with manufacturing information, analytical data and any available clinical data or literature, to the FDA as part of the IND. The sponsor must also include a protocol detailing, among other things, the objectives of the initial clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the initial clinical trial lends itself to an efficacy evaluation. Some pre-clinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions related to a proposed clinical trial and places the trial on a clinical hold within that 30-day period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns or non-compliance, and may be imposed on all drug products within a certain class of drugs. The FDA also can impose partial clinical holds, for example, prohibiting the initiation of clinical trials of a certain duration or for a certain dose.

All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCP regulations. These regulations include the requirement that all research subjects provide informed consent in writing before their participation in any clinical trial. Further, an IRB must review and approve the plan for any clinical trial before it commences at any institution, and the IRB must conduct continuing review and reapprove the study at least annually. An IRB considers, among other things, whether the risks to individuals participating in the clinical trial are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the information regarding the clinical trial and the consent form that must be provided to each clinical trial subject or his or her legal Representative and must monitor the clinical trial until completed.

Each new clinical protocol and any amendments to the protocol must be submitted for FDA review, and to the IRBs for approval. Protocols detail, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety.

Human clinical trials are typically conducted in three sequential phases that may overlap or be combined. The phases are described below. For the TAUG Pharma product, however, the safety profile of the API is known, and a Phase 1 program is not expected. Therefore, it is anticipated that that the first-time-in-human (FTIH) study will be a Phase 2 study.

● Phase 1. The product is initially introduced into a small number of healthy human subjects or patients and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain early evidence on effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product is suspected or known to be unavoidably toxic, the initial human testing may be conducted in patients.

● Phase 2. Involves clinical trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage and schedule.

● Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit relationship of the product and provide an adequate basis for product labeling.

Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 trials. Companies that conduct certain clinical trials also are required to register them and post the results of completed clinical trials on a government-sponsored database, such as ClinicalTrials.gov in the United States, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.

Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events, findings from other studies that suggest a significant risk to humans exposed to the product, findings from animal or in vitro testing that suggest a significant risk to human subjects, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or Investigator Brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the clinical trial Sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the product has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check points based on access to certain data from the study. The clinical trial Sponsor may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate.

The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

NDA and FDA Review Process

The results of product development, pre-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the drug, proposed labeling and other relevant information, are submitted to the FDA as part of an NDA for a new drug, requesting approval to market the product. The submission of an NDA is subject to the payment of a substantial user fee, and the sponsor of an approved NDA is also subject to an annual program user fee; although a waiver of such fee may be obtained under certain limited circumstances. For example, the agency will waive the application fee for the first human drug application that a small business or its affiliate submits for review.

The FDA reviews all NDAs submitted before it accepts them for filing and may request additional information rather than accepting an NDA for filing. The FDA typically makes a decision on accepting an NDA for filing within 60 days of receipt. The decision to accept the NDA for filing means that the FDA has made a threshold determination that the application is sufficiently complete to permit a substantive review. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act (“PDUFA”), the FDA’s goal to complete its substantive review of a standard NDA and respond to the applicant is ten months from the receipt of the NDA. The FDA does not always meet its PDUFA goal dates, and the review process is often significantly extended by FDA requests for additional information or clarification and may go through multiple review cycles.

After the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMPs to assure and preserve the product’s identity, strength, quality and purity. The FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA will likely re-analyze the clinical trial data, which could result in extensive discussions between the FDA and us during the review process. The review and evaluation of an NDA by the FDA is extensive and time consuming and may take longer than originally planned to complete, and we may not receive a timely approval, if at all.

Before approving an NDA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. In addition, before approving an NDA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all the specific deficiencies in the NDA identified by the FDA. The Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive, and the FDA may interpret data differently than the Sponsor interprets the same data.

New York State Department of Health

The New York State Department of Health (NYDPH) has begun implementing regulations concerning the processing and retail sale of hemp derived cannabinoids. Under the regulations, “cannabinoid” is broadly defined as “any phytocannabinoid found in hemp, including but not limited to, Tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabielsoin (CBE), cannabicitran (CBT). Cannabinoids do not include synthetic cannabinoids as that term is defined [under New York law].”

These regulations came into effect on January 1, 2021, and all “cannabinoid hemp processors” and “cannabinoid hemp retailers” operating within the state of New York must be licensed by the NYDPH. The regulations expressly allow for food and beverages to contain “cannabinoids”, so long as such products meet certain requirements. To this end, the Company has submited its license application with the NYDPH in compliance with this legislation. These regulations are evolving and the NYDPH recently issued a set of proposed regulations to address the use of industrial hemp derived Δ8- Tetrahydrocannabinol (Δ8 THC) and Δ10- Tetrahydrocannabinol (Δ10 THC) in cannabinoid hemp products manufactured and sold in New York. These proposed regulations are currently in a public comment period, and it is unclear at this time as to what the final regulations to be implemented will include.

The product requirements under the current regulations, include but are not limited to: the product must not contain more than 0.3% total Δ9- Tetrahydrocannabinol concentration; the product must not contain tobacco or alcohol; the product must not be in the form of an injectable, transdermal patch, inhaler, suppository, flower product including cigarette, cigar or pre-roll, or any other disallowed form as determined by the NYDPH; if the product is sold as a food or beverage product, it must not have more than 25mg of cannabinoids per product; and, if sold as an inhalable cannabinoid hemp product, the product will be subject to a number of additional safety measures.

Furthermore, all cannabinoid products sold at retail are subject to a series of labeling requirements. All such products must be labeled with the amount of cannabinoids in the product and the amount of milligrams per serving. If the product contains THC, the amount of THC in the product needs to be stated on the label in milligrams on a per serving and per package basis. In addition, all products are required to have a scannable bar code or QR code which links to a certificate of analysis and the packaging is prohibited from being attractive to consumers under 18 years of age. Products are also required to list appropriate warnings for consumer awareness. The Company’s entire product line will comply with the above standards.

See our Risk Factors and going concern opinion in this report for more information about these items, as well as certain related disclosures included our Results of Operations under the heading “Going Concern”.

The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding, success in developing and marketing its products and the level of competition and potential regulatory enforcement actions. These risks and others are described in greater detail in the Risk Factors set forth in this periodic report and our annual reports that we have filed and will also file in the future.

OTHER BUSINESS ITEMS

Certified by Wal-Mart, Inc. to become a Domestic Supplier

On December 23, 2019, the Company announced that is has been certified by Wal-Mart, Inc. (“Walmart”) to become a domestic supplier. This certification from Walmart was obtained by the Company on December 19, 2019. On May 26, 2020, we also announced that our Walmart marketplace seller application had been officially approved. In joining Walmart marketplace, the Company has the opportunity to expand the presence of its products and product lines, with access to over a hundred million monthly customers. The Company is also approved to both list products on Walmart.com and sell directly to Walmart buyers. As of March 31, 2021, the Company has not recognized any sales through this channel. The Company was designated, by Walmart, Supplier ID # 36223459 and SAP Supplier # 1600179472.

Approval to Operate Global Seller Account by Alibaba Group

On January 6, 2020, the Company announced that is has been approved by Chinese multinational conglomerate, Alibaba Group (“Alibaba”), to operate a Global Seller Account. In addition, the Company has been designated as a Gold Supplier (Gold Tier Level Supplier). This Alibaba approval opens up the global marketplace to the Company, its products, its product lines, as well as future business opportunities. The Company has a relationship with a fulfillment facility in mainland China and is focusing on meeting buyers and virtual Alibaba Tradeshows. As of March 31, 2021, the Company has not recognized any sales through this channel.

Certified as Affiliate Vendor by The National Association of College Stores

On January 7, 2020, the Company announced that is has been certified by the National Association of College Stores (“NACS”) as an affiliate vendor. As a vendor of NACS, the Company has joined the most comprehensive group of campus retailers working to provide the best services and selections to college students across the United States. On January 12, 2021, the Company announced that its status as an affiliate vendor has been renewed by the NACS. The Company has been designated, by NACS, its Affiliate Vendor ID # 113921.

Investment Agreement and Registration Rights Agreement

On January 21, 2020, the Company entered into a $5,000,000 equity line financing agreement (“Investment Agreement”) with Tangiers Global, LLC (“Tangiers”), as well as a registration right agreement related thereto (“Registration Rights Agreement”). The term of the financing is over a period of 36 months. Pursuant to the Registration Rights Agreement, a maximum of 76,000,000 shares of our Common Stock may be sold to Tangiers from time to time, which were registered on our Form S-1 Registration Statement and declared effective by the Securities and Exchange Commission on March 16, 2020.

Subject to the terms and conditions of the equity line documents, from time to time, the Company was, at its sole discretion, permitted to deliver put notices to Tangiers which states the number of shares that the Company intends to sell to Tangiers on a closing date. The maximum amount of shares of common stock that the Company was entitled to put to Tangiers per any applicable put notice was the amount of shares up to or equal to two hundred percent (200%) of the average of the daily trading volume (U.S. market only) of the common stock for the ten (10) consecutive trading days immediately prior to the applicable put notice date (the “Put Amount”) so long as such amount is at least five thousand dollars ($5,000) and did not exceed three hundred fifty thousand dollars ($350,000), as calculated by multiplying the Put Amount by the average daily VWAP for the ten (10) consecutive trading days immediately prior to the applicable put notice date. The “Purchase Price” of the shares of our Common Stock that we were able to sell to Tangiers was 88% of the lowest VWAP of the common stock during the five (5) consecutive Trading Days including and immediately following the applicable to the put notice.

As of March 31, 2021, we had issued 13,910,000 shares of Common Stock in exchange for an aggregate of $400,514 under this equity line of credit facility. The final put notice was issued October 1, 2020.

On January 6, 2021, the Company determined to terminate its equity line of credit facility by terminating each of the Investment Agreement and Registration Rights Agreement, and on January 8, 2021 filed a Post-Effective Amendment to its Form S-1 Registration Statement (333-236923) removing from registration all shares of common stock not previously sold thereunder.

Whole Foods Market, Inc. Registration

On June 8, 2020, the Company, announced that became a Registered Whole Foods Market, Inc. (“Whole Foods”) Vendor (“Supplier”). The Company’s information has now been updated in the Whole Foods Vendor Reporting Portal. As of March 31, 2021, the Company has not recognized any sales through this channel.

Federal Award Management Registration

On October 6, 2020, the Company announced that it was officially approved to operate as a U.S. Government Vendor. The Company has retained Federal Award Management Registration (“FAMR”) to commence the bidding process on several identified potential U.S. Government Contracts (“Contracts”). These potential Contracts are presented by the Department of Defense (“DOD”). FAMR is an independent consulting firm that specializes in: Registrations, Certifications, and Federal Contracting. The Company’s Commercial & Government Entity (“CAGE”) Code # is: 8QXV4 with an expiration date of October 1, 2021.

KushCo Holdings, Inc.

Effective July 10, 2020, the Company and KushCo Holdings, Inc., a Nevada corporation (“KushCo”), entered into a Product Placement Membership Agreement (the “Placement Agreement”). Under the terms of the Placement Agreement, KushCo will provide placement services of the Company’s Tauri-Gum™ product line(s), and will assist with retail activation, product incubation, branding and marketing solutions, and sales management services. As compensation for providing such services and placement of the Company’s products, when KushCo or one of its affiliates consummates a purchase, distribution or sale of products (either directly or through third parties), KushCo will be paid a fee equal to 10% of the total gross sales for such transaction(s) (the “Placement Fee”). The Placement Fee shall be earned as of the date of the respective transaction and shall be paid in cash by the Company on a monthly basis and no later than the last calendar day of each calendar month. The Placement Agreement has a term of two (2) years, unless earlier terminated upon sixty (60) days’ notice to the Company, as provided under the KushCo Agreement. As of March 31, 2021, the Company has not recognized any sales through this channel.

HISTORICAL BUSINESS ITEMS

Honeywood

Following the termination of a proposed 2014 merger between the Company and California-based Honeywood LLC (“Honeywood”), a developer of a topical medicinal cannabis product, on August 1, 2017, the Company entered into a debt conversion agreement, whereby the Company agreed to convert an $170,000 note receivable due from Honeywood, including accrued interest into a 5% membership interest in Honeywood. At the time of the Honeywood debt conversion agreement, the receivable balance under the Note of $199,119 had been fully written off by the Company in a prior period. As a result of the debt conversion agreement, the Company deemed the investment to have no current value.

Pilus Energy

On January 28, 2014, the Company acquired Pilus Energy, LLC (“Pilus”), an Ohio limited liability company and a developer of alternative cleantech energy platforms using proprietary microbial solutions that create electricity while consuming polluting molecules from wastewater. On December 22, 2016, the Company entered in a membership interest transfer agreement with Open Therapeutics whereby the Company sold 80% of its membership interest in Pilus back to Open Therapeutics for consideration of the termination of 80% of the unexercised portion of the warrants to purchase the Company’s common stock. Open Therapeutics agreed to pay to the Company 20% of the net profit generated Pilus Energy from its previous year’s earnings, if any. On January 12, 2019, the Company and Open Therapeutics agreed to extinguish a contingent liability in exchange for a one-time issuance of 500,000 restricted shares of Company’s common stock. As of March 31, 2021, these warrants have expired.

Blink Charging Company

On March 29, 2018 the Company’s then named subsidiary - Tauriga Biz Dev Corp. - entered into an independent sales representative agreement with Blink Charging Company (NASDAQ: BLNK) (“BLINK”). Under this agreement we became a non-exclusive independent sales representative to solicit orders from potential customers for EV (“Electric Vehicle”) Station’s placement. This sales agreement has a three-tier compensation model based on whether we contract the new customer to purchase equipment outright from BLINK or enter into one of two revenue-sharing agreements. On June 29, 2018, the Company purchased four BLINK Level – 2 - 40” pedestal chargers for permanent placement in a retail location or locations whereby the Company will pay a variable annual fee based on 7% of total revenue per charging unit. The rest of the proceeds will be split 80/20 between the Company and the host location owner or its assignee. As of March 31, 2021, we had not installed any of these machines in any locations, and no revenue has been generated through the Blink contract. April 1, 2021, the Company had decided to abandon this business line, and therefore, we have reclassified these assets as held for sale.

GOING CONCERN

During the fourth quarter of the year ended March 31, 2019, the Company began sales and marketing efforts for its Mint flavored Tauri-GumTM product. During the year ended March 31, 2021, the Company recognized net sales of $285,319 and a gross profit of $122,692, compared to net sales of $239,388 and a gross profit of $54,235 for the same period during the same period in the prior year. At March 31, 2021, the Company had a working capital surplus of $1,291,211 compared to a working capital deficit of $334,832 for the year ended March 31, 2020. The improvement is largely resultant from increased inventory levels and an increase in value of trading securities. Although the Company has a working capital surplus, there is no guarantee that this will continue therefore it still believes that there is uncertainty with respect to continuing as a going concern.

On July 1, 2019, months after the NYC Department of Heath announced a ban on cannabidiol in foods and beverages (mainly focused on restaurants and baked goods), the result of which was that the updated New York City Health Code now includes an embargoing of CBD-infused Edible(s) Products (including packaged products). The Company is hopeful that due to the recent regulatory regime for cannabinoid products implemented by the NYDPH, the New York City Council will remove the current CBD ban and implement regulations surrounding CBD products in a logical and prompt manner. The Company believes it is well positioned under the current regulatory structure, and has taken a conservative approach towards its products, including, for example, ensuring that its product manufacturer periodically tests for compliance with the Agricultural Improvement Act of 2018, such as utilizing CBD oils from hemp plants which contain 0.3% or less THC content. Subsequent to the balance sheet date, the State of New York has determined that it is allowable to sell CBD Infused Edible products in the forms of both food and drink (inclusive of chewing gum). It was also determined that no time can CBD be sold in products that contain either alcohol or tobacco. Additionally, the State of New York also said that NO CBD product may be sold if it contains more than 0.3% (1/333rd by Composition) THC. No Individual food or beverage product may contain more than 25mg of Hemp-Extracted Cannabinoids (“CBD” or “CBG”) per serving. Food and drink infused with CBD and Other Hemp Extracts must be packaged by the manufacturer and extracts cannot be added at the retail level. The Company’s entire product line will comply with these standards.

The Company, in the short term, intends to continue funding its operations either through cash-on-hand or through financing alternatives. Management’s plans with respect to this include raising capital through equity markets to fund future operations as well as the possible sale of its remaining marketable securities which had a market value of $1,246,050 at March 31, 2021. In the event the Company cannot raise additional capital to fund and/or expand operations or fails to raise adequate capital and generate adequate sales revenue, or if the regulatory landscape were to become more difficult or result in regulatory enforcement, it could result in the Company having to curtail or cease operations.

Additionally, even if the Company does raise sufficient capital to support its operating expenses and generate adequate revenues in the short term, there can be no assurances that the revenues will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations to achieve profitability thereby eliminating its reliance on alternative sources of funding. Although management believes that the Company continues to strengthen its financial position over time, there is still no guarantee that profitable operations with sufficient cashflow to sustain operations can or will be achieved without the need of alternative financing, which is limited. These matters still raise significant doubt about the Company’s ability to continue as a going concern as determined by management. The Company believes that there is uncertainty with respect to continuing as a going concern until the operating business can achieve sufficient sales to maintain profitable operations and sustain cash flow to operate the Company for a period of twelve months. In the event the Company does need to raise additional capital to fund operations or engage in a transaction, failure to raise adequate capital and generate adequate sales revenues could result in the Company having to curtail or cease operations.

Even if the Company does raise sufficient capital to support its operating expenses, acquire new license agreements or ownership interests in life science companies and generate adequate revenues, or the agreements entered into recently are successful, there can be no assurances that the revenues will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Company’s ability to continue as a going concern as determined by management. However, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

In an effort to support the Company’s future capital needs, on January 21, 2020, the Company entered into a $5,000,000 equity line financing agreement with Tangiers, as well as a registration right agreement related thereto. The financing is over a maximum of 36 months. Pursuant to the Registration Rights Agreement, a maximum of 76,000,000 shares of our common stock, par value $.00001 per share that we may sell to Tangiers from time to time will be registered by us on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended, for this financing. As a result of the Company’s Collaboration Agreement with Aegea, whereby seventy percent (70%) of the Net Proceeds from the sale of the initial 10,000,000 shares of stock of Tauriga using the ELOC were transferred to and invested in Aegea for the purchase of common stock of Aegea. Additionally, the Company has excluded 4,000,000 shares under this agreement to cover liabilities and expenses related to the establishment and maintenance of this agreement. (See earlier in this Note for a more complete description under Investment Agreement and Registration Rights Agreement). As of March 31, 2021, the Company has issued 3,910,000 of the excluded 4,000,000 shares. On January 8, 2021, the Company filed a Post-Effective Amendment to its January 21, 2020 S-1 Investment Agreement and Registration Rights Agreement to terminate the effectiveness of the Registration Statement and to remove from registration all securities registered but not sold under the Registration Statement.

XML

Summary of Significant Accounting Policies

12 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

CONSOLIDATED FINANCIAL STATEMENTS

These consolidated financial statements include the accounts and activities of Tauriga Sciences, Inc., its wholly-owned Canadian subsidiary, its wholly-owned subsidiary Tauriga Pharma Corp. (f/k/a Tauriga Biz Dev Corp – or “Tauriga BDC” and referenced herein as Tauriga BDC for contextual purposes only in describing the Blink contractual arrangement) and Tauriga Sciences Limited. All intercompany transactions have been eliminated in consolidation. As of March 31, 2021 and 2020, there is no activity in any of the Company’s subsidiaries other than Tauriga Pharma Corp. holding the electric car chargers.

SEGMENT INFORMATION

The Company has adopted provisions of ASC 280-10 Segment Reporting for the years ended March 31, 2021 and 2020. This standard requires that companies disclose operating segments based on the manner in which management disaggregates the Company in making internal operating decisions. The Company and its Chief Operating Decision Makers determined that the Company’s operations consist of two segments: (i) The first division consists of all retail, wholesale and e-commerce product sales of CBD/CBG Tauri-Gum^TM, Tauri-Gummies^TM, and other CBD/CBG products, and (ii) the second segment will be a research and development division that consist of liabilities and results from any activity relative to the progress in the development of the Company’s FDA IND application for Phase II Trial of its proposed pharmaceutical grade version of Tauri-Gum™. The cost basis investment in Aegea has been treated as a non-operating asset and will therefore not be reported as a part of the research and development division.

	Tauri-gum			Pharma			Adjustments, eliminations and unallocated items		Consolidated
Total revenue, net	$	285,319		$	-		$	-	$	285,319
Cost of Sales		(162,627	)		-			-		(162,627	)
Gross Profit		122,692			-			-		122,692
General and Administrative expense		2,778,282			80,675			-		2,858,957
Research and development		50,885			222,500			-		273,385
Selling and fulfillment expense		379,824			-			-		379,824
Operating Loss	$	(2,761,045	)	$	(303,175	)	$	-	$	(3,389,474	)
Total Assets	$	2,288,263		$	200,440		$	-	$	2,488,703
Total Liabilities	$	1,076,038		$	141,418		$	-	$	1,217,456

REVENUE RECOGNITION

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective October 1, 2017 as the Company commenced sales of HerMan® using the full retrospective method. The new standard did not have a material impact on its financial position and results of operations, as it did not change the manner or timing of recognizing revenue.

Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.

On March 29, 2018 the Company, through Tauriga BDC, entered into an independent sales representative agreement with Blink to be a non-exclusive independent sales representative. Under the agreement with Blink, the Company may solicit orders from potential customers for EV charging station placement. On June 29, 2018, the Company purchased four Blink Level 2 - 40” pedestal chargers for permanent placement in a retail location or locations whereby the Company will pay a variable annual fee based on 7% of total revenue per charging unit. The remainder of the proceeds will be split 80/20 between the Company and the host location owner or its assignee. The host location owner will pay for the cost of providing power to these unit as well as installation costs. As of March 31, 2021, we have not installed any of these machines in any locations, and no revenue has been generated through the Blink contract. The Company has decided to abandon this business line, and therefore, we have reclassified these assets as held for sale.

The Company recognizes revenue upon the satisfaction of the performance obligation. The Company considers the performance obligation met upon shipment of the product or delivery of the product. For ecommerce orders, the Company’s products are shipped by a fulfillment company and payment is made in advance of shipment either through credit card or PayPal. The Company also delivers the product to its customers that they market to in the metropolitan New York Tri-State area that are not covered under any existing distribution agreements. The Company generally collects payment within 30 to 60 days of completion of its performance obligation, and the Company has no agency relationships. The Company recognized net revenue from operations in the amount of $285,319 during the year ended March 31, 2021 compared to $234,389 for the prior year. All revenue is from the sale of the Company’s Tauri-Gum^TM product line and there were accounts receivable, net of allowance for doubtful accounts in the amount of $7,015 outstanding for these sales, as of March 31, 2021.

ALLOWANCE FOR DOUBTFUL ACCOUNTS

The Company maintains an allowance for doubtful accounts, which includes sales returns, sales allowances and bad debts. The allowance adjusts the carrying value of trade receivables for the estimate of accounts that will ultimately not be collected. An allowance for doubtful accounts is generally established as trade receivables age beyond their due dates, whether as bad debts or as sales returns and allowances. As past due balances age, higher valuation allowances are established, thereby lowering the net carrying value of receivables. The amount of valuation allowance established for each past-due period reflects the Company’s historical collections experience, including that related to sales returns and allowances, as well as current economic conditions and trends. The Company also qualitatively establishes valuation allowances for specific problem accounts and bankruptcies, and other accounts that the Company deems relevant for specifically identified allowances. The amounts ultimately collected on past-due trade receivables are subject to numerous factors including general economic conditions, the financial condition of individual customers and the terms of reorganization for accounts exiting bankruptcy. Changes in these conditions impact the Company’s collection experience and may result in the recognition of higher or lower valuation allowances. At March 31, 2021, the Company has established an allowance for doubtful accounts in the amount of $93,550.

SALES REFUNDS

The Company’s refund policy allows customers to return product for any reason except where the customer does not like the taste of the product. The customer has 30 days from the date of purchase to initiate the process. Returns are limited to one return or exchange per customer. Only purchases up to $100 qualify for a refund. Approved return/refund requests are typically processed within 1-2 business days. For product purchases made through a Tauri-Gum^TM distributor or retailer, the customer is required to work with original purchase location for any return or exchange. The Company has not established a reserve for returns as of March 31, 2021 however will monitor the refunds to estimate whether a reserve will be required.

USE OF ESTIMATES

The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

CASH EQUIVALENTS

For purposes of reporting cash flows, cash equivalents include investment instruments purchased with an original maturity of three months or less. At March 31, 2021, the Company’s cash on deposit with financial institutions did not exceed the total FDIC insurance limit of $250,000. At March 31, 2021 and March 31, 2020, the Company had a cash balance of $49,286 and $5,348, respectively. The Company’s does not expect, in the near term, for its cash balance to exceed the total FDIC insurance limit of $250,000 for other than very short periods of time where the Company would use such cash in excess of insurance in the very short-term in operating activities. To reduce its risk associated with the failure of such financial institution, the Company holds its cash deposits in more than one financial institution and evaluates at least annually the rating of the financial institution in which it holds its deposits. The Company had no cash equivalents as of March 31, 2021 and March 31, 2020.

INVESTMENT IN TRADING SECURITIES

Investment in trading securities consist of investments in shares of common stock of companies traded on public markets as well as publicly traded warrants of these companies should there be a market for them. These securities are carried on the Company’s balance sheet at fair value based on the closing price of the shares owned on the last trading day before the balance sheet date of this report. Fluctuations in the underlying bid price of the stocks result in unrealized gains or losses. The Company recognizes these fluctuations in value as other income or loss. For investments sold, the Company recognizes the gains and losses attributable to these investments as realized gains or losses in other income or loss.

INVESTMENT – COST METHOD

Investment in other companies that are not currently trading, are valued based on the cost method as the Company holds less than 20% ownership in these companies and has no influence over operational and financial decisions of the companies. The Company will evaluate, at least annually, whether impairment of these investments is necessary under ASC 320. As of March 31, 2021, the Company has recorded a loss on the impairment on two of its cost method investments in the amount of $244,706. The Company did not record a loss on the impairment on investments for the year ended March 31, 2020.

INVENTORY

Inventory consists of finished goods in salable condition stated at the lower of cost or market determined by the first-in, first-out method. The inventory consists of packaged and labeled salable inventory. Shipping of product to finished good inventory fulfilment center is also included in the total inventory cost. Shipping of product upon sale for e-commerce sales is paid by the customer upon ordering for orders of single packs of Tauri-Gum^TM. For multiple pack or wholesale product orders shipping cost is paid by the Company. As of March 31, 2021, the Company’s inventory on hand had a value of $201,372. The Company has not established any inventory reserve on the Tauri-Gum^TM as of March 31, 2021. As of March 31, 2021, the Company had $423,200 in funds paid for inventory not received.

SHIPPING AND HANDLING COSTS

The Company’s fulfillment handling costs are provided by independent contractors through fixed fee arrangements which may also include incentives. These fees also contain a large degree of consultative, administrative and warehousing services as part of the fixed fee. Management believes that due to these factors it is more representative to include these amounts as general and administrative costs instead of cost of goods sold. For the year ended March 31, 2021, the Company incurred fulfillment costs in the amount of $106,519 and $42,050, respectively.

Shipping cost for the Company consists of product movement to and from trade shows, between office locations, mailing of samples and product shipments. The cost of shipping is typically not charged to the customer when they order more than one product from on the website. Customer shipping of large customers wholesale orders are done on a reimbursement basis therefore any shipping revenue and shipping expense are largely recorded as offsetting gross revenues and cost of goods sold. The Company had net shipping expense:

	Year Ended March 31,
	2021			2020
Shipping revenue	$	6,240		$	24,438
Shipping expense		(24,693	)		(31,114	)
Net shipping expense	$	(18,453	)	$	(6,706	)

PROPERTY AND EQUIPMENT

Property and equipment are stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.

INTANGIBLE ASSETS

Intangible assets consisted of licensing fees and a patent prior to being impaired which were stated at cost. Licenses were amortized over the life of the agreement and patents were amortized over the remaining life of the patent at the date of acquisition.

NET LOSS PER COMMON SHARE

The Company computes per share amounts in accordance with FASB ASC Topic 260 “Earnings per Share” (“EPS”), which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of common stock and common stock equivalents outstanding during the periods; however, potential common shares are excluded for period in which the Company incurs losses, as their effect is anti-dilutive. For the years ended March 31, 2021 and 2020, basic and fully diluted earnings per share were the same as the Company had losses in this period.

STOCK-BASED COMPENSATION

The Company accounts for Stock-Based Compensation under ASC 718 “Compensation-Stock Compensation,” which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.

The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, “Equity-Based Payments to Non-Employees.” Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted on the grant date as either the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in stockholders’ equity over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.

The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value on the grant date of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services over the term of the related services.

IMPAIRMENT OF LONG-LIVED ASSETS

Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if it’s carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.

RESEARCH AND DEVELOPMENT

The Company expenses research and development costs as incurred. Research and development costs were $273,385 and $6,923 for the years ended March 31, 2021 and 2020, respectively. The Company is continually evaluating products and technologies, and incurs expenses relative to these evaluations, including in the natural wellness space, such as Tauri-Gum™ product development of new flavor formulations and other CBD delivery products, as well as development of a Cannabigerol (“CBG”) Isolate Infused version of its Tauri-Gum™ brand. We also incur expenses relative to collaboration agreements and any activity relative to the progress in the development of the Company’s FDA IND application for Phase II Trial of its proposed pharmaceutical grade version of Tauri-Gum™, as well as intellectual property or other related technologies. As the Company investigates and develops relationships in these areas, resultant expenses for trademark filings, license agreements, website and product development and design materials will be expensed as research and development. Some costs will be accumulated for subsidiaries prior to formation of any new entities.

FAIR VALUE MEASUREMENTS

ASC 820 “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosure about fair value measurements.

The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable:

Level 1- fair value measurements are those derived from quoted prices (unadjusted in active markets for identical assets or liabilities);

Level 2- fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

Level 3- fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Financial instruments classified as Level 1 – quoted prices in active markets include cash.

These consolidated financial instruments are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment to estimation. Valuations based on unobservable inputs are highly subjective and require significant judgments. Changes in such judgments could have a material impact on fair value estimates. In addition, since estimates are as of a specific point in time, they are susceptible to material near-term changes. Changes in economic conditions may also dramatically affect the estimated fair values.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management for the respective periods. The respective carrying value of certain financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, investments, short-term notes payable, accounts payable and accrued expenses.

RECLASSIFICATIONS

Certain prior year amounts have been reclassified to conform to the current period presentation. The reclassifications had no effect on the net loss or cash flows of the Company.

SHARE SETTLED DEBT

The general measurement guidance in ASC 480 requires obligations that can be settled in shares with a fixed monetary value at settlement to be carried at fair value unless other accounting guidance specifies another measurement attribute. The Company has determined that ASC 835-30 is the appropriate accounting guidance for the share-settled debt, which is what was done by setting up the debt discount which is to be amortized to interest expense over the term of the instrument. Amortization of discounts are to be amortized using the effective interest method over the term of the note.

ASC 480-10-25-14 requires liability accounting for (1) any financial instrument that embodies and unconditional obligation to transfer a variable number of shares or (2) a financial instrument other than an outstanding share that embodies a conditional obligation to transfer a variable number of shares, provided that the monetary value of the obligation is based solely or predominantly on any of the following: 1. A fixed monetary amount known at inception (e.g. stock settled debt); 2. Variations in something other than the fair value of the issuer’s equity shares (e.g. a preferred share that will be settled in a variable number of common shares with tits monetary value tied to a commodity price); and 3. Variations in the fair value of the issuer’s equity shares, but the monetary value to the counterparty moves inversely to the value of the issuer’s shares (e.g. net share settled written put options, net share settled forward purchase contracts).

Notwithstanding the fact that the above instruments can be settled in shares, FASB concluded that equity classification is not appropriate because instruments with those characteristics do not expose the counterparty to risks and rewards similar to those of an owner and, therefore do not create a shareholder relationship. The issuer is instead using its shares as the currency to settle its obligation.

The Company has multiple notes that contain discount provisions whereby the holder can exercise conversion rights at a discount to the market price for a 15 or 20 day trailing period based on the market volume average weighted price. ASC 470-20 defines this as a beneficial conversion feature which that shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value, not to exceed the face value of the note, to additional paid in capital. This segmented value, is to be amortized using the effective interest method over the term of the note.

INCOME TAXES

Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases.

Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized, or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.

ASC 740 “Income Taxes” clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.

As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company does not meet the more-likely-than-not threshold as of March 31, 2021.

RECENT ACCOUNTING PRONOUNCEMENTS

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contract’s in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the impact that this new guidance will have on its consolidated financial statements.

In June 2018, the FASB issued ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” which addresses accounting for issuance of all share-based payments on the same accounting model. Previously, accounting for share-based payments to employees was covered by ASC Topic 718 while accounting for such payments to non-employees was covered by ASC Subtopic 505-50. As it considered recently issued updates to ASC 718, the FASB, as part of its simplification initiatives, decided to replace ASC Subtopic 505-50 with Topic 718 as the guidance for non-employee share based awards. Under this new guidance, both sets of awards, for employees and non-employees, will essentially follow the same model, with small variations related to determining the term assumption when valuing a non-employee award as well as a different expense attribution model for non-employee awards as opposed to employee awards. The ASU is effective for public business entities beginning in 2019 calendar years and one year later for non-public business entities. The Company has determined that there is not a material impact on their consolidated financial position and results of operations as a result of this standard.

In February 2016, FASB issued ASU 2016-02, “Leases (Topic 842).” The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The new guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period and is applied retrospectively. The Company has adopted this standard as of April 1, 2019 (See Note 7).

There are several other new accounting pronouncements issued or proposed by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial position or operating results.

SUBSEQUENT EVENTS

In accordance with ASC 855 “Subsequent Events” the Company evaluated subsequent events after the balance sheet date through the date of issuance of this report.

XML

Revenue

12 Months Ended

Mar. 31, 2021

Revenue from Contract with Customer [Abstract]

Revenue

NOTE 3 - REVENUE

The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers, which the Company adopted simultaneous with the commencement of sales in March 2019. No cumulative adjustment to accumulated deficit was done, and the adoption did not have an impact on our consolidated financial statements, as no material arrangements prior to the adoption were impacted by the new pronouncement.

The following table disaggregates the Company’s net revenue by sales channel for the years ended March 31:

	2021		2020
Revenue:
Distributor	$	-	$	62,441
E-Commerce		233,995		34,439
Wholesale		51,324		137,509
	$	285,319	$	234,389

Revenues from the Company’s E-Commerce channel represented 82% of total net sales for the year ended March 31, 2021 compared to 14.7% for the prior year. As of March 31, 2021, the Company’s had an allowance for doubtful account collectability in the amount of $93,550 which was wholly attributable to the Wholesale channel. There were no significant contract asset or contract liability balances for periods presented. The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed. Collections of the amounts billed are typically paid by the customers within 30 to 60 days.

XML

Inventory

12 Months Ended

Mar. 31, 2021

Inventory Disclosure [Abstract]

Inventory

NOTE 4– INVENTORY

The following chart is the inventory value by product as of: 

	March 31, 2021		March 31, 2020
CBD/CBG Tauri-GumTM	$	173,207	$	120,480
Tauri-GummiesTM		22,829		4,029
Other Gummies (1)		-		2,425
Other (2)		5,336		1,776
Total Inventory	$	201,372	$	128,710

(1)	This segment of inventory is stock that was purchased in conjunction with Resale Agreement with OG Laboratories, LLC.
(2)	Other inventory consists of holiday pouches sold as a bundled of Tauri-GumTM, other CBD products and skin care.

At March 31, 2021, there were $423,200 of prepayments on deposit with manufactures of Company products.

At March 31, 2020, the Company had deposits to Per Os Bio in the amount of $96,688 for the manufacturing costs of Tauri-Gum^TM for goods not yet available for sale.

XML

Property and Equipment

12 Months Ended

Mar. 31, 2021

Property, Plant and Equipment [Abstract]

Property and Equipment

NOTE 5– PROPERTY AND EQUIPMENT

The Company’s property and equipment is as follows:

	March 31, 2021			March 31, 2020			Estimated Life
Computers, office furniture and other equipment	$	24,789		$	69,638		3-5 years
Less: accumulated depreciation		(1,642	)		(56,160	)
Net	$	23,147			13,478

During the year ended March 31, 2021, the Company purchased office furniture in the amount of $8,722 for its new company headquarters in Wappingers Falls, New York. The furniture will be depreciated over 60 months commencing when it is put into service in the new Company headquarters on January 6, 2021.

During the year ended March 31, 2021, the Company disposed of and removed from its books all obsolete and out of service fully depreciated computers, office furniture and other equipment in the amount of $55,942. The same amount was removed from accumulated depreciated so there was no change in net fixed assets as a result of this disposal.

On June 29, 2018, the Company purchased four Blink Level 2 – 40” pedestal chargers for permanent placement in one or more retail locations whereby the Company would share revenue from these electric car vehicle charging units with such location owner. No depreciation expense has been recorded for the charging units as of March 31, 2021 due to the fact that they have not been placed in service. As of April 1, 2020, these charging units were reclassified as assets held for resale.

Depreciation expense for the years ended March 31, 2021 and was $1,425 and $913, respectively.

XML

Leasehold Improvements

12 Months Ended

Mar. 31, 2021

Leases [Abstract]

Leasehold Improvements

NOTE 6 –LEASEHOLD IMPROVEMENTS

Associated with the Company’s January 6, 2021, relocation of its headquarters to Wappingers Falls the Company implemented certain leasehold improvements including signage and a sales display buildout at a total cost of $5,000. The Company has entered a two-year lease with a two-year extension option. The Company expects that it will exercise these two extension options and has chosen to amortize these leasehold improvements over 48 months.

	March 31, 2021			March 31, 2020		Expected Usage
Wappingers Falls office signage and sales display	$	5,000		$	-	48 months
Less: amortization		(313	)		-
Net	$	4,687			-

XML

Operating Lease

12 Months Ended

Mar. 31, 2021

Leases [Abstract]

Operating Lease

NOTE 7 – OPERATING LEASE

The Company has adopted ASU No. 2016-02, Leases (Topic 842), as of April 1, 2019 and will account for new leases in terms of the right of use assets and offsetting lease liability obligations for this new lease under this pronouncement. In accordance with ASC 842 – Leases, effective April 1, 2019, the Company recorded a net lease right of use asset and a lease liability at present value of approximately $7,492 and $7,895, respectively. The Company recorded these amounts at present value, in accordance with the standard, using a discount rate of 8% which is representative of the last borrowing rates for notes issued to non-related parties. The right of use asset is composed of the sum of all lease payments, at present value, and is amortized over the life of the expected lease term. For the expected term of the lease the Company used the initial term of the two-year lease. Upon the election by the Company to extend the lease for additional years, that election will be treated as a lease modification and the lease will be reviewed for remeasurement. This lease will be treated as an operating lease under the new standard.

The Company chose to implement this standard using the modified retrospective model approach with a cumulative-effect adjustment, which does not require the Company to adjust the comparative periods presented when transitioning to the new guidance on April 1, 2019. The Company has also elected to utilize the transition related practical expedients permitted by the new standard. The modified retrospective approach provides a method for recording existing leases at adoption and in comparative periods that approximates the results of a modified retrospective approach. Adoption of the new standard resulted in the recording of additional net lease assets and lease liabilities of approximately $7,492 and $7,895 as of April 1, 2019, respectively. The difference between the additional lease assets and lease liabilities, net of the deferred tax impact, will be recorded as an adjustment to retained earnings. The standard is not expected to materially impact our consolidated net earnings and had no impact on cash flows.

CORPORATE OFFICE

New York City Office – former headquarters

On December 1, 2017, the Company relocated its corporate headquarters from Danbury, Connecticut to New York, New York. The Company has entered into a two-year lease at $1,010 per month for the term of the lease. The lease right of use asset for this lease at adoption was $7,492 and will be amortized on a straight-line basis over the remaining term of the lease. For the year March 31, 2021 and 2020, the Company recorded a lease expense of $8,062 and $6,322. On September 1, 2019, the Company entered into a two-year lease extension with the modified lease expiring November 30, 2021. The lease modification required the Company to remeasure the lease asset and lease liability based on the original lease. The Company recorded a net lease right of use asset and a lease liability at present value of approximately $26,093 for each. The Company recorded these amounts at present value, in accordance with the standard, using a discount rate of 8.98% which was representative of the weighted average borrowing rates for all notes issued to non-related parties based on the respective principal balances at the time of the lease extension. During October 2020, the Company terminated this lease and recorded a gain on lease disposal of $750. As of December 31, 2020, as a result of the lease termination the Company had neither an unamortized lease right of use asset or a lease liability associated with this lease.

Wappingers Falls, New York – Corporate headquarters

Effective January 6, 2021, the Company moved its corporate headquarters to 4 Nancy Court, Suite 4, Wappingers Falls, New York 12590. The Company’s telephone number remains the same, phone: 917-796-9926. The Company entered into a two-year lease, expiring January 31, 2023. Tenant will pay $19,200 annually ($1,600 per month) during the term of the lease. The Company paid $1,600 as a security deposit as part of this lease. The Company has the option to one two-year extension. The Company expects it will exercise this option. Tenant will pay $21,000 annually ($1,750 per month) during the option term. The Company recorded a right of use asset and liability in the amount of $67,938 representing the sum of all lease payments discounted using the Company’s weighted average borrowing rate based on outstanding debt at March 31, 2021.

BARCELONA OFFICE

On June 11, 2019, the Company entered into a two-year lease, expiring on September 30, 2021. The office is located at Regus World Trade Centre Muelle de Barcelona, edif. Sur, 2a Planta Barcelona Cataluña 08039 Spain. Monthly rent payments was approximately $201 per month (based on the contractual rate of €178 multiplied by the exchange rate of 1.13 on the day the lease agreement was entered into). In accordance with ASC 842 - Leases, effective June 11, 2019, the Company will record additional net lease right of use asset and a lease liability at present value of approximately $4,574, respectively as a result of this lease. The lease will be initially recorded using an exchange rate of 1.13. Any fluctuations in the currency rate were recorded as gain or loss on currency translation. During October 2020, the Company terminated this lease and recorded a gain on lease disposal of $86. As of March 31, 2021, as a result of the lease termination the Company had neither an unamortized lease right of use asset or a lease liability associated with this lease.

For the years ended March 31, 2021 and 2020, the Company recorded lease expense of $11,087 and $13,233, respectively. As of March 31, 2021, the value of the unamortized lease right of use asset is $64,301. As of March 31, 2020, the Company’s lease liability was $64,526.

The following chart shows the Company’s operating lease cost for the years ended March 31, 2021 and 2020:

	For the year ended March 31,
	2021		2020
Amortization of right of lease asset	$	10,311	$	13,233
Lease interest cost		2,324		1,666
Total Lease cost	$	12,635	$	14,899

Maturity of Operating Lease Liability for fiscal year ended March 31,
2022	$	14,426
2023		16,201
2024		18,990
2025		14,910
Total lease payments	$	64,527

	March 31, 2021		March 31, 2020
Right of Use (ROU) asset	$	64,301	$	22,090

	March 31, 2020		March 31, 2020
Operating lease liability:
Current	$	14,426	$	13,891
Non-Current		50,100		8,933
Total	$	64,526	$	22,824

XML

Notes Payable

12 Months Ended

Mar. 31, 2021

Debt Disclosure [Abstract]

Notes Payable

NOTE 8 – NOTES PAYABLE

CONVERTIBLE NOTES

		March 31, 2021			March 31, 2020
GS Capital Partners LLC – Mar 2019	(a)		-			175,000
GS Capital Partners LLC – Jun 2019	(b)		-			60,000
Odyssey Funding, LLC – Sep 2019	(c)		-			80,000
BHP Capital NY Inc. – Oct 2019	(d)		-			55,000
Tangiers Global, LLC – Nov 2019	(e)		-			137,500
Odyssey Funding, LLC – Dec 2019	(f)		-			100,000
Jefferson Street Capital LLC – Dec 2019	(g)		-			55,000
BHP Capital NY Inc. – Jan 2020	(h)		-			44,000
ADAR Alef, LLC – Jan 2020	(i)		-			44,000
GS Capital LLC – Jan 2020	(j)		-			110,000
Tangiers Global, LLC – Feb 2020	(k)		-			65,000
Crown Bridge Partners, LLC – Feb 2020	(l)		-			55,000
ADAR Alef, LLC – Mar 2020	(m)		-			44,000
Tangiers Global, LLC – Mar 2020	(n)		-			43,050
GS Capital Partners, LLC – Apr 2020	(o)		-			-
ADAR Alef, LLC – Apr – 2020	(p)		-			-
Tangiers Global, LLC – May 2020	(q)		-			-
First Fire Investments – May 2020	(r)		-			-
GS Capital LLC – Jun 2020	(s)		-			-
Tangiers Global, LLC – Jun 2020	(t)		-			-
Tangiers Global, LLC – Dec 2020	(u)		-			-
Total notes payable and convertible notes		$	-		$	1,067,550
Less – note discounts			(-	)		(482,416	)
Less – current portion of these notes			(-	)		(585,134	)
Total notes payable and convertible notes, net discounts		$	-		$	-

(a)   On March 14, 2019, the Company entered into a 12-month $300,000 principal face value 8.0% convertible debenture with GS Capital, with a maturity date of March 13, 2020. The GS Capital Note carried a $20,000 original issue discount (OID) and, as such, the initial net proceeds to the Company was $280,000. In connection with this agreement, the Company was obligated to issue 750,000 commitment shares having a value of $142,500 ($0.19 per share) which is reflected as interest expense in the Company’s consolidated statement of operations during the year ended March 31, 2019. These shares were issued on June 20, 2019. The Holder was entitled, at its option, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company’s common stock at a price for each share of Common Stock equal to 68% of the lowest daily VWAP of the Common Stock as reported on the National Quotations Bureau OTC Markets exchange for the fifteen (15) prior trading days. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the full-face value of the note which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. Also, in conjunction with this note, the 213,334 five-year cashless warrants, associated with the June 27, 2017, $80,000 5% one-year note were fully cancelled. As of March 31, 2021, the noteholder fully converted the $300,000 of principal and $26,009 of accrued interest into 14,473,254 shares of the Company’s common stock ($0.0225 per share). Upon conversion, the balance of the share reserve was returned to treasury.

(b) On June 21, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note had a maturity date of June 21, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on June 21, 2019). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 2,650,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the “Share Reserve”) and maintain a 2.5 times reserve for the amount then outstanding. On June 3, 2020, the noteholder converted the entire $60,000 of principal and $4,937 of accrued interest into 3,162,115 shares of common stock ($0.0205 per share) and the balance of the reserved shares were returned to the treasury.

(c) On September 13, 2019, the Company entered into a one year 8% $100,000 Convertible Note with Odyssey Funding, LLC (“Investor”) pursuant to the terms of a Securities Purchase Agreement (the “Odyssey Note”). The Odyssey Note has a maturity date of September 13, 2020 and carried a $5,000 original issue discount (such that $95,000 was funded to the Company at closing). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the Odyssey Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 64% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the Odyssey Note, the Company issued irrevocable transfer agent instructions reserving 22,727,000 shares (the “Share Reserve”) of its Common Stock for conversions under this Note. As of March 31, 2021, the full principal of $100,000 and accrued interest in the amount of $4,443 as well as $500 in fees were converted into 5,543,332 shares of common stock ($0.0188 per share). Upon conversion, all shares remaining in the Share Reserve were cancelled and returned to the treasury.

(d) On October 17, 2019, the Company entered into a Convertible Promissory Note (“BHP Note”), bearing an interest rate of 10% per annum, pursuant to a Securities Purchase Agreement with BHP Capital NY, Inc. dated October 7, 2019. The BHP Note had a maturity date of July 3, 2020 and carried a $5,000 original issue discount (such that $50,000 was funded to the Company on October 8, 2019). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the BHP Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Holder was entitled to deduct $500 from the conversion amount in each Notice of Conversion to cover Holder’s deposit fees associated with each Notice of Conversion. The Borrower was required at all times to have authorized and reserved three times the number of shares that would be issuable upon full conversion of the Note (assuming that the 4.99% limitation is not exceeded) in effect, initially 7,000,000 shares. On October 16, 2019, the Company issued 250,000 commitment shares to noteholder, BHP Capital NY, Inc. pursuant to the BHP Note. The shares had a value of $9,750 ($0.039 per share) which was recorded as interest expense on the Company’s consolidated balance sheet. As of March 31, 2021, the noteholder converted the full principal of $55,000, accrued interest in the amount of $2,795 as well as $500 in fees into 3,060,931shares of common stock ($0.0191 per share). Upon conversion, all shares remaining in the Share Reserve were cancelled and returned to the treasury.

(e)   On November 7, 2019, the Company effectuated a nine-month convertible promissory note with Tangiers Global, LLC (the “Tangiers Note”). The Company received funds in the amount of $125,000 after reduction of the Original Issue Discount of $12,500. The $137,500 face value note matured on August 5, 2020 and bears and interest rate of 10%, guaranteed. The Note holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the Tangiers Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty (20) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Holder may not engage in any “shorting” or “hedging” transaction(s) in the Common Stock of the Company prior to conversion. In connection with the Tangiers Note, the Company issued irrevocable transfer agent instructions reserving 35,000,000 shares (the “Share Reserve”) of its Common Stock for conversions under this Note, which Share Reserve has since been reduced as a result of conversions and other transactions between the parties. As of March 31, 2021, Tangiers fully converted all outstanding principal of $137,500 and accrued interest of $13,750 under this note. Interest on this note was guaranteed and prorated over the term of the note. Note principal and interest totaling $151,250 converted into 8,839,041 shares (average of $0.017112 per share). As a result, this note is fully repaid and retired and no further obligations or remuneration is due and owing thereunder, and any remaining shares of common stock in the Share Reserve were returned to treasury.

(f)   On December 18, 2019, the Company entered into a one year 8% $100,000 Convertible Note with Odyssey Capital, LLC (“Odyssey”) pursuant to the terms of a Securities Purchase Agreement (the “Odyssey Note”). The Odyssey Note has a maturity date of December 18, 2020 and carried a $5,000 original issue discount (such that $95,000 was funded to the Company at closing). The Investor was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the Odyssey Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 64% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the Odyssey Note, the Company issued irrevocable transfer agent instructions reserving 22,084,000 shares (the “Share Reserve”) of its Common Stock for conversions under this Odyssey Note. As of March 31, 2021, the Company fully paid and retired this note including accrued interest $4,252 and a prepayment penalty in the amount of $45,748. Upon full conversion of this note, any shares remaining in the Share Reserve were returned to treasury.

(g) On December 26, 2019, the Company entered into a one year 10% $55,000 Convertible Note with Jefferson Street Capital LLC (“Jefferson Street”) pursuant to the terms of a Securities Purchase Agreement (the “Jefferson Street Note”). The Jefferson Street Note had a maturity date of December 26, 2020 and carried a $5,000 original issue discount (such that $50,000 was funded to the Company at closing). The Investor was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the Jefferson Street Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Commencing on the date which is 180 days following the date of this Jefferson Street Note and ending on the later of: (i) the Maturity Date and (ii) the date of payment of the Default Amount, this Jefferson Street Note may be converted by Jefferson Street in whole or in part at any time from time to time after the Issue Date as noted in the Jefferson Street Note. In connection with the Jefferson Street Note, the Company was required at all times to have authorized and reserved six times the number of common shares that would be issuable upon full conversion of the Jefferson Street Note in effect, initially reserved at 20,000,000 common shares (the “Share Reserve”) of its Common Stock for conversions under this Jefferson Street Note. Upon full conversion of this note, remaining in the Share Reserve were cancelled. As of March 31, 2021, the noteholder converted the full principal of $55,000 plus accrued interest of $2,750 and $1,000 in fees for 3,095,362 shares of common stock ($0.01898 per share). Upon full conversion of this note, any shares remaining in the Share Reserve were returned to treasury.

(h) On January 3, 2020, the Company entered into a one-year 2% $44,000 Convertible Promissory Note with BHP Capital NY Inc. (“BHP Capital”) pursuant to the terms of a Securities Purchase Agreement (the “BHP Capital Note”). The BHP Capital Note has a maturity date of January 3, 2021 and carries a $4,000 original issue discount (such that $40,000 was funded to the Company at closing). Subsequent to this note funding, BHP exercised a most favored nations clause increasing this notes interest rate to 8%, based on subsequent notes issued by the Company. BHP had the right from time to time, and at any time after closing, to convert all or any amount of the principal face amount of the BHP Capital Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest one-day volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty (20) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the BHP Capital Note, the Company issued irrevocable transfer agent instructions pursuant to which the Company is required at all times to have reserved three times the number of shares that would be issuable upon full conversion of the Note (assuming that the 4.99% beneficial ownership limitation is not in effect) (based on the respective Conversion Price of the Note in effect from time to time, initially 14,100,000 shares of its Common Stock (the “Share Reserve”) for conversions under this BHP Capital Note. As of March 31, 2021, the noteholder fully converted the full principal of $44,000 plus accrued interest of $2,290 and $1,000 fees for 3,095,362 common shares ($0.01512 per shares). Upon full conversion of this note, any shares remaining in the Share Reserve were returned to treasury.

(i) On January 15, 2020, the Company entered into security purchase agreement with Adar Alef, LLC whereby the Company issued an 8% convertible redeemable note in the principal amount of $44,000. The note was funded with net proceeds of $37,800 after the deduction of $4,000 for OID and $2,200 in legal fees. The note has a maturity date of January 15, 2021. The face value amount plus accrued interest under the note are convertible into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the 20 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. The Company established an initial reserve of 6,296,000 shares of its common stock and at all times reserve a minimum of 4 times the amount of shares required if the note were to fully convert. As of March 31, 2021, the noteholder converted the full principal of $44,000 plus accrued interest of $2,750 and $1,000 in fees for 3,095,362 shares of common stock ($0.01898 per share). The full share reserve was released upon satisfaction of the note and returned to treasury.

(j) On January 17, 2020, the Company entered into a one year 8% $110,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note had a maturity date of January 21, 2021 and carried a $10,000 original issue discount (such that $100,000 was funded to the Company on January 21, 2020). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty (20) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 5,150,000 shares of its Common Stock for conversions under this Note (the “Share Reserve”) within 5 days from the date of execution and maintained a 2.5 times reserve for the amount then outstanding. Upon full conversion or repayment of this Note, all remaining shares in the Share Reserve were cancelled. Pursuant to this note, the Company issued to the noteholder 400,000 shares of its restricted common stock as debt commitment shares valued at $20,960 ($0.0524 per share). As of March 31, 2021, the noteholder converted the full principal of $110,000 plus accrued interest of $4,388 for 6,045,769 shares of common stock ($0.01898 per share). Upon full conversion of this note, any shares remaining in the Share Reserve were returned to treasury.

(k)   On February 7, 2020, the Company effectuated a six-month convertible promissory note with Tangiers Global, LLC (the “Tangiers Note”). The Company received funds in the amount of $60,000 after reduction of the Original Issue Discount of $5,000. The $65,000 face value note matured on August 6, 2020 and bore an interest rate of 2%, guaranteed. This note had a fixed conversion price of $0.03 per share. The Company established an initial reserve of 7,000,000 shares of its common stock and has agreed to reserve a multiple of shares to fully convert under the terms of this note. The Note was retired after the Maturity Date, therefore was subject to the terms hereof and restrictions and limitations contained herein, the Holder had the right, at the Holder’s sole option, to convert in whole or in part the outstanding and unpaid principal amount under this note into shares of common stock at the “Variable Conversion Price” which was equal to the lower of: (a) the Fixed Conversion Price or (b) 65% of the lowest volume weighted average price of the Company’s Common Stock during the 20 consecutive trading days prior to the date on which holder elected to convert all or part of the note. Accrued interest in the amount of $1,300 has been recognized on this note as of March 31, 2021. As of March 31, 2021, the noteholder converted the full principal of $65,000 plus accrued interest of $1,300 for 4,444,891 shares of common stock ($0.014916 per share). Upon full conversion of this note, any shares remaining in the Share Reserve were returned to treasury.

(l)

Effective February 11, 2020 the Company entered into a one-year 10% convertible promissory note with Crown Bridge Partners, LLC (“Crown”), having a face value of $55,000. The Company received funds in the amount of $50,000 on February 23, 2020, after reduction of the Original Issue Discount of $5,000. The $55,000 face value note had a maturity date of February 11, 2021. Crown had the right at any time to convert all or any part of the outstanding and unpaid principal amount and accrued and unpaid interest of this note into fully paid and non-assessable shares of common stock. The “Conversion Amount”, with respect to any conversion of this note, the sum of (1) the principal amount of this note to be converted in such conversion plus (2) at Crown’s option, accrued and unpaid interest, if any, on such principal amount at the interest rates provided in this note to the conversion date, plus (3) at Crown’s option, default interest, if any. The conversion price shall be the lesser of (i) 65% multiplied by the lowest volume weighted average price on the OTCQB, or applicable trading market during the previous twenty (20) trading day period ending on the latest complete trading day prior to the date of this note or (ii) the variable conversion price which meant 65% multiplied by lowest intraday trading price of any market makers for the common stock during the twenty (20) trading day period ending on the last complete trading day prior to the conversion date. The Company agreed that during the period the conversion right exists, the Company will reserve from its authorized and unissued common stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of common stock upon the full conversion of this note. The Company was required at all times to have authorized and reserved six times the number of shares that is actually issuable upon full conversion of the note. The Company, on February 24, 2020, issued 250,000 debt commitment shares in conjunction with this note. The commitment shares had a value of $13,500 ($0.054 per share). The Company, on August 25, 2020 agreed issue 125,000 additional make-whole shares valued at $4,438 ($0.0355). As of March 31, 2021, the noteholder converted $8,543 on note principal including $1,500 of interest for 500,000 shares $0.020085. On January 5, 2021, the Company and the noteholder agreed to fully settle and retire this note for the amount of $75,0000. Along with $46,458 of note principal and $4,053 of accrued interest a prepayment penalty of $24,438 was recorded as a loss on conversion of debt. Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(m)

On March 17, 2020, the Company entered into security purchase agreement with Adar Alef, LLC whereby the Company issued an 8% convertible redeemable note in the principal amount of $44,000. The note was funded with net proceeds of $37,800, after the deduction of $4,000 of Original Issue Discount and $2,200 in legal fees. The note had a maturity date of March 17, 2021. The face value amount plus accrued interest under the note are convertible into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market for the 20 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. The Company established an initial reserve of 7,584,500 shares of its common stock and at all times reserved a minimum of 4 times the amount of shares required if the note were to fully convert. As of March 31, 2021, the noteholder converted $44,000 of note principal and accrued interest of $1,989 for 2,600,620 ($ 0.017684 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(n) On March 23, 2020, the Company effectuated a six-month convertible promissory note with Tangiers Global, LLC. The Company received funds in the amount of $41,000 after reduction $2,050 of Original Issue Discount. The $43,050 face value note matured on September 23, 2020 and bore an interest rate of 5%, guaranteed. This note had a fixed conversion price of $0.03 per share. The Company agreed that it would, at all times, reserve and keep available for Tangiers, out of its authorized and unissued Common Stock a multiple of the number of shares of Common Stock issuable upon the full conversion of this note. Since this note was not converted as of the maturity date, Tangiers had the right, at its sole option, to convert in whole or in part the outstanding and unpaid Principal Amount under this Note into shares of Common Stock at the Variable Conversion Price which was equal to the lower of: (a) the Fixed Conversion Price or (b) 65% of the lowest volume weighted average price of the Company’s Common Stock during the 20 consecutive Trading Days prior to the date on which Tangiers elects to convert all or part of the Note. As of March 31, 2021, the note holder converted $43,050 in note principal and $2,153 of accrued interest for 2,826,923 shares ($0.01599 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(o) On April 17, 2020, the Company entered into a one-year 8% $55,000 convertible note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement (“GS Note”). The GS Note had a maturity date of April 17, 2021 and carried a $5,000 Original Issue Discount (such that $50,000 was funded to the Company on April 17, 2020). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty (20) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 5,717,000 shares of its common Stock for conversions under this and agreed to maintain a 2.5 times reserve for the amount then outstanding. The Company issued to the noteholder 150,000 shares of its restricted common stock as debt commitment shares valued at $5,000 ($0.03 per share). As of March 31, 2021, this noteholder converted note principal of $55,000 and accrued interest of $2,662 for 4,650,335 shares ($0.01408 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(p)

On April 30, 2020, the Company entered into securities purchase agreement with Adar Alef, LLC whereby the Company issued an 8% convertible redeemable note in the principal amount of $44,000. The note was funded with net proceeds of $37,800, after the deduction of $4,000 for Original Issue Discount and $2,200 in legal fees. The note has a maturity date of April 30, 2021. The face value amount plus accrued interest under the note was convertible into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the 20 prior trading days including the day upon which a notice of conversion was received by the Company or its transfer agent. The Company established an initial reserve of 7,736,000 shares of its common stock and at all times reserve a minimum of 4 times the amount of shares required if the note were to fully convert. As of March 31, 2021, the noteholder converted note principal of $44,000 and accrued interest $1,975 for 3,701,000 shares ($0.01242 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(q)

On May 8, 2020, the Company effectuated a six-month fixed convertible promissory note with Tangiers Global, LLC with a total face value of $102,500 containing an Original Issue Discount of $2,500. On May 8, 2020 and June 10, 2020, the Company received funds, on each date, in the amount of $50,000 and recognized Original Issue Discount of $1,250. This note matured on November 8, 2020 and bore an interest rate of 5%, guaranteed. This note has a fixed conversion price of $0.03 per share. The Company agreed that it would, at all times, reserve and keep available for Tangiers, out of its authorized and unissued Common Stock a multiple of the number of shares of Common Stock as were issuable upon the full conversion of this note. Since the note was not retired on or before the maturity date, it was subject to the terms hereof and restrictions and limitations contained herein, Tangiers had the right, at the its sole option, to convert in whole or in part the outstanding and unpaid principal amount under this note into shares of Common Stock at the variable conversion price which shall be equal to the lower of: (a) the fixed conversion price or (b) 70% of the lowest volume weighted average price of the Company’s Common Stock during the 15 consecutive trading days prior to the date on which Tangiers elects to convert all or part of the note. As of March 31, 2021, the noteholder converted note principal of $102,500 and accrued interest $5,125 for 5,823,864 shares ($0.01848 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(r) On May 18, 2020, the Company entered into a Securities Purchase Agreement with Firstfire Global Opportunities Fund, LLC (“Firstfire”) pursuant to a convertible promissory note in the principal amount of $88,333, having an Original Issue Discount in the amount of $8,833. On May 24, 2020, the Company received funds in the amount of $75,000 after the deduction of legal fees in the amount of $4,500. This note bore an annual interest rate of 8%. The per share conversion price into which principal amount and interest under this note was convertible into shares of Common Stock hereunder equal to 65% multiplied by the average of the two (2) lowest volume weighted average prices of the common stock during the fifteen (15) consecutive trading day period immediately preceding the date of the respective conversion. The borrower agreed that at all times until the note is satisfied in full, the borrower will reserve from its authorized and unissued Common Stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of a number of conversion shares equal to the greater of: (a) 8,500,000 shares of Common Stock or (b) the sum of the number of Conversion Shares issuable upon the full conversion of this Note multiplied by (ii) three and a half (3.5). The Company issued to the noteholder 375,000 shares of its restricted common stock as debt commitment shares valued at $12,075 ($0.0322 per share). As of March 31, 2021, the noteholder converted note principal of $88,333 and accrued interest $3,501 for 6,020,000 shares ($0.015255 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(s) On June 4, 2020, the Company entered into a one-year 8% $33,000 convertible note with GS Capital Partners, LLC (the “GS Note”) pursuant to the terms of a Securities Purchase Agreement. The GS Note had a maturity date of June 4, 2021 and carried $3,000 of original issue discount (such that $30,000 was funded to the Company on or about June 4, 2020). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest daily volume weighted average price of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty (20) prior trading days including the day upon which a notice of conversion was received by the Company or its transfer agent. Accrued but unpaid interest was subject to conversion. In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 3,678,000 shares of its Common Stock for conversions under this note and maintained a 2.5 times reserve for the amount then outstanding. The Company issued to the noteholder 90,000 shares of its restricted common stock as debt commitment shares valued at $3,105 ($0.0345 per share). As of March 31, 2021, the noteholder converted note principal of $33,000 and accrued interest $1,807 for 2,369,458 shares ($0.01469 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(t)

On June 24, 2020, the Company effectuated a six-month fixed convertible promissory note with Tangiers Global, LLC with a total face value of $210,000 containing Original Issue Discount of $10,000. On June 26, 2020, the Company received proceeds of $200,000, net Original Issue Discount of $10,000. This note matured on December 24, 2020 and bore an interest rate of 8%, guaranteed. This note has a fixed conversion price of $0.03 per share. Since the note was not retired on or before the maturity date, then at any time and from time to time after the maturity date, and subject to the terms hereof and restrictions and limitations contained herein, Tangiers had the right, at the Tangiers’s sole option, to convert in whole or in part the outstanding and unpaid principal amount under this note into shares of Common Stock at the variable conversion price which was equal to the lower of: (a) the fixed conversion price or (b) 70% of the lowest volume weighted average price of the Company’s Common Stock during the 15 consecutive trading days prior to the date on which Tangiers elected to convert all or part of the note. During January 2021, the noteholder converted $210,000 of note principal and accrued interest $16,800 for 12,221,861 shares ($0.01856 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(u)

On December 21, 2020, the Company effectuated a $210,000 six-month fixed convertible promissory note with Tangiers Global, LLC containing Original Issue Discount of $10,000. This note had a mature date of June 22, 2021 with an interest rate of 8%, guaranteed. This note had a fixed conversion price of $0.03 per share. If the Note was not retired on or before the maturity date, then at any time and from time to time after the maturity date, and subject to the terms hereof and restrictions and limitations contained herein, the Tangiers had the right, at the Tangiers’ sole option, to convert in whole or in part the outstanding and unpaid principal amount under this note into shares of common stock at the variable conversion price which was equal to the lower of: (a) the Fixed Conversion Price or (b) 70% of the lowest volume weighted average price of the Company’s common stock during the 15 consecutive trading days prior to the date on which Tangiers elected to convert all or part of the note. During March 2021, the noteholder converted $135,000 of note principal and accrued interest $16,800 for 5,060,000 shares ($0.03 per share). The Company paid $75,000 cash to convert the remaining note principal. Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

OTHER NOTES

On October 5, 2020, the Company entered into (i) an Inventory Financing Promissory Note in the aggregate principal amount of $135,000 with Jefferson Street Capital LLC, and (ii) a Securities Purchase Agreement. The note has a maturity date of October 5, 2021, carries $10,000 original issue discount (and a $3,000 due diligence fee paid to Moody Capital Solutions, Inc., the placement agent on behalf of Jefferson Street), and carries interest on the unpaid principal balance hereof at the rate of ten percent (10%) per annum beginning on the issuance date of October 5, 2020. Any amount of principal or interest on the note which is not paid when due shall bear interest at the rate of eighteen percent (18%) per annum from the due date thereof until the same is paid or converted in accordance with the terms of the note. The repayment of this note shall be in seven equal cash monthly installments beginning on April 5, 2021 and ending on October 5, 2021, for an aggregate amount of $148,500 (assuming no defaults). This note may not be converted by noteholder into shares of our Common Stock unless we default in our monthly repayment obligation pursuant to the cash repayment schedule noted above. In the event of a default of the note, noteholder shall have the right to convert all or any part of the outstanding and unpaid amounts into fully paid and non-assessable shares of Common Stock; provided, however, that in no event shall the holder be entitled to convert any portion of the note in excess of that portion of the note upon the conversion of which would result in beneficial ownership by noteholder and its affiliates of more than 4.99% of the outstanding shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and Regulations 13D-G thereunder. The beneficial ownership limitations noted above may not be waived by noteholder. The conversion price shall equal (subject to customary adjustments for stock splits, stock dividends or rights offerings, recapitalization, reclassifications, extraordinary distributions and similar events) 75% multiplied by the market price, which is defined to mean the lowest one day volume weighted average price of our Common Stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. The note contains a number of default or penalty provisions, including, but not limited to, the following: (a) at any time after October 5, 2020, if in the case that the Company’s Common Stock is not deliverable by DWAC for any reason, an additional 10% discount will apply for all future conversions under all notes. If in the case that the Company’s Common Stock is “chilled” for deposit into the DTC system and only eligible for clearing deposit, an additional 15% discount shall apply for all future conversions under the Note while the “chill” is in effect; (ii) if both the events noted in (i) above were to occur, an additional cumulative 25% discount shall apply; (iii) if the Company ceases to be a reporting company pursuant to the 1934 Act or if the Note cannot be converted into free trading shares after one hundred eighty-one (181) days from the issuance date, an additional 15% discount will be attributed to the conversion price; if the Company ceases to be a reporting company under the 1934 Act, (iv) if, at any time the Borrower does not maintain the Share Reserve (defined below); (v) the Company fails to pay the principal or interest under the Note when due under the terms thereof (including the five (5) calendar day cure period); (vi) a cross-default by the Company of another of its outstanding notes; or (vii) the completion of a reverse stock split while this Note is outstanding (and without consent). Subject to certain exempt issuances by the Company, during the period where any portion of the Note remains outstanding to Jefferson Street, if the Company engages in any future financing transactions with a third party investor, the Company will provide Jefferson Street with written notice thereof promptly but in no event less than 10 days prior to closing any financing transactions, and if applicable, the Company shall adjust the terms of the note to such more favorable terms of a subsequent financing, if any. In connection with the note, the Company issued irrevocable transfer agent instructions reserving 21,000,000 shares of the Company’s Common Stock (“Share Reserve”) for the amount then outstanding. Upon full conversion or repayment of this note, any shares remaining in such share reserve shall be cancelled and placed back into the treasury of the Company and available for issuance at a future date. On October 22, 2020, the Company issued to Jefferson Street 1,250,000 shares of its restricted common stock as debt commitment shares valued at $40,000 ($0.032 per share). At March 31, 2021, the note had accrued interest of $3,218. As of this report date, the Company has made all scheduled payments under this note.

On November 18, 2020, we consummated an inventory financing transaction and entered into (i) a Promissory Note in the aggregate principal amount of $110,000 with SE Holdings, LLC, a Nevada limited liability company (“SE”), and (ii) a Securities Purchase Agreement (“SPA”). The note has a maturity date of September 11, 2021, and carries $10,000 original issue discount, and guaranteed interest of 12%. Any amount of principal or interest on the note which is not paid when due shall bear interest at the rate of twenty four percent per annum from the due date thereof until the same is paid or converted in accordance with the terms of the note. Principal payments shall be made in five (5) installments, each in the amount of US$22,500.00 commencing one the fifth monthly anniversary following the issue date and continuing thereafter each thirty (30) days for five (5) months (assuming no defaults or partial or complete conversions of our Common Stock as a form of repayment). This note may not be converted by SE into shares of our Common Stock unless we default in our monthly repayment obligation pursuant to the cash repayment schedule noted above. In the event of a default of the note, SE shall have the right to convert all or any part of the outstanding and unpaid amount of the note into fully paid and non-assessable shares of Common Stock at the lowest market price for the preceding five trading days; provided, however, that in no event shall SE be entitled to convert any portion of the note in excess of that portion of the note upon the conversion of which would result in beneficial ownership by SE and its affiliates of more than 4.99% of the outstanding shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and Regulations 13D-G thereunder. The note contains a number of additional covenants and other provisions, including default or penalty clauses, cross-default, right to proceeds from other financings, reservation of share requirements and other such provisions, each as set forth in more detail in the note and SPA. At March 31, 2021, the note had accrued interest of $7,008 with the full principal balance due. As of this report date, the Company has made all scheduled payments under this note.

On March 5, 2021, the Company entered into a Securities Purchase Agreement and a non-convertible redeemable note with GS Partners Capital, LLC. The $273,000 aggregate principal note has a maturity date of December 5, 2021 and carries $5,000 original issue discount with an interest rate of 6%. This note may be prepaid without penalty, provided that an event of default has not occurred. Upon an event of default, interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. This note contains a number of additional covenants and other provisions, including default or penalty clauses, cross-default and other such provisions, each as set forth in more detail in the note and SPA. At March 31, 2021, the note had accrued interest of $1,167 with the full principal balance due.

During the year ended March 31, 2021, the Company issued 93,197,109 shares of common stock to holders of convertible notes to retire $1,588,926 in principal and $111,749 of accrued interest (at an average conversion price of $0.01825 per share) under the convertible notes.

During the year ended March 31, 2020, the Company issued 21,295,495 shares of common stock to holders of convertible notes to retire $467,500 and $28,762 of note principal and accrued interest, respectively (average conversion price of $0.0233 per share.)

Interest expense for the year ended March 31, 2021 was $1,093,071 compared to $902,228 during the prior year. Accrued interest at March 31, 2021 and 2020 was $14,722 and $39,384, respectively.

XML

Related Parties

12 Months Ended

Mar. 31, 2021

Related Party Transactions [Abstract]

Related Parties

NOTE 9 – RELATED PARTIES

On December 26, 2019, Chief Executive Officer, Seth Shaw, deposited $50,159 to be used for operating expenses. This is an interest free loan to the Company. During January and February 2021, Mr. Shaw was fully repaid, thus this note was fully repaid as of March 31, 2021.

In conjunction with and consideration for a July 22, 2019, 10% convertible note, in the amount of $55,000, under a Securities Purchase Agreement the Company entered into with Jefferson Street Capital, LLC, the Chief Executive Officer had personally guaranteed the prompt, full and complete payment of the outstanding principal amount, accrued and unpaid interest, default interest (if any) and applicable fees (if any), owing by the Company under the note. This personal guaranty was to remain in effect until such time that the Company was able to reserve at least six times the amount of common shares issuable upon full conversion of the note. As a result of the increase in the authorized shares taking effect on September 13, 2019, this personal guaranty was removed and the Company reserved the appropriate number of shares on October 2, 2019.

XML

Stockholders' Equity (Deficit)

12 Months Ended

Mar. 31, 2021

Equity [Abstract]

Stockholders' Equity (Deficit)

NOTE 10 – STOCKHOLDERS’ EQUITY (DEFICIT)

COMMON STOCK

As of March 31, 2021, the Company was authorized to issue 400,000,000 shares of its common stock. As of March 31, 2021 and June 28, 2021 there were 275,858,714 and 283,496,214 shares, respectively of common stock issued and outstanding.

S-1 Registration Statement and Investment Agreement with Tangiers Global, LLC.

On March 5, 2020, the Company filed an S-1 Registration Statement pursuant to the January 21, 2020, Investment Agreement and Registration Rights Agreement entered into Tangiers in order to establish a source of funding for our operations. Under the Investment Agreement, Tangiers agreed to provide us with a maximum of up to $5,000,000 of funding during the period ending three years from the date of effectiveness of the S-1 Registration Statement, under which we registered a maximum of 76,000,000 million shares for sale under the terms of the Investment Agreement. We were, in our sole discretion, allowed to deliver a Put Notice to Tangiers under this facility. The Put Notice would specify the number of shares of common stock which we intended to sell to Tangiers on a closing date. The closing of a purchase by Tangiers of the shares specified by us in the Put Notice would occur on the date which is no earlier than five and no later than seven trading days following the date Tangiers receives the Put Notice. On the closing date we would sell to Tangiers the shares specified in the Put Notice, and Tangiers would pay us an amount equal to the Purchase Price multiplied by the number of shares specified in the Put Notice.

The S-1 Registration statement became effective March 16, 2020. As of March 31, 2021, the Company has initiated put notices to Tangiers for a total of 13,910,000 shares receiving net proceeds in the amount of $400,514.

On January 6, 2021, the Company’s board of directors voted unanimously determined to terminate this equity line of credit facility by terminating each of the Investment Agreement and Registration Rights Agreement, and on January 8, 2021 filed a Post-Effective Amendment to its Form S-1 Registration Statement (333-236923) removing from registration all shares of common stock not previously sold thereunder.

Fiscal Year 2020

During the year ended March 31, 2020, the Company issued 2,450,000 shares under our various distribution agreements, as more fully described in Note 1. Common shares issued had a value of $496,261 ($0.08 to $0.2092 per share).

During the year ended March 31, 2020, the Company issued 21,295,495 shares for conversion of debt in the amount of $467,500 as well as accrued interest in the amount of $28,762 ($0.01412 to $0.04725 per share).

During the year ended March 31, 2020, the Company issued 250,000 shares issued to Vice President of Distribution and Marketing.

During the year ended March 31, 2020, the Company issued 7,100,000 shares issued for services rendered.

During the year ended March 31, 2020, the Company issued 2,350,000 shares for debt commitments in the amount of $218,460 ($0.039 to $0.19 per share).

During the year ended March 31, 2020, the Company recognized $569,636 in beneficial conversion feature for convertible notes whereby the holder can exercise conversion rights at a discount to the market price.

During the year ended March 31, 2020, the Company issued 5,470,286 shares under stock purchase agreements in consideration for $143,420 ($0.02 to $0.07 per share) to accredited investors that are unrelated third parties.

On March 27, 2020, the Company entered into a stock purchase agreement with an accredited investor to purchase 200,000 restricted shares of Company’s common stock for $5,000 ($0.025 per share.) As of this report date, these shares have not been issued.

Fiscal Year 2021

During the year ended March 31, 2021, the Company issued 13,910,000 shares pursuant to put notices issued to Tangiers under the equity line of credit facility, with the Company receiving proceeds in the amount of $369,482 ($0.02614 to $0.03344 per share).

During the year ended March 31, 2021, the Company issued 93,197,109 shares of common stock to holders of convertible notes to retire $1,588,926 in principal and $111,749 of accrued interest (at an average conversion price of $0.01825 per share) under the convertible notes.

During the year ended March 31, 2021, the Company issued 7,687,500 shares for services rendered ($0.0306 to $0.050 per share).

During the year ended March 31, 2021, the Company issued 5,740,000 shares for debt commitments in the amount of $253,869 ($0.028 to $0.092 per share).

During the year ended March 31, 2021, the Company recognized $208,806 in beneficial conversion feature for convertible notes whereby the holder can exercise conversion rights at a discount to the market price.

During the year ended March 31, 2021, the Company issued 40,084,998 shares under stock purchase agreements in consideration for $1,587,214 ($0.024 to $0.09 per share) to accredited investors that are unrelated third parties.

During the year ended March 31, 2021, the Company issued 2,500,000 shares to two directors at a value of $0.092 per share.

On July 10, 2020, the Company’s Chief Executive Officer purchased 700,000 shares of the Company’s Common Stock for an aggregate purchase price of $35,000, at $0.05 per share.

Pursuant to the April 3, 2020, collaboration agreement the Company entered into with Aegea Biotechnologies Inc. (“Aegea”) the Company issued to Aegea 5,000,000 unregistered common shares of Tauriga common stock. The shares were valued at $155,000 ($0.031 per share). For a more complete description of this arrangement please refer to Note 1 to the financial statements under the subheading “Collaboration Agreement with Aegea Biotechnologies Inc.” as well as the agreement exhibits related thereto.

In connection with some of the consulting agreements and board advisory agreements the Company has entered into, as the following clauses are part of the compensation arrangements: (a) the consultant will be reimbursed for all reasonable out of pocket expenses and (b) the Company, in its sole discretion, may make additional cash payments and/or issue additional shares of common stock to the consultant based upon the consultant’s performance. The Company recognized $1,019,814 and $569,636 in stock-based compensation expense related to these agreements in the year ended March 31, 2021 and 2020.

WARRANTS FOR COMMON STOCK

The following table summarizes warrant activity for the years ended March 31, 2021 and 2020:

				Weighted		Average
				Average		Remaining		Aggregate
				Exercise		Contractual		Intrinsic
	Shares			Price		Term		Value
Outstanding at March 31, 2019		1,210,276		$	1.2		1.28 Years	$	—
Granted		—			—				—
Expired		(488,011	)		0.75
Exercised		—			—
Canceled		—			—
Outstanding and exercisable March 31, 2020		722,265		$	1.19		0.83 Years	$	—
Granted		—			—				—
Expired		(722,265	)		—
Exercised		—			—
Canceled		—			—
Outstanding and exercisable March 31, 2021		—		$	—			$	—

During the year ended March 31, 2021, 722,265 seven-year warrants expired which were issued to Pilus Energy, LLC. These warrants had a strike price of $1.50.

During the year ended March 31, 2020, 488,011 three-year warrants expired which were awarded to investors in conjunction with security purchase agreements. These warrants had a strike price of $0.75.

STOCK OPTIONS

On February 1, 2012, the Company awarded to each of two executives’, one current and one former, options to purchase 66,667 common shares, an aggregate of 133,334 shares. These options vested immediately and were for services performed.

The following table summarizes option activity for the year ended March 31, 2021 and 2020:

					Weighted
			Weighted-		Average
			Average		Remaining		Aggregate
			Exercise		Contractual		Intrinsic
	Shares		Price		Term		Value
Outstanding at March 31, 2019		133,334	$	7.50		2.85 Years	$	—
Granted		—		—
Expired		—		—
Exercised		—		—
Outstanding at March 31, 2020		133,334	$	7.50		1.85 Years	$	—
Granted		—		—
Expired		—		—
Exercised		—		—
Outstanding and exercisable March 31, 2021		133,334	$	7.50		0.85 Years	$	—

XML

Provision for Income Taxes

12 Months Ended

Mar. 31, 2021

Income Tax Disclosure [Abstract]

Provision for Income Taxes

NOTE 11 – PROVISION FOR INCOME TAXES

Deferred income taxes are determined using the liability method for the temporary differences between the financial reporting basis and income tax basis of the Company’s assets and liabilities. Deferred income taxes are measured based on the tax rates expected to be in effect when the temporary differences are included in the Company’s tax return. Deferred tax assets and liabilities are recognized based on anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases.

The following table summarizes the significant differences between the U.S. Federal statutory tax rate and the Company’s effective tax rate for financial statement purposes for year and year ended March 31, 2021 and March 31, 2020:

	March 31, 2021			March 31,2020
Federal income taxes at statutory rate		21.00	%		21.00	%
State income taxes at statutory rate		0.00	%		0.00	%
Temporary differences		11.83	%		2.42	%
Permanent differences		0.03	%		(0.87	)%
Impact of Tax Reform Act		0.00	%		(0.00	)%
Change in valuation allowance		(32.86	)%		(22.55	)%
Totals		0.00	%		0.00	%

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry-forwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company recorded a valuation allowance.

	As of			As of
	March 31, 2021			March 31, 2020
Deferred tax assets:
Net operating losses before non-deductible items	$	4,586,526		$	4,269,938
Loss on disposal of fixed assets		-			613
Stock-based compensation		543,375			329,214
Unrealized gains (losses) on investments		164,666			(50,290	)
Total deferred tax assets		5,294,567			4,599,765
Less: Valuation allowance		(5,294,567	)		(4,599,765	)
Net deferred tax assets	$	-		$	-

At March 31, 2021, the Company had a U.S. net operating loss carry-forward in the approximate amount of $21.7 million available to offset future taxable income through 2038. The Company established valuation allowances equal to the full amount of the deferred tax assets due to the uncertainty of the utilization of the operating losses in future periods. The valuation allowance increased by $657,752 in the year ended March 31, 2021 and decreased by $657,980 in the year ended March 31, 2020. The net decreases were the result of the tax effects of the Tax Cuts and Jobs Act (the “TCJA”) offset by taxable losses net of timing differences in each of the years.

XML

Investments

12 Months Ended

Mar. 31, 2021

Investments, Debt and Equity Securities [Abstract]

Investments

NOTE 12 – INVESTMENTS

TRADING SECURITIES

For investments in securities of other companies that are owned, the Company records them at fair value with unrealized gains and losses reflected in other operating income or loss. For investments in these securities that are sold by us, the Company recognizes the gains and losses attributable to these securities investments as realized gains or losses in other operating income or loss on a first in first out basis.

Investment in Trading Securities:

At March 31, 2020

Company		Beginning of Period Cost		Purchases		Sales Proceeds		End of Period Cost		Fair Value		Realized Gain (Loss)		Unrealized Gain (Loss)
VistaGen Therapeutics Inc (VTGN)	(a)		287,500		-		-		287,500	$	101,200		-		(186,300	)
Basanite Inc. (BASA)	(b)		30,000		-		40,000		-		-		10,000		-
Totals		$	317,500	$	-	$	40,000	$	287,500	$	101,200	$	-	$	(186,300	)*

At March 31, 2021

Company		Beginning of Period Cost		Purchases		Sales Proceeds		End of Period Cost		Fair Value		Realized Gain (Loss)		Unrealized Gain (Loss)
VistaGen Therapeutics Inc (VTGN)	(a)		287,500		277,500		302,827		408,750	$	1,246050		146,577		837,300	*

*This amount represents the cumulative unrealized loss as of March 31, 2021 and March 31, 2020.

(a) On December 11, 2017 the Company invested $480,000 in the common stock of VistaGen Therapeutics, Inc. (VTGN). The Company purchased 320,000 common shares along with 320,000 five-year warrants with a strike price of $1.50. On March 26, 2018, the Company purchased an additional 10,000 common shares. The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company’s investment in VTGN has a cost of $490,117, unrealized loss of $183,910 and a fair value of $306,207 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 59,380 shares of VTGN for $61,998 (average price per share of $1.04 per share) in the open market. During the period of June 22, 2018 through August 1, 2018, the Company sold 389,380 shares of VTGN for $517,485 ($1.33 per share) for a realized loss of $34,630. The Company also purchased in a direct offering 230,000 restricted common shares directly from VTGN during the year ended March 31, 2019 for a cost of $287,500. On December 11, 2019, the Company purchased 250,000 three-year restricted warrant at a cost of $0.15 each (total value of $37,500). As of March 31, 2021, the Company has recognized an unrealized gain on these shares in the amount of $59,110, compared to an unrealized loss of $74,301 for the nine months ended December 31, 2019 in VTGN. As December 31, 2019, these shares were on deposit held with a broker. On December 29, 2020, the Company exercised 480,000 of its $0.50 warrants in VTGN. The new cost basis for these warrant shares is the $0.50 paid to covert each warrant in to shares (230,000 shares) as well as an addition $0.15 per share on the purchased options (250,000) shares. During February and March 2021, the Company sold 125,000 shares of VTGN for proceeds of $302,827. The Company recognized a gain on the sale of these shares of $146,577.

(b) On July 5, 2018, the Company purchased 100,000 shares of Basanite Industries Inc. (BASA) (formerly Paymeon, Inc. (PAYM)) for $12,998 ($0.13 per share) in the open market. During July 2018 the Company sold the 100,000 shares for $10,821 ($0.11 per share) for a realized loss of $2,177. On July 9, 2018, the Company purchased 400,000 restricted common shares directly from the Company for $30,000 ($0.075 per share). During the year ended March 31, 2020, the Company sold its 400,000 shares for $40,000 ($0.10 per share) recognizing a profit of $10,000.

At March 31, 2021, the Company held warrants for AYTU to purchase 5,555 common shares at a strike price of $10.80 with an expiration of March 6, 2023. The strike price and number of shares were adjusted for the August 10, 2018, 1 for 20 reverse stock-split and again on December 8, 2020, as a result of a 1 for 10 shares held (herein referred to collectively as the “Reverse Stock Split”). All share and per share amounts in this report have been adjusted to reflect the effect of the Reverse Stock Split. At March 31, 2021, these warrants were out of the money by $102.49 per share and are not publicly traded, and the Company has not recognized the value of these warrants as they are not liquid.

TRADING SECURITIES (CONTINUED)

On December 11, 2019, the Company purchased three year warrants exercisable for up to 250,000 shares of common stock of Vistagen Therapeutics Inc. at a cost of $0.15 each (total purchase price of $37,500). These warrants have a strike price of $0.50 each. As of March 31, 2021, these warrants were exercised, in full, and the resultant shares have a cost basis of $0.65 per share.

In addition to the 250,000 Vistagen warrants noted above, at March 31, 2021, the Company currently holds warrants in Vistagen to purchase 320,000 shares of common stock at a strike price of $1.50 per share with an expiration of December 13, 2022. At March 31, 2021 these warrants were in of the money by $0.44 each. The Company also owned warrants for Vistagen to purchase 230,000 shares of common stock at a strike price of $1.50 per share with an expiration of February 28, 2022. On December 4, 2019, Vistagen adjusted the strike price of the February 2022 warrants to $0.50 each. As of March 31, 2021, these warrants were exercised and the resultant shares have a cost basis of $0.50 per share. The Company still holds 320,000 total warrants at a strike price of $1.50 per share. Since these warrants are not publicly traded, the Company has not recognized the value of these warrants as they are not liquid.

On February 18, 2021, the Company’s board of directors authorized the open market sale of 220,000 of the 710,000 shares it holds in Vistagen Therapeutics Inc.

On May 18, 2021, the Company exercised 180,000 of its Vistagen Therapeutics, Inc. five-year $1.50 registered warrants for $270,000 cash.

EQUITY INVESTMENTS

COST BASED INVESTMENTS

SciSparc Ltd.

On March 1, 2021, the Company invested $88,375 for 12,500 units of SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments. The Company’s investment (acquisition of an equity stake with warrants) into SciSparc Ltd., was pursuant to an $8,150,000 private placement offering, comprised 1,152,628 Units to certain institutional and accredited investors in a private placement at an offering price of $7.07 per Unit. Each Unit consists of 1 American Depositary Share (“ADS”), 1 Series A Warrant and ½ Series B Warrant. The Series A Warrants have an exercise price of $7.07, subject to adjustments therein. The Series B Warrants have an exercise price equal to $10.60, subject to adjustments therein. The Series A Warrants and the Series B Warrants are exercisable six months from the date of issuance and have a term of exercise equal to five years from the initial exercise date. 278,744 of the Units included a Pre-Funded Warrant instead of an ADS. The Pre-Funded Warrants have an exercise price of $0.001 per full ADS. Aegis Capital Corp. acted as Exclusive Placement Agent in the United States in connection with the offering. The Company has recorded this investment at cost and will test for impairment annually.

Paz Gum LLC

Effective February 5, 2021, the Company purchased five percent of the membership units in Paz Gum LLC, a Nevada limited liability company under the terms of a Membership Unit Purchase Agreement for an aggregate purchase price of $50,000. The Company and Paz will endeavor to cross market and increase sales of our products, along with such other products that Paz Gum undertakes in their discretion.

COST BASED INVESTMENTS (CONTINUED)

Aegea Biotechnologies Inc.

On April 3, 2020, Tauriga Sciences, Inc. entered into a collaboration agreement (“Collaboration Agreement”) with Aegea Biotechnologies Inc. (“Aegea”), for the purpose of developing a Rapid, Multiplexed Novel Coronavirus (COVID-19) Point of Care Test with Superior Sensitivity and Selectivity (the “SARS-Col 2 Test”). The parties believed that the benefits of the SARS-CoV-2 Test were the following: a Rapid SARS-CoV-2 test with the sensitivity and specificity to eliminate false negatives and false positives, and with the ability to detect and measure viral shed, even in patients who are asymptomatic. This SARS-CoV-2 test would use Aegea’s patented technologies, to take coronavirus testing to the next level by differentiating different strains of SARS-CoV-2. The test, if successful, would be adaptable to additional SARS-CoV-2 strain types as necessary and as the virus mutates. It also has the possibility to be rapidly be customized to provide similarly sensitive and specific assays for other viruses. The Company committed to raise funding for the purposes set forth in under the Collaboration Agreement from its $5,000,000 Equity Line of Credit (“ELOC”) with Tangiers Global, LLC, which became effective on March 16, 2020. Seventy percent (70%) of the net proceeds from the sale of the initial 10,000,000 shares of stock of Tauriga under the ELOC were invested in Aegea for the development of the Covid Test and used to purchase shares of common stock of Aegea, at a purchase price of $4.00 per share. The $4.00 stock price corresponds to a current pre-money valuation of Aegea of $25,000,000 for each tranche of cash, up to the first $2,000,000 of our investment in Aegea. Additionally, as part of our agreement with Aegea, on May 26, 2020, Tauriga issued to Aegea 5,000,000 unregistered common shares of Tauriga common stock. On August 10, 2020, the Company and Aegea amended their Collaboration Agreement. Under the terms of the amendment, having invested 70% of the proceeds from the sale of the initial 10,000,000 shares of Tauriga stock under the ELOC with Tangiers, the Company increased the percentage of proceeds it invested in Aegea on the sale of the remaining shares available under the ELOC agreement from 20% to 40%.

On January 6, 2021, however, the Company determined to terminate its ELOC by terminating each of the Investment Agreement and Registration Rights Agreement, and on January 8, 2021 filed a Post-Effective Amendment to its Form S-1 Registration Statement (333-236923) which removed from registration all shares not previously sold thereunder. This effectively also eliminates our obligation to any additional funding to Aegea under the Collaboration Agreement. As of March 31, 2021, the Company had invested $278,212 in Aegea for 69,553 shares, representing an ownership percentage of 1.03%. As of March 31, 2021, resultant delays of project milestones have led the Company to determined that full recovery of its investment in Aegea is in doubt and has recorded a 50% impairment loss on its consolidated Statement of Operations in the amount of $139,106. Aegea is still moving forward on this project and the Company will continue to monitor the progress.

On February 26, 2021, as part of a settlement agreement concluding the Collaboration Agreement, the Company acquired an additional 69,552 common shares of Aegea, increasing the Company’s total holdings to 139,104 Aegea shares (representing a 2.04% stake in Aegea as of March 31, 2021).

Küdzoo, Inc.

As of March 31, 2020, the Company had invested, in a total of $105,600 in Küdzoo, Inc. (“Küdzoo”), a privately held company. Küdzoo is the developer of a mobile application that rewards students for their grades and achievements with deals and opportunities. The investments were recorded at cost and represents 0.2% of the value of Küdzoo based on a pre-money valuation of $10,200,000. The Company had made a total of six investments beginning September 4, 2018 and each were valued at the same pre-money valuation. As of March 31, 2021, the Company owned 1.41% of Küdzoo. As of March 31, 2021, it was discovered by the Company that Küdzoo has failed to raise sufficient capital to sustain ongoing operations. During its annual impairment testing the Company has fully impaired this investment and does not expect to recover any of its investment.

Serendipity

On October 31, 2018, the Company invested $35,000 in Serendipity Brands LLC (dba Serendipity Ice Cream Co.) (“Serendipity”), a privately held Company. Serendipity is an ice cream distribution company providing wholesale distribution to retail customers. The investment was recorded at cost and represents 0.24% of the value of Serendipity based on a pre-money valuation of approximately $14 million.

The Company tested the investment value for Serendipity as of March 31, 2021 for impairment. It was noted that the value of the company has maintained its value through reviews of their financial performance, therefore, the Company does not believe there is any impairment of this investment as of March 31, 2021.

XML

Fair Value Measurements

12 Months Ended

Mar. 31, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurements

NOTE 13 – FAIR VALUE MEASUREMENTS

The following summarizes the Company’s financial assets and liabilities that are measured at fair value on a recurring basis at March 31, 2021 and March 31, 2020:

	March 31, 2021
	Level 1		Level 2		Level 3		Total
Assets
Investment-trading securities	$	1,246,050	$	-	$	-	$	1,246,050
Cost method investment – Küdzoo	$	-	$	-	$	-	$	-
Cost method investment – Serendipity Brands	$	-	$	-	$	35,000	$	35,000
Cost method investment - Aegea Biotechnologies, Inc.	$	-	$	-	$	139,106	$	139,106

	March 31, 2020
	Level 1		Level 2		Level 3		Total
Assets
Investment-trading securities	$	101,200	$	-	$	-	$	101,200
Cost method investment – Küdzoo	$	-	$	-	$	105,600	$	106,600
Cost method investment – Serendipity Brands	$	-	$	-	$	35,000	$	35,000

XML

Concentrations

12 Months Ended

Mar. 31, 2021

Risks and Uncertainties [Abstract]

Concentrations

NOTE 14 – CONCENTRATIONS

During the year ended March 31, 2021, we had one supplier for our product CBD/CBG Tauri-Gum^TM. The Tauri-Gum^TM product line represents approximately 71% of net sales.

During the year ended March 31, 2020, we have one supplier for our Tauri-Gum^TM product which accounted for 100% sales for the year.

XML

Subsequent Events

12 Months Ended

Mar. 31, 2021

Subsequent Events [Abstract]

Subsequent Events

NOTE 15 – SUBSEQUENT EVENTS

Subsequent to March 31, 2021, the Company issued additional shares of common stock as follows: (i); 5,737,500 shares under consulting agreements, (ii) 1,800,000 shares of restricted common stock for commitment shares and (iii)2,300,000 shares of restricted common stock to accredited investors for proceeds totaling $174,000 (average of $0.0757/per share).

Subsequent to March 31, 2021, the Company received funds in the amount of $100,000 under a private placement agreement with an accredited investor to issue 2,500,000 shares of restricted common stock.

On May 18, 2021, the Company exercised 180,000 of its Vistagen Therapeutics, Inc. five-year $1.50 registered warrants for $270,000 cash. As of June 25, 2021 and subsequent to March 31, 2021, the Company has sold 485,000 shares of its holdings in Vistagen for proceeds of $1,153,645.

Corporate

On April 14, 2021, the Company formed NFTauriga Corp. in the State of Nevada, and wholly owned subsidiary. The Company is the sole holder of total authorized 100 shares having a par value of $0.00001. The Company’s Chief Executive Officer, Seth M. Shaw is the initial sole member of the board of directors, to serve until a successor is duly elected and qualified. Mr. Shaw will also serve as the Chief Executive Officer and Secretary. The registered office of NFTauriga Corp. in the State of Delaware shall be at 1013 Centre Road, Suite 403-B, Wilmington, DE 19805 in the County of New Castle. The name of its registered agent at such address is Vcorp Services, LLC. NFTauriga Corp. will have the same fiscal year and principal executive office and the Company.

Consulting agreements

On June 14, 2021, the Company entered into a 12-month Strategic Marketing and Consulting Agreement with Mayer & Associates. Under this agreement the Company will pay $150,000 along with the issuance of 3,500,000 shares of restricted common shares of Company stock. Half of the cash payment ($75,000) was paid upon execution of the agreement and the other half will be paid 90 days later. Upon execution, the Company shall issue 2,200,000 of the above-mentioned shares. The remaining 1,300,000 above-mentioned shares will be issued 90 days after this contract was executed. Mayer and Associate will provide the Company with opportunities relating to the world of professional sports, with respect to its products and product lines. This includes but is not limited to: introductions to professional sports leagues, celebrity (professional athletes) influencers/brand ambassadors/brand liaison(s), research and development opportunities, hosting of small periodic events for the Company and a diversified group of high-profile contacts and relationships, use social media exposure, podcasts backing of various elements from professional sports as well as assist the Company in advising of potential merger partners and developing corporate partnering relationships. The Company, at the sole discretion of its board, may pay an additional payment of $75,000 as permitted under this agreement. This additional payment will be recorded as a contingent liability on the Company consolidated balance sheet until formally authorized by the Company’s board of directors. This agreement is terminable after six months. As of the date of this annual report date the aforementioned shares have been issued and are reflected above in subsequent issuances.

Notes payable

Tangiers April 2021 Fixed convertible note ( $0.075 per share)

On April 5, 2021, the Company effectuated a $525,000 six-month fixed convertible promissory note with Tangiers Global, LLC containing an original issue discount of $25,000. This note matures on October 5, 2021 and bears an interest rate of 8%, guaranteed. This note has a fixed conversion price of $0.075 per share. The Company may redeem the note by paying to Tangiers an amount as follows: (i) if within the first 90 days of the issuance date, then for an amount equal to 110% of the unpaid principal amount so paid of this Note along with any interest that has accrued during that period, and (ii) if after the 91st day, but by the 180^th day of the issuance date, then for an amount equal to 120%. After 180 days from the effective date, the Company may not pay this note in cash, in whole or in part without prior written consent by Holder. The Company covenants that it will at all times reserve out of its authorized and unissued Common Stock the number of shares of Common Stock as shall be issuable upon the conversion of this note. Tangiers may not engage in any “shorting” or “hedging” transaction(s) in the Common Stock of the Company prior to conversion. The note contains a number of additional covenants and other provisions, including default or penalty clauses, cross-default, restrictions on note proceeds, maintain exchange and SEC requirements, delivery of shares, reservation of share requirements and other such provisions, each as set forth in more detail in the note and SPA. If an Event of Default occurs, the outstanding Principal Amount of this Note owing in respect thereof through the date of acceleration, shall become, at the Tangiers’s election, immediately due and payable in cash at the “Mandatory Default Amount”. The Mandatory Default Amount means 20% of the outstanding Principal Amount of this Note will be automatically added to the Principal Sum of the Note and tack back to the Effective Date for purposes of Rule 144. Commencing 5 days after the occurrence of any Event of Default that results in the eventual acceleration of this Note, this Note shall accrue additional interest, at a rate equal to the lesser of 18% per annum or the maximum rate permitted under applicable law. The Company has issued 1,000,000 of its restricted common debt incentive shares having a value of $129,000 ($.0129/share).

GS Capital Partners, LLC. Non-convertible debenture

On April 30, 2021, the Company entered into a Securities Purchase Agreement and a non-convertible redeemable note with GS Capital Partners, LLC. The $313,000 aggregate principal note has a maturity date of June 1, 2022 and carries $23,000 Original Issue Discount with an interest rate of 8%. This note may be prepaid without penalty, provided that an event of default has not occurred. Upon an event of default, interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. This note contains a number of additional covenants and other provisions, including default or penalty clauses, cross-default and other such provisions, each as set forth in more detail in the note and SPA.

XML

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Consolidated Financial Statements

CONSOLIDATED FINANCIAL STATEMENTS

These consolidated financial statements include the accounts and activities of Tauriga Sciences, Inc., its wholly-owned Canadian subsidiary, its wholly-owned subsidiary Tauriga Pharma Corp. (f/k/a Tauriga Biz Dev Corp – or “Tauriga BDC” and referenced herein as Tauriga BDC for contextual purposes only in describing the Blink contractual arrangement) and Tauriga Sciences Limited. All intercompany transactions have been eliminated in consolidation. As of March 31, 2021 and 2020, there is no activity in any of the Company’s subsidiaries other than Tauriga Pharma Corp. holding the electric car chargers.

Segment Information

SEGMENT INFORMATION

The Company has adopted provisions of ASC 280-10 Segment Reporting for the years ended March 31, 2021 and 2020. This standard requires that companies disclose operating segments based on the manner in which management disaggregates the Company in making internal operating decisions. The Company and its Chief Operating Decision Makers determined that the Company’s operations consist of two segments: (i) The first division consists of all retail, wholesale and e-commerce product sales of CBD/CBG Tauri-Gum^TM, Tauri-Gummies^TM, and other CBD/CBG products, and (ii) the second segment will be a research and development division that consist of liabilities and results from any activity relative to the progress in the development of the Company’s FDA IND application for Phase II Trial of its proposed pharmaceutical grade version of Tauri-Gum™. The cost basis investment in Aegea has been treated as a non-operating asset and will therefore not be reported as a part of the research and development division.

	Tauri-gum			Pharma			Adjustments, eliminations and unallocated items		Consolidated
Total revenue, net	$	285,319		$	-		$	-	$	285,319
Cost of Sales		(162,627	)		-			-		(162,627	)
Gross Profit		122,692			-			-		122,692
General and Administrative expense		2,778,282			80,675			-		2,858,957
Research and development		50,885			222,500			-		273,385
Selling and fulfillment expense		379,824			-			-		379,824
Operating Loss	$	(2,761,045	)	$	(303,175	)	$	-	$	(3,389,474	)
Total Assets	$	2,288,263		$	200,440		$	-	$	2,488,703
Total Liabilities	$	1,076,038		$	141,418		$	-	$	1,217,456

Revenue Recognition

REVENUE RECOGNITION

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective October 1, 2017 as the Company commenced sales of HerMan® using the full retrospective method. The new standard did not have a material impact on its financial position and results of operations, as it did not change the manner or timing of recognizing revenue.

Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.

On March 29, 2018 the Company, through Tauriga BDC, entered into an independent sales representative agreement with Blink to be a non-exclusive independent sales representative. Under the agreement with Blink, the Company may solicit orders from potential customers for EV charging station placement. On June 29, 2018, the Company purchased four Blink Level 2 - 40” pedestal chargers for permanent placement in a retail location or locations whereby the Company will pay a variable annual fee based on 7% of total revenue per charging unit. The remainder of the proceeds will be split 80/20 between the Company and the host location owner or its assignee. The host location owner will pay for the cost of providing power to these unit as well as installation costs. As of March 31, 2021, we have not installed any of these machines in any locations, and no revenue has been generated through the Blink contract. The Company has decided to abandon this business line, and therefore, we have reclassified these assets as held for sale.

The Company recognizes revenue upon the satisfaction of the performance obligation. The Company considers the performance obligation met upon shipment of the product or delivery of the product. For ecommerce orders, the Company’s products are shipped by a fulfillment company and payment is made in advance of shipment either through credit card or PayPal. The Company also delivers the product to its customers that they market to in the metropolitan New York Tri-State area that are not covered under any existing distribution agreements. The Company generally collects payment within 30 to 60 days of completion of its performance obligation, and the Company has no agency relationships. The Company recognized net revenue from operations in the amount of $285,319 during the year ended March 31, 2021 compared to $234,389 for the prior year. All revenue is from the sale of the Company’s Tauri-Gum^TM product line and there were accounts receivable, net of allowance for doubtful accounts in the amount of $7,015 outstanding for these sales, as of March 31, 2021.

Allowance for Doubtful Accounts

ALLOWANCE FOR DOUBTFUL ACCOUNTS

The Company maintains an allowance for doubtful accounts, which includes sales returns, sales allowances and bad debts. The allowance adjusts the carrying value of trade receivables for the estimate of accounts that will ultimately not be collected. An allowance for doubtful accounts is generally established as trade receivables age beyond their due dates, whether as bad debts or as sales returns and allowances. As past due balances age, higher valuation allowances are established, thereby lowering the net carrying value of receivables. The amount of valuation allowance established for each past-due period reflects the Company’s historical collections experience, including that related to sales returns and allowances, as well as current economic conditions and trends. The Company also qualitatively establishes valuation allowances for specific problem accounts and bankruptcies, and other accounts that the Company deems relevant for specifically identified allowances. The amounts ultimately collected on past-due trade receivables are subject to numerous factors including general economic conditions, the financial condition of individual customers and the terms of reorganization for accounts exiting bankruptcy. Changes in these conditions impact the Company’s collection experience and may result in the recognition of higher or lower valuation allowances. At March 31, 2021, the Company has established an allowance for doubtful accounts in the amount of $93,550.

Sales Refunds

SALES REFUNDS

The Company’s refund policy allows customers to return product for any reason except where the customer does not like the taste of the product. The customer has 30 days from the date of purchase to initiate the process. Returns are limited to one return or exchange per customer. Only purchases up to $100 qualify for a refund. Approved return/refund requests are typically processed within 1-2 business days. For product purchases made through a Tauri-Gum^TM distributor or retailer, the customer is required to work with original purchase location for any return or exchange. The Company has not established a reserve for returns as of March 31, 2021 however will monitor the refunds to estimate whether a reserve will be required.

Use of Estimates

USE OF ESTIMATES

The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash Equivalents

CASH EQUIVALENTS

For purposes of reporting cash flows, cash equivalents include investment instruments purchased with an original maturity of three months or less. At March 31, 2021, the Company’s cash on deposit with financial institutions did not exceed the total FDIC insurance limit of $250,000. At March 31, 2021 and March 31, 2020, the Company had a cash balance of $49,286 and $5,348, respectively. The Company’s does not expect, in the near term, for its cash balance to exceed the total FDIC insurance limit of $250,000 for other than very short periods of time where the Company would use such cash in excess of insurance in the very short-term in operating activities. To reduce its risk associated with the failure of such financial institution, the Company holds its cash deposits in more than one financial institution and evaluates at least annually the rating of the financial institution in which it holds its deposits. The Company had no cash equivalents as of March 31, 2021 and March 31, 2020.

Investment in Trading Securities

INVESTMENT IN TRADING SECURITIES

Investment in trading securities consist of investments in shares of common stock of companies traded on public markets as well as publicly traded warrants of these companies should there be a market for them. These securities are carried on the Company’s balance sheet at fair value based on the closing price of the shares owned on the last trading day before the balance sheet date of this report. Fluctuations in the underlying bid price of the stocks result in unrealized gains or losses. The Company recognizes these fluctuations in value as other income or loss. For investments sold, the Company recognizes the gains and losses attributable to these investments as realized gains or losses in other income or loss.

Investment - Cost Method

INVESTMENT – COST METHOD

Investment in other companies that are not currently trading, are valued based on the cost method as the Company holds less than 20% ownership in these companies and has no influence over operational and financial decisions of the companies. The Company will evaluate, at least annually, whether impairment of these investments is necessary under ASC 320. As of March 31, 2021, the Company has recorded a loss on the impairment on two of its cost method investments in the amount of $244,706. The Company did not record a loss on the impairment on investments for the year ended March 31, 2020.

Inventory

INVENTORY

Inventory consists of finished goods in salable condition stated at the lower of cost or market determined by the first-in, first-out method. The inventory consists of packaged and labeled salable inventory. Shipping of product to finished good inventory fulfilment center is also included in the total inventory cost. Shipping of product upon sale for e-commerce sales is paid by the customer upon ordering for orders of single packs of Tauri-Gum^TM. For multiple pack or wholesale product orders shipping cost is paid by the Company. As of March 31, 2021, the Company’s inventory on hand had a value of $201,372. The Company has not established any inventory reserve on the Tauri-Gum^TM as of March 31, 2021. As of March 31, 2021, the Company had $423,200 in funds paid for inventory not received.

Shipping and Handling Costs

SHIPPING AND HANDLING COSTS

The Company’s fulfillment handling costs are provided by independent contractors through fixed fee arrangements which may also include incentives. These fees also contain a large degree of consultative, administrative and warehousing services as part of the fixed fee. Management believes that due to these factors it is more representative to include these amounts as general and administrative costs instead of cost of goods sold. For the year ended March 31, 2021, the Company incurred fulfillment costs in the amount of $106,519 and $42,050, respectively.

Shipping cost for the Company consists of product movement to and from trade shows, between office locations, mailing of samples and product shipments. The cost of shipping is typically not charged to the customer when they order more than one product from on the website. Customer shipping of large customers wholesale orders are done on a reimbursement basis therefore any shipping revenue and shipping expense are largely recorded as offsetting gross revenues and cost of goods sold. The Company had net shipping expense:

	Year Ended March 31,
	2021			2020
Shipping revenue	$	6,240		$	24,438
Shipping expense		(24,693	)		(31,114	)
Net shipping expense	$	(18,453	)	$	(6,706	)

Property and Equipment

PROPERTY AND EQUIPMENT

Property and equipment are stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.

Intangible Assets

INTANGIBLE ASSETS

Intangible assets consisted of licensing fees and a patent prior to being impaired which were stated at cost. Licenses were amortized over the life of the agreement and patents were amortized over the remaining life of the patent at the date of acquisition.

Net Loss Per Common Share

NET LOSS PER COMMON SHARE

The Company computes per share amounts in accordance with FASB ASC Topic 260 “Earnings per Share” (“EPS”), which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of common stock and common stock equivalents outstanding during the periods; however, potential common shares are excluded for period in which the Company incurs losses, as their effect is anti-dilutive. For the years ended March 31, 2021 and 2020, basic and fully diluted earnings per share were the same as the Company had losses in this period.

Stock-Based Compensation

STOCK-BASED COMPENSATION

The Company accounts for Stock-Based Compensation under ASC 718 “Compensation-Stock Compensation,” which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.

The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, “Equity-Based Payments to Non-Employees.” Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted on the grant date as either the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in stockholders’ equity over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.

The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value on the grant date of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services over the term of the related services.

Impairment of Long-Lived Assets

IMPAIRMENT OF LONG-LIVED ASSETS

Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if it’s carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.

Research and Development

RESEARCH AND DEVELOPMENT

The Company expenses research and development costs as incurred. Research and development costs were $273,385 and $6,923 for the years ended March 31, 2021 and 2020, respectively. The Company is continually evaluating products and technologies, and incurs expenses relative to these evaluations, including in the natural wellness space, such as Tauri-Gum™ product development of new flavor formulations and other CBD delivery products, as well as development of a Cannabigerol (“CBG”) Isolate Infused version of its Tauri-Gum™ brand. We also incur expenses relative to collaboration agreements and any activity relative to the progress in the development of the Company’s FDA IND application for Phase II Trial of its proposed pharmaceutical grade version of Tauri-Gum™, as well as intellectual property or other related technologies. As the Company investigates and develops relationships in these areas, resultant expenses for trademark filings, license agreements, website and product development and design materials will be expensed as research and development. Some costs will be accumulated for subsidiaries prior to formation of any new entities.

Fair Value Measurements

FAIR VALUE MEASUREMENTS

ASC 820 “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosure about fair value measurements.

The following provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which fair value is observable:

Level 1- fair value measurements are those derived from quoted prices (unadjusted in active markets for identical assets or liabilities);

Level 2- fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

Level 3- fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Financial instruments classified as Level 1 – quoted prices in active markets include cash.

These consolidated financial instruments are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment to estimation. Valuations based on unobservable inputs are highly subjective and require significant judgments. Changes in such judgments could have a material impact on fair value estimates. In addition, since estimates are as of a specific point in time, they are susceptible to material near-term changes. Changes in economic conditions may also dramatically affect the estimated fair values.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management for the respective periods. The respective carrying value of certain financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, investments, short-term notes payable, accounts payable and accrued expenses.

Reclassifications

RECLASSIFICATIONS

Certain prior year amounts have been reclassified to conform to the current period presentation. The reclassifications had no effect on the net loss or cash flows of the Company.

Share Settled Debt

SHARE SETTLED DEBT

The general measurement guidance in ASC 480 requires obligations that can be settled in shares with a fixed monetary value at settlement to be carried at fair value unless other accounting guidance specifies another measurement attribute. The Company has determined that ASC 835-30 is the appropriate accounting guidance for the share-settled debt, which is what was done by setting up the debt discount which is to be amortized to interest expense over the term of the instrument. Amortization of discounts are to be amortized using the effective interest method over the term of the note.

ASC 480-10-25-14 requires liability accounting for (1) any financial instrument that embodies and unconditional obligation to transfer a variable number of shares or (2) a financial instrument other than an outstanding share that embodies a conditional obligation to transfer a variable number of shares, provided that the monetary value of the obligation is based solely or predominantly on any of the following: 1. A fixed monetary amount known at inception (e.g. stock settled debt); 2. Variations in something other than the fair value of the issuer’s equity shares (e.g. a preferred share that will be settled in a variable number of common shares with tits monetary value tied to a commodity price); and 3. Variations in the fair value of the issuer’s equity shares, but the monetary value to the counterparty moves inversely to the value of the issuer’s shares (e.g. net share settled written put options, net share settled forward purchase contracts).

Notwithstanding the fact that the above instruments can be settled in shares, FASB concluded that equity classification is not appropriate because instruments with those characteristics do not expose the counterparty to risks and rewards similar to those of an owner and, therefore do not create a shareholder relationship. The issuer is instead using its shares as the currency to settle its obligation.

The Company has multiple notes that contain discount provisions whereby the holder can exercise conversion rights at a discount to the market price for a 15 or 20 day trailing period based on the market volume average weighted price. ASC 470-20 defines this as a beneficial conversion feature which that shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value, not to exceed the face value of the note, to additional paid in capital. This segmented value, is to be amortized using the effective interest method over the term of the note.

Income Taxes

INCOME TAXES

Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases.

Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized, or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized.

ASC 740 “Income Taxes” clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.

As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by ASC 740 and concluded that the tax position of the Company does not meet the more-likely-than-not threshold as of March 31, 2021.

Recent Accounting Pronouncements

RECENT ACCOUNTING PRONOUNCEMENTS

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contract’s in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the impact that this new guidance will have on its consolidated financial statements.

In June 2018, the FASB issued ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” which addresses accounting for issuance of all share-based payments on the same accounting model. Previously, accounting for share-based payments to employees was covered by ASC Topic 718 while accounting for such payments to non-employees was covered by ASC Subtopic 505-50. As it considered recently issued updates to ASC 718, the FASB, as part of its simplification initiatives, decided to replace ASC Subtopic 505-50 with Topic 718 as the guidance for non-employee share based awards. Under this new guidance, both sets of awards, for employees and non-employees, will essentially follow the same model, with small variations related to determining the term assumption when valuing a non-employee award as well as a different expense attribution model for non-employee awards as opposed to employee awards. The ASU is effective for public business entities beginning in 2019 calendar years and one year later for non-public business entities. The Company has determined that there is not a material impact on their consolidated financial position and results of operations as a result of this standard.

In February 2016, FASB issued ASU 2016-02, “Leases (Topic 842).” The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The new guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period and is applied retrospectively. The Company has adopted this standard as of April 1, 2019 (See Note 7).

There are several other new accounting pronouncements issued or proposed by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial position or operating results.

Subsequent Events

SUBSEQUENT EVENTS

In accordance with ASC 855 “Subsequent Events” the Company evaluated subsequent events after the balance sheet date through the date of issuance of this report.

XML

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Schedule of Segment Information

	Tauri-gum			Pharma			Adjustments, eliminations and unallocated items		Consolidated
Total revenue, net	$	285,319		$	-		$	-	$	285,319
Cost of Sales		(162,627	)		-			-		(162,627	)
Gross Profit		122,692			-			-		122,692
General and Administrative expense		2,778,282			80,675			-		2,858,957
Research and development		50,885			222,500			-		273,385
Selling and fulfillment expense		379,824			-			-		379,824
Operating Loss	$	(2,761,045	)	$	(303,175	)	$	-	$	(3,389,474	)
Total Assets	$	2,288,263		$	200,440		$	-	$	2,488,703
Total Liabilities	$	1,076,038		$	141,418		$	-	$	1,217,456

Schedule of Shipping Expense

The Company had net shipping expense:

	Year Ended March 31,
	2021			2020
Shipping revenue	$	6,240		$	24,438
Shipping expense		(24,693	)		(31,114	)
Net shipping expense	$	(18,453	)	$	(6,706	)

XML

Revenue (Tables)

12 Months Ended

Mar. 31, 2021

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation Revenue

The following table disaggregates the Company’s net revenue by sales channel for the years ended March 31:

	2021		2020
Revenue:
Distributor	$	-	$	62,441
E-Commerce		233,995		34,439
Wholesale		51,324		137,509
	$	285,319	$	234,389

XML

Inventory (Tables)

12 Months Ended

Mar. 31, 2021

Inventory Disclosure [Abstract]

Schedule of Inventory

The following chart is the inventory value by product as of: 

	March 31, 2021		March 31, 2020
CBD/CBG Tauri-GumTM	$	173,207	$	120,480
Tauri-GummiesTM		22,829		4,029
Other Gummies (1)		-		2,425
Other (2)		5,336		1,776
Total Inventory	$	201,372	$	128,710

(1)	This segment of inventory is stock that was purchased in conjunction with Resale Agreement with OG Laboratories, LLC.
(2)	Other inventory consists of holiday pouches sold as a bundled of Tauri-GumTM, other CBD products and skin care.

XML

Property and Equipment (Tables)

12 Months Ended

Mar. 31, 2021

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

The Company’s property and equipment is as follows:

	March 31, 2021			March 31, 2020			Estimated Life
Computers, office furniture and other equipment	$	24,789		$	69,638		3-5 years
Less: accumulated depreciation		(1,642	)		(56,160	)
Net	$	23,147			13,478

XML

Leasehold Improvements (Tables)

12 Months Ended

Mar. 31, 2021

Leases [Abstract]

Schedule of Leasehold Improvements

	March 31, 2021			March 31, 2020		Expected Usage
Wappingers Falls office signage and sales display	$	5,000		$	-	48 months
Less: amortization		(313	)		-
Net	$	4,687			-

XML

Operating Lease (Tables)

12 Months Ended

Mar. 31, 2021

Leases [Abstract]

Schedule of Operating Lease Cost

The following chart shows the Company’s operating lease cost for the years ended March 31, 2021 and 2020:

	For the year ended March 31,
	2021		2020
Amortization of right of lease asset	$	10,311	$	13,233
Lease interest cost		2,324		1,666
Total Lease cost	$	12,635	$	14,899

Schedule of Maturity of Operating Lease Liability

Maturity of Operating Lease Liability for fiscal year ended March 31,
2022	$	14,426
2023		16,201
2024		18,990
2025		14,910
Total lease payments	$	64,527

Schedule of Right of Use Asset and Operating Lease Liability

	March 31, 2021		March 31, 2020
Right of Use (ROU) asset	$	64,301	$	22,090

	March 31, 2020		March 31, 2020
Operating lease liability:
Current	$	14,426	$	13,891
Non-Current		50,100		8,933
Total	$	64,526	$	22,824

XML

Notes Payable (Tables)

12 Months Ended

Mar. 31, 2021

Debt Disclosure [Abstract]

Schedule of Convertible Notes

CONVERTIBLE NOTES

		March 31, 2021			March 31, 2020
GS Capital Partners LLC – Mar 2019	(a)		-			175,000
GS Capital Partners LLC – Jun 2019	(b)		-			60,000
Odyssey Funding, LLC – Sep 2019	(c)		-			80,000
BHP Capital NY Inc. – Oct 2019	(d)		-			55,000
Tangiers Global, LLC – Nov 2019	(e)		-			137,500
Odyssey Funding, LLC – Dec 2019	(f)		-			100,000
Jefferson Street Capital LLC – Dec 2019	(g)		-			55,000
BHP Capital NY Inc. – Jan 2020	(h)		-			44,000
ADAR Alef, LLC – Jan 2020	(i)		-			44,000
GS Capital LLC – Jan 2020	(j)		-			110,000
Tangiers Global, LLC – Feb 2020	(k)		-			65,000
Crown Bridge Partners, LLC – Feb 2020	(l)		-			55,000
ADAR Alef, LLC – Mar 2020	(m)		-			44,000
Tangiers Global, LLC – Mar 2020	(n)		-			43,050
GS Capital Partners, LLC – Apr 2020	(o)		-			-
ADAR Alef, LLC – Apr – 2020	(p)		-			-
Tangiers Global, LLC – May 2020	(q)		-			-
First Fire Investments – May 2020	(r)		-			-
GS Capital LLC – Jun 2020	(s)		-			-
Tangiers Global, LLC – Jun 2020	(t)		-			-
Tangiers Global, LLC – Dec 2020	(u)		-			-
Total notes payable and convertible notes		$	-		$	1,067,550
Less – note discounts			(-	)		(482,416	)
Less – current portion of these notes			(-	)		(585,134	)
Total notes payable and convertible notes, net discounts		$	-		$	-

(a)   On March 14, 2019, the Company entered into a 12-month $300,000 principal face value 8.0% convertible debenture with GS Capital, with a maturity date of March 13, 2020. The GS Capital Note carried a $20,000 original issue discount (OID) and, as such, the initial net proceeds to the Company was $280,000. In connection with this agreement, the Company was obligated to issue 750,000 commitment shares having a value of $142,500 ($0.19 per share) which is reflected as interest expense in the Company’s consolidated statement of operations during the year ended March 31, 2019. These shares were issued on June 20, 2019. The Holder was entitled, at its option, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company’s common stock at a price for each share of Common Stock equal to 68% of the lowest daily VWAP of the Common Stock as reported on the National Quotations Bureau OTC Markets exchange for the fifteen (15) prior trading days. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the full-face value of the note which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. Also, in conjunction with this note, the 213,334 five-year cashless warrants, associated with the June 27, 2017, $80,000 5% one-year note were fully cancelled. As of March 31, 2021, the noteholder fully converted the $300,000 of principal and $26,009 of accrued interest into 14,473,254 shares of the Company’s common stock ($0.0225 per share). Upon conversion, the balance of the share reserve was returned to treasury.

(b) On June 21, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note had a maturity date of June 21, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on June 21, 2019). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 2,650,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the “Share Reserve”) and maintain a 2.5 times reserve for the amount then outstanding. On June 3, 2020, the noteholder converted the entire $60,000 of principal and $4,937 of accrued interest into 3,162,115 shares of common stock ($0.0205 per share) and the balance of the reserved shares were returned to the treasury.

(c) On September 13, 2019, the Company entered into a one year 8% $100,000 Convertible Note with Odyssey Funding, LLC (“Investor”) pursuant to the terms of a Securities Purchase Agreement (the “Odyssey Note”). The Odyssey Note has a maturity date of September 13, 2020 and carried a $5,000 original issue discount (such that $95,000 was funded to the Company at closing). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the Odyssey Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 64% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the Odyssey Note, the Company issued irrevocable transfer agent instructions reserving 22,727,000 shares (the “Share Reserve”) of its Common Stock for conversions under this Note. As of March 31, 2021, the full principal of $100,000 and accrued interest in the amount of $4,443 as well as $500 in fees were converted into 5,543,332 shares of common stock ($0.0188 per share). Upon conversion, all shares remaining in the Share Reserve were cancelled and returned to the treasury.

(d) On October 17, 2019, the Company entered into a Convertible Promissory Note (“BHP Note”), bearing an interest rate of 10% per annum, pursuant to a Securities Purchase Agreement with BHP Capital NY, Inc. dated October 7, 2019. The BHP Note had a maturity date of July 3, 2020 and carried a $5,000 original issue discount (such that $50,000 was funded to the Company on October 8, 2019). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the BHP Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Holder was entitled to deduct $500 from the conversion amount in each Notice of Conversion to cover Holder’s deposit fees associated with each Notice of Conversion. The Borrower was required at all times to have authorized and reserved three times the number of shares that would be issuable upon full conversion of the Note (assuming that the 4.99% limitation is not exceeded) in effect, initially 7,000,000 shares. On October 16, 2019, the Company issued 250,000 commitment shares to noteholder, BHP Capital NY, Inc. pursuant to the BHP Note. The shares had a value of $9,750 ($0.039 per share) which was recorded as interest expense on the Company’s consolidated balance sheet. As of March 31, 2021, the noteholder converted the full principal of $55,000, accrued interest in the amount of $2,795 as well as $500 in fees into 3,060,931shares of common stock ($0.0191 per share). Upon conversion, all shares remaining in the Share Reserve were cancelled and returned to the treasury.

(e)   On November 7, 2019, the Company effectuated a nine-month convertible promissory note with Tangiers Global, LLC (the “Tangiers Note”). The Company received funds in the amount of $125,000 after reduction of the Original Issue Discount of $12,500. The $137,500 face value note matured on August 5, 2020 and bears and interest rate of 10%, guaranteed. The Note holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the Tangiers Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty (20) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Holder may not engage in any “shorting” or “hedging” transaction(s) in the Common Stock of the Company prior to conversion. In connection with the Tangiers Note, the Company issued irrevocable transfer agent instructions reserving 35,000,000 shares (the “Share Reserve”) of its Common Stock for conversions under this Note, which Share Reserve has since been reduced as a result of conversions and other transactions between the parties. As of March 31, 2021, Tangiers fully converted all outstanding principal of $137,500 and accrued interest of $13,750 under this note. Interest on this note was guaranteed and prorated over the term of the note. Note principal and interest totaling $151,250 converted into 8,839,041 shares (average of $0.017112 per share). As a result, this note is fully repaid and retired and no further obligations or remuneration is due and owing thereunder, and any remaining shares of common stock in the Share Reserve were returned to treasury.

(f)   On December 18, 2019, the Company entered into a one year 8% $100,000 Convertible Note with Odyssey Capital, LLC (“Odyssey”) pursuant to the terms of a Securities Purchase Agreement (the “Odyssey Note”). The Odyssey Note has a maturity date of December 18, 2020 and carried a $5,000 original issue discount (such that $95,000 was funded to the Company at closing). The Investor was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the Odyssey Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 64% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the Odyssey Note, the Company issued irrevocable transfer agent instructions reserving 22,084,000 shares (the “Share Reserve”) of its Common Stock for conversions under this Odyssey Note. As of March 31, 2021, the Company fully paid and retired this note including accrued interest $4,252 and a prepayment penalty in the amount of $45,748. Upon full conversion of this note, any shares remaining in the Share Reserve were returned to treasury.

(g) On December 26, 2019, the Company entered into a one year 10% $55,000 Convertible Note with Jefferson Street Capital LLC (“Jefferson Street”) pursuant to the terms of a Securities Purchase Agreement (the “Jefferson Street Note”). The Jefferson Street Note had a maturity date of December 26, 2020 and carried a $5,000 original issue discount (such that $50,000 was funded to the Company at closing). The Investor was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the Jefferson Street Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Commencing on the date which is 180 days following the date of this Jefferson Street Note and ending on the later of: (i) the Maturity Date and (ii) the date of payment of the Default Amount, this Jefferson Street Note may be converted by Jefferson Street in whole or in part at any time from time to time after the Issue Date as noted in the Jefferson Street Note. In connection with the Jefferson Street Note, the Company was required at all times to have authorized and reserved six times the number of common shares that would be issuable upon full conversion of the Jefferson Street Note in effect, initially reserved at 20,000,000 common shares (the “Share Reserve”) of its Common Stock for conversions under this Jefferson Street Note. Upon full conversion of this note, remaining in the Share Reserve were cancelled. As of March 31, 2021, the noteholder converted the full principal of $55,000 plus accrued interest of $2,750 and $1,000 in fees for 3,095,362 shares of common stock ($0.01898 per share). Upon full conversion of this note, any shares remaining in the Share Reserve were returned to treasury.

(h) On January 3, 2020, the Company entered into a one-year 2% $44,000 Convertible Promissory Note with BHP Capital NY Inc. (“BHP Capital”) pursuant to the terms of a Securities Purchase Agreement (the “BHP Capital Note”). The BHP Capital Note has a maturity date of January 3, 2021 and carries a $4,000 original issue discount (such that $40,000 was funded to the Company at closing). Subsequent to this note funding, BHP exercised a most favored nations clause increasing this notes interest rate to 8%, based on subsequent notes issued by the Company. BHP had the right from time to time, and at any time after closing, to convert all or any amount of the principal face amount of the BHP Capital Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest one-day volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty (20) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the BHP Capital Note, the Company issued irrevocable transfer agent instructions pursuant to which the Company is required at all times to have reserved three times the number of shares that would be issuable upon full conversion of the Note (assuming that the 4.99% beneficial ownership limitation is not in effect) (based on the respective Conversion Price of the Note in effect from time to time, initially 14,100,000 shares of its Common Stock (the “Share Reserve”) for conversions under this BHP Capital Note. As of March 31, 2021, the noteholder fully converted the full principal of $44,000 plus accrued interest of $2,290 and $1,000 fees for 3,095,362 common shares ($0.01512 per shares). Upon full conversion of this note, any shares remaining in the Share Reserve were returned to treasury.

(i) On January 15, 2020, the Company entered into security purchase agreement with Adar Alef, LLC whereby the Company issued an 8% convertible redeemable note in the principal amount of $44,000. The note was funded with net proceeds of $37,800 after the deduction of $4,000 for OID and $2,200 in legal fees. The note has a maturity date of January 15, 2021. The face value amount plus accrued interest under the note are convertible into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the 20 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. The Company established an initial reserve of 6,296,000 shares of its common stock and at all times reserve a minimum of 4 times the amount of shares required if the note were to fully convert. As of March 31, 2021, the noteholder converted the full principal of $44,000 plus accrued interest of $2,750 and $1,000 in fees for 3,095,362 shares of common stock ($0.01898 per share). The full share reserve was released upon satisfaction of the note and returned to treasury.

(j) On January 17, 2020, the Company entered into a one year 8% $110,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note had a maturity date of January 21, 2021 and carried a $10,000 original issue discount (such that $100,000 was funded to the Company on January 21, 2020). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty (20) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 5,150,000 shares of its Common Stock for conversions under this Note (the “Share Reserve”) within 5 days from the date of execution and maintained a 2.5 times reserve for the amount then outstanding. Upon full conversion or repayment of this Note, all remaining shares in the Share Reserve were cancelled. Pursuant to this note, the Company issued to the noteholder 400,000 shares of its restricted common stock as debt commitment shares valued at $20,960 ($0.0524 per share). As of March 31, 2021, the noteholder converted the full principal of $110,000 plus accrued interest of $4,388 for 6,045,769 shares of common stock ($0.01898 per share). Upon full conversion of this note, any shares remaining in the Share Reserve were returned to treasury.

(k)   On February 7, 2020, the Company effectuated a six-month convertible promissory note with Tangiers Global, LLC (the “Tangiers Note”). The Company received funds in the amount of $60,000 after reduction of the Original Issue Discount of $5,000. The $65,000 face value note matured on August 6, 2020 and bore an interest rate of 2%, guaranteed. This note had a fixed conversion price of $0.03 per share. The Company established an initial reserve of 7,000,000 shares of its common stock and has agreed to reserve a multiple of shares to fully convert under the terms of this note. The Note was retired after the Maturity Date, therefore was subject to the terms hereof and restrictions and limitations contained herein, the Holder had the right, at the Holder’s sole option, to convert in whole or in part the outstanding and unpaid principal amount under this note into shares of common stock at the “Variable Conversion Price” which was equal to the lower of: (a) the Fixed Conversion Price or (b) 65% of the lowest volume weighted average price of the Company’s Common Stock during the 20 consecutive trading days prior to the date on which holder elected to convert all or part of the note. Accrued interest in the amount of $1,300 has been recognized on this note as of March 31, 2021. As of March 31, 2021, the noteholder converted the full principal of $65,000 plus accrued interest of $1,300 for 4,444,891 shares of common stock ($0.014916 per share). Upon full conversion of this note, any shares remaining in the Share Reserve were returned to treasury.

(l)

Effective February 11, 2020 the Company entered into a one-year 10% convertible promissory note with Crown Bridge Partners, LLC (“Crown”), having a face value of $55,000. The Company received funds in the amount of $50,000 on February 23, 2020, after reduction of the Original Issue Discount of $5,000. The $55,000 face value note had a maturity date of February 11, 2021. Crown had the right at any time to convert all or any part of the outstanding and unpaid principal amount and accrued and unpaid interest of this note into fully paid and non-assessable shares of common stock. The “Conversion Amount”, with respect to any conversion of this note, the sum of (1) the principal amount of this note to be converted in such conversion plus (2) at Crown’s option, accrued and unpaid interest, if any, on such principal amount at the interest rates provided in this note to the conversion date, plus (3) at Crown’s option, default interest, if any. The conversion price shall be the lesser of (i) 65% multiplied by the lowest volume weighted average price on the OTCQB, or applicable trading market during the previous twenty (20) trading day period ending on the latest complete trading day prior to the date of this note or (ii) the variable conversion price which meant 65% multiplied by lowest intraday trading price of any market makers for the common stock during the twenty (20) trading day period ending on the last complete trading day prior to the conversion date. The Company agreed that during the period the conversion right exists, the Company will reserve from its authorized and unissued common stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of common stock upon the full conversion of this note. The Company was required at all times to have authorized and reserved six times the number of shares that is actually issuable upon full conversion of the note. The Company, on February 24, 2020, issued 250,000 debt commitment shares in conjunction with this note. The commitment shares had a value of $13,500 ($0.054 per share). The Company, on August 25, 2020 agreed issue 125,000 additional make-whole shares valued at $4,438 ($0.0355). As of March 31, 2021, the noteholder converted $8,543 on note principal including $1,500 of interest for 500,000 shares $0.020085. On January 5, 2021, the Company and the noteholder agreed to fully settle and retire this note for the amount of $75,0000. Along with $46,458 of note principal and $4,053 of accrued interest a prepayment penalty of $24,438 was recorded as a loss on conversion of debt. Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(m)

On March 17, 2020, the Company entered into security purchase agreement with Adar Alef, LLC whereby the Company issued an 8% convertible redeemable note in the principal amount of $44,000. The note was funded with net proceeds of $37,800, after the deduction of $4,000 of Original Issue Discount and $2,200 in legal fees. The note had a maturity date of March 17, 2021. The face value amount plus accrued interest under the note are convertible into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market for the 20 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. The Company established an initial reserve of 7,584,500 shares of its common stock and at all times reserved a minimum of 4 times the amount of shares required if the note were to fully convert. As of March 31, 2021, the noteholder converted $44,000 of note principal and accrued interest of $1,989 for 2,600,620 ($ 0.017684 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(n) On March 23, 2020, the Company effectuated a six-month convertible promissory note with Tangiers Global, LLC. The Company received funds in the amount of $41,000 after reduction $2,050 of Original Issue Discount. The $43,050 face value note matured on September 23, 2020 and bore an interest rate of 5%, guaranteed. This note had a fixed conversion price of $0.03 per share. The Company agreed that it would, at all times, reserve and keep available for Tangiers, out of its authorized and unissued Common Stock a multiple of the number of shares of Common Stock issuable upon the full conversion of this note. Since this note was not converted as of the maturity date, Tangiers had the right, at its sole option, to convert in whole or in part the outstanding and unpaid Principal Amount under this Note into shares of Common Stock at the Variable Conversion Price which was equal to the lower of: (a) the Fixed Conversion Price or (b) 65% of the lowest volume weighted average price of the Company’s Common Stock during the 20 consecutive Trading Days prior to the date on which Tangiers elects to convert all or part of the Note. As of March 31, 2021, the note holder converted $43,050 in note principal and $2,153 of accrued interest for 2,826,923 shares ($0.01599 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(o) On April 17, 2020, the Company entered into a one-year 8% $55,000 convertible note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement (“GS Note”). The GS Note had a maturity date of April 17, 2021 and carried a $5,000 Original Issue Discount (such that $50,000 was funded to the Company on April 17, 2020). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty (20) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 5,717,000 shares of its common Stock for conversions under this and agreed to maintain a 2.5 times reserve for the amount then outstanding. The Company issued to the noteholder 150,000 shares of its restricted common stock as debt commitment shares valued at $5,000 ($0.03 per share). As of March 31, 2021, this noteholder converted note principal of $55,000 and accrued interest of $2,662 for 4,650,335 shares ($0.01408 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(p)

On April 30, 2020, the Company entered into securities purchase agreement with Adar Alef, LLC whereby the Company issued an 8% convertible redeemable note in the principal amount of $44,000. The note was funded with net proceeds of $37,800, after the deduction of $4,000 for Original Issue Discount and $2,200 in legal fees. The note has a maturity date of April 30, 2021. The face value amount plus accrued interest under the note was convertible into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the 20 prior trading days including the day upon which a notice of conversion was received by the Company or its transfer agent. The Company established an initial reserve of 7,736,000 shares of its common stock and at all times reserve a minimum of 4 times the amount of shares required if the note were to fully convert. As of March 31, 2021, the noteholder converted note principal of $44,000 and accrued interest $1,975 for 3,701,000 shares ($0.01242 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(q)

On May 8, 2020, the Company effectuated a six-month fixed convertible promissory note with Tangiers Global, LLC with a total face value of $102,500 containing an Original Issue Discount of $2,500. On May 8, 2020 and June 10, 2020, the Company received funds, on each date, in the amount of $50,000 and recognized Original Issue Discount of $1,250. This note matured on November 8, 2020 and bore an interest rate of 5%, guaranteed. This note has a fixed conversion price of $0.03 per share. The Company agreed that it would, at all times, reserve and keep available for Tangiers, out of its authorized and unissued Common Stock a multiple of the number of shares of Common Stock as were issuable upon the full conversion of this note. Since the note was not retired on or before the maturity date, it was subject to the terms hereof and restrictions and limitations contained herein, Tangiers had the right, at the its sole option, to convert in whole or in part the outstanding and unpaid principal amount under this note into shares of Common Stock at the variable conversion price which shall be equal to the lower of: (a) the fixed conversion price or (b) 70% of the lowest volume weighted average price of the Company’s Common Stock during the 15 consecutive trading days prior to the date on which Tangiers elects to convert all or part of the note. As of March 31, 2021, the noteholder converted note principal of $102,500 and accrued interest $5,125 for 5,823,864 shares ($0.01848 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(r) On May 18, 2020, the Company entered into a Securities Purchase Agreement with Firstfire Global Opportunities Fund, LLC (“Firstfire”) pursuant to a convertible promissory note in the principal amount of $88,333, having an Original Issue Discount in the amount of $8,833. On May 24, 2020, the Company received funds in the amount of $75,000 after the deduction of legal fees in the amount of $4,500. This note bore an annual interest rate of 8%. The per share conversion price into which principal amount and interest under this note was convertible into shares of Common Stock hereunder equal to 65% multiplied by the average of the two (2) lowest volume weighted average prices of the common stock during the fifteen (15) consecutive trading day period immediately preceding the date of the respective conversion. The borrower agreed that at all times until the note is satisfied in full, the borrower will reserve from its authorized and unissued Common Stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of a number of conversion shares equal to the greater of: (a) 8,500,000 shares of Common Stock or (b) the sum of the number of Conversion Shares issuable upon the full conversion of this Note multiplied by (ii) three and a half (3.5). The Company issued to the noteholder 375,000 shares of its restricted common stock as debt commitment shares valued at $12,075 ($0.0322 per share). As of March 31, 2021, the noteholder converted note principal of $88,333 and accrued interest $3,501 for 6,020,000 shares ($0.015255 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(s) On June 4, 2020, the Company entered into a one-year 8% $33,000 convertible note with GS Capital Partners, LLC (the “GS Note”) pursuant to the terms of a Securities Purchase Agreement. The GS Note had a maturity date of June 4, 2021 and carried $3,000 of original issue discount (such that $30,000 was funded to the Company on or about June 4, 2020). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest daily volume weighted average price of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty (20) prior trading days including the day upon which a notice of conversion was received by the Company or its transfer agent. Accrued but unpaid interest was subject to conversion. In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 3,678,000 shares of its Common Stock for conversions under this note and maintained a 2.5 times reserve for the amount then outstanding. The Company issued to the noteholder 90,000 shares of its restricted common stock as debt commitment shares valued at $3,105 ($0.0345 per share). As of March 31, 2021, the noteholder converted note principal of $33,000 and accrued interest $1,807 for 2,369,458 shares ($0.01469 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(t)

On June 24, 2020, the Company effectuated a six-month fixed convertible promissory note with Tangiers Global, LLC with a total face value of $210,000 containing Original Issue Discount of $10,000. On June 26, 2020, the Company received proceeds of $200,000, net Original Issue Discount of $10,000. This note matured on December 24, 2020 and bore an interest rate of 8%, guaranteed. This note has a fixed conversion price of $0.03 per share. Since the note was not retired on or before the maturity date, then at any time and from time to time after the maturity date, and subject to the terms hereof and restrictions and limitations contained herein, Tangiers had the right, at the Tangiers’s sole option, to convert in whole or in part the outstanding and unpaid principal amount under this note into shares of Common Stock at the variable conversion price which was equal to the lower of: (a) the fixed conversion price or (b) 70% of the lowest volume weighted average price of the Company’s Common Stock during the 15 consecutive trading days prior to the date on which Tangiers elected to convert all or part of the note. During January 2021, the noteholder converted $210,000 of note principal and accrued interest $16,800 for 12,221,861 shares ($0.01856 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

(u)

On December 21, 2020, the Company effectuated a $210,000 six-month fixed convertible promissory note with Tangiers Global, LLC containing Original Issue Discount of $10,000. This note had a mature date of June 22, 2021 with an interest rate of 8%, guaranteed. This note had a fixed conversion price of $0.03 per share. If the Note was not retired on or before the maturity date, then at any time and from time to time after the maturity date, and subject to the terms hereof and restrictions and limitations contained herein, the Tangiers had the right, at the Tangiers’ sole option, to convert in whole or in part the outstanding and unpaid principal amount under this note into shares of common stock at the variable conversion price which was equal to the lower of: (a) the Fixed Conversion Price or (b) 70% of the lowest volume weighted average price of the Company’s common stock during the 15 consecutive trading days prior to the date on which Tangiers elected to convert all or part of the note. During March 2021, the noteholder converted $135,000 of note principal and accrued interest $16,800 for 5,060,000 shares ($0.03 per share). The Company paid $75,000 cash to convert the remaining note principal. Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

XML

Stockholders' Equity (Deficit) (Tables)

12 Months Ended

Mar. 31, 2021

Equity [Abstract]

Schedule of Warrants Activity

The following table summarizes warrant activity for the years ended March 31, 2021 and 2020:

				Weighted		Average
				Average		Remaining		Aggregate
				Exercise		Contractual		Intrinsic
	Shares			Price		Term		Value
Outstanding at March 31, 2019		1,210,276		$	1.2		1.28 Years	$	—
Granted		—			—				—
Expired		(488,011	)		0.75
Exercised		—			—
Canceled		—			—
Outstanding and exercisable March 31, 2020		722,265		$	1.19		0.83 Years	$	—
Granted		—			—				—
Expired		(722,265	)		—
Exercised		—			—
Canceled		—			—
Outstanding and exercisable March 31, 2021		—		$	—			$	—

Schedule of Stock Options Activity

The following table summarizes option activity for the year ended March 31, 2021 and 2020:

					Weighted
			Weighted-		Average
			Average		Remaining		Aggregate
			Exercise		Contractual		Intrinsic
	Shares		Price		Term		Value
Outstanding at March 31, 2019		133,334	$	7.50		2.85 Years	$	—
Granted		—		—
Expired		—		—
Exercised		—		—
Outstanding at March 31, 2020		133,334	$	7.50		1.85 Years	$	—
Granted		—		—
Expired		—		—
Exercised		—		—
Outstanding and exercisable March 31, 2021		133,334	$	7.50		0.85 Years	$	—

XML

Provision for Income Taxes (Tables)

12 Months Ended

Mar. 31, 2021

Income Tax Disclosure [Abstract]

Schedule of Effective Income Tax Rate

The following table summarizes the significant differences between the U.S. Federal statutory tax rate and the Company’s effective tax rate for financial statement purposes for year and year ended March 31, 2021 and March 31, 2020:

	March 31, 2021			March 31,2020
Federal income taxes at statutory rate		21.00	%		21.00	%
State income taxes at statutory rate		0.00	%		0.00	%
Temporary differences		11.83	%		2.42	%
Permanent differences		0.03	%		(0.87	)%
Impact of Tax Reform Act		0.00	%		(0.00	)%
Change in valuation allowance		(32.86	)%		(22.55	)%
Totals		0.00	%		0.00	%

Schedule of Deferred Tax Assets

As the achievement of required future taxable income is uncertain, the Company recorded a valuation allowance.

	As of			As of
	March 31, 2021			March 31, 2020
Deferred tax assets:
Net operating losses before non-deductible items	$	4,586,526		$	4,269,938
Loss on disposal of fixed assets		-			613
Stock-based compensation		543,375			329,214
Unrealized gains (losses) on investments		164,666			(50,290	)
Total deferred tax assets		5,294,567			4,599,765
Less: Valuation allowance		(5,294,567	)		(4,599,765	)
Net deferred tax assets	$	-		$	-

XML

Investments (Tables)

12 Months Ended

Mar. 31, 2021

Investments, Debt and Equity Securities [Abstract]

Schedule of Investment in Trading Securities

Investment in Trading Securities:

At March 31, 2020

Company		Beginning of Period Cost		Purchases		Sales Proceeds		End of Period Cost		Fair Value		Realized Gain (Loss)		Unrealized Gain (Loss)
VistaGen Therapeutics Inc (VTGN)	(a)		287,500		-		-		287,500	$	101,200		-		(186,300	)
Basanite Inc. (BASA)	(b)		30,000		-		40,000		-		-		10,000		-
Totals		$	317,500	$	-	$	40,000	$	287,500	$	101,200	$	-	$	(186,300	)*

At March 31, 2021

Company		Beginning of Period Cost		Purchases		Sales Proceeds		End of Period Cost		Fair Value		Realized Gain (Loss)		Unrealized Gain (Loss)
VistaGen Therapeutics Inc (VTGN)	(a)		287,500		277,500		302,827		408,750	$	1,246050		146,577		837,300	*

*This amount represents the cumulative unrealized loss as of March 31, 2021 and March 31, 2020.

(a) On December 11, 2017 the Company invested $480,000 in the common stock of VistaGen Therapeutics, Inc. (VTGN). The Company purchased 320,000 common shares along with 320,000 five-year warrants with a strike price of $1.50. On March 26, 2018, the Company purchased an additional 10,000 common shares. The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company’s investment in VTGN has a cost of $490,117, unrealized loss of $183,910 and a fair value of $306,207 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 59,380 shares of VTGN for $61,998 (average price per share of $1.04 per share) in the open market. During the period of June 22, 2018 through August 1, 2018, the Company sold 389,380 shares of VTGN for $517,485 ($1.33 per share) for a realized loss of $34,630. The Company also purchased in a direct offering 230,000 restricted common shares directly from VTGN during the year ended March 31, 2019 for a cost of $287,500. On December 11, 2019, the Company purchased 250,000 three-year restricted warrant at a cost of $0.15 each (total value of $37,500). As of March 31, 2021, the Company has recognized an unrealized gain on these shares in the amount of $59,110, compared to an unrealized loss of $74,301 for the nine months ended December 31, 2019 in VTGN. As December 31, 2019, these shares were on deposit held with a broker. On December 29, 2020, the Company exercised 480,000 of its $0.50 warrants in VTGN. The new cost basis for these warrant shares is the $0.50 paid to covert each warrant in to shares (230,000 shares) as well as an addition $0.15 per share on the purchased options (250,000) shares. During February and March 2021, the Company sold 125,000 shares of VTGN for proceeds of $302,827. The Company recognized a gain on the sale of these shares of $146,577.

(b) On July 5, 2018, the Company purchased 100,000 shares of Basanite Industries Inc. (BASA) (formerly Paymeon, Inc. (PAYM)) for $12,998 ($0.13 per share) in the open market. During July 2018 the Company sold the 100,000 shares for $10,821 ($0.11 per share) for a realized loss of $2,177. On July 9, 2018, the Company purchased 400,000 restricted common shares directly from the Company for $30,000 ($0.075 per share). During the year ended March 31, 2020, the Company sold its 400,000 shares for $40,000 ($0.10 per share) recognizing a profit of $10,000.

XML

Fair Value Measurements (Tables)

12 Months Ended

Mar. 31, 2021

Fair Value Disclosures [Abstract]

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following summarizes the Company’s financial assets and liabilities that are measured at fair value on a recurring basis at March 31, 2021 and March 31, 2020:

	March 31, 2021
	Level 1		Level 2		Level 3		Total
Assets
Investment-trading securities	$	1,246,050	$	-	$	-	$	1,246,050
Cost method investment – Küdzoo	$	-	$	-	$	-	$	-
Cost method investment – Serendipity Brands	$	-	$	-	$	35,000	$	35,000
Cost method investment - Aegea Biotechnologies, Inc.	$	-	$	-	$	139,106	$	139,106

	March 31, 2020
	Level 1		Level 2		Level 3		Total
Assets
Investment-trading securities	$	101,200	$	-	$	-	$	101,200
Cost method investment – Küdzoo	$	-	$	-	$	105,600	$	106,600
Cost method investment – Serendipity Brands	$	-	$	-	$	35,000	$	35,000

XML

Basis of Operations and Going Concern (Details Narrative)																									3 Months Ended		12 Months Ended
	Mar. 31, 2021 USD ($) $ / shares	Feb. 26, 2021 USD ($) shares	Feb. 01, 2021	Dec. 23, 2020 USD ($)	Dec. 16, 2020 USD ($)	Sep. 24, 2020	Aug. 15, 2020 USD ($) shares	Aug. 10, 2020 shares	Jul. 15, 2020 shares	Jul. 10, 2020	Jun. 29, 2020	Jun. 15, 2020	May 29, 2020	Apr. 03, 2020 USD ($) $ / shares shares	Apr. 03, 2020 USD ($) $ / shares shares	Mar. 05, 2020 USD ($) shares	Jan. 21, 2020 USD ($) shares	Dec. 30, 2019	Apr. 30, 2019 shares	Apr. 08, 2019 USD ($) shares	Apr. 02, 2019 USD ($) shares	Jan. 12, 2019 shares	Jun. 29, 2018	Aug. 01, 2017 USD ($)	Jun. 29, 2021 USD ($) $ / shares shares	Mar. 31, 2021 USD ($) $ / shares	Mar. 31, 2021 USD ($) $ / shares shares	Mar. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)	Dec. 22, 2016
Common stock shares issued, value																											$ 1,587,212	$ 143,420
Impairment loss on investment percentage	50.00%																									50.00%	50.00%
Impairment loss on investment																											$ (244,706)
Number of restricted shares issued during the period, value																											35,000
Product liability	$ 8,000,000																									$ 8,000,000	8,000,000
Revenues																											285,319	234,389
Debt conversion																											253,868	218,460
Variable annual fee, percentage																							0.07
Net sales																											285,319	234,389
Gross profit																											122,692	54,235
Working capital surplus	1,291,211																									1,291,211	1,291,211
Working capital deficit																												334,832
Marketable securities	$ 1,246,050																									$ 1,246,050	$ 1,246,050	$ 101,200
Maximum [Member]
Ownership interest	20.00%																									20.00%	20.00%
Rainbow Deluxe Sampler Pack[Member]
Ownership interest, description												The Rainbow Pack is comprised of one blister pack of each Tauri-Gum's™ flavors (6 blister packs in total) and will be available exclusively on the Company's E-Commerce website (www.taurigum.com). The Rainbow Pack is comprised of three Tauri-Gum™ flavors of Cannabidiol ("CBD") infused (Mint, Blood Orange, Pomegranate), two of the Tauri-Gum™ flavors are Cannabigerol ("CBG") infused (Peach-Lemon, Black Currant), and one Tauri-Gum™ flavor is Vitamin C + Zinc ("Immune Booster") infused (Pear Bellini). The introductory price of the Rainbow Pack is $99.99 per pack. The Rainbow pack commercially launched in late September 2020.
Other Products [Member]
Ownership interest, description																										The Company, from time to time, will offer various formats of CBD product through its e-commerce website. As of this report date the Company is currently offering a 70% dark chocolate 20mg CBD non-GMO dietary supplement and 100mg CBD scented bath bombs (Mint, Pomegranate and Blood Orange). The Company's current offering includes a line of skin care products sold on its ecommerce website under the product line name of Uncle Bud's. The skin care products include three different 4.2mg CBD facemasks (collagen, detoxifying and tightening masks), 100mg CBD daily moisturizer, 30mg CBD anti-wrinkle dream, hand and foot cream with hemp seed oil, 120mg CBD massage and body oil, 240mg CBD body revive roll-on, 35mg CBD transdermal patch and 120mg CBD body spray. Additionally, on December 1, 2020 the Company announced the commencement of development of a Caffeine infused version of Tauri-Gum™. When production run is complete, this will represent the 7th SKU of the Tauri-Gum™ product line.
Cannabigerol [Member] | Chewing Gum Contains 10mg [Member]
Ownership interest, description																		This initial production run had been completed in its Peach-Lemon flavor (and each piece of Chewing Gum contains 10mg CBG isolate). This initial production run yielded roughly 8,300 blister packs. The product is Kosher Certified, Vegan Formulated, Lab Tested, NON-GMO, Allergen Free, Gluten Free, containing no THC, and 100% Made in the USA. MSRP has been established at $19.99 per Blister Pack.
Cannabigerol [Member] | Chewing Gum Contains 15mg [Member]
Ownership interest, description																		Kosher Certified, Vegan, Halal, Lab-Tested, NON-GMO, Allergen Free, Gluten Free, 15mg CBG/Piece of Chewing Gum, 100% Made in the USA.
Cannabigerol [Member] | 60mg of Vitamin C [Member]
Ownership interest, description													The Company announced that it has commenced development of an Immune Booster version of Tauri-Gum™, which commenced sales during the three months ended September 30, 2020. This product contains 60mg of Vitamin C and 10mg of Elemental Zinc ("Zinc") in each piece of chewing gum. This product does not contain any phytocannabinoids (i.e., CBD or CBG). The Company's Immune Booster Tauri-Gum™ product, is: Kosher certified, Halal Vegan, Lab-Tested, non-GMO, allergen free, gluten free, infused with 60mg Vitamin C & 10mg Elemental Zinc/per each piece of gum, no phytocannabinoids, and 100% made in the United States of America.
Dr. Keith Aqua [Member]
Agreement description									Carries a term of 12 months from inception, expiring on July 15, 2021.
Restricted common stock issued during period | shares							62,500		750,000																		1,187,500
Number of restricted shares issued during the period, value							$ 4,000																				$ 46,906
Shares issued price per share | $ / shares	$ 0.0395																									$ 0.0395	$ 0.0395
Dr. Keith Aqua [Member] | Subsequent Event [Member]
Restricted common stock issued during period | shares																									187,500
Number of restricted shares issued during the period, value																									$ 7,406
Shares issued price per share | $ / shares																									$ .0395
Ms. Neelima Lekkala [Member]
Commission earned	$ 1,143
Tangier's Global, LLC [Member]
Number of common stock shares issued | shares																											13,910,000
Shares issued price per share | $ / shares	$ 0.01848																									$ 0.01848	$ 0.01848
Debt conversion																											$ 102,500
Aegea Biotechnologies Inc [Member]
Ownership interest		2.04%
Investment		$ 139,104
Collaboration Agreement [Member] | Tangier's Global, LLC [Member]
Equity line of credit														$ 5,000,000	$ 5,000,000
Collaboration Agreement [Member] | Aegea Biotechnologies Inc [Member]
Net proceeds from sale of stock, percentage								70.00%						70.00%
Number of common stock shares issued | shares								10,000,000						10,000,000
Stock price per share | $ / shares														$ 4.00	$ 4.00
Collaboration agreement, description								The Company increased the percentage of proceeds it invested in Aegea on the sale of the remaining shares available under the ELOC agreement from 20% to 40%.						The $4.00 stock price corresponds to a current pre-money valuation of Aegea of $25,000,000 for each tranche of cash, up to the first $2,000,000 of our investment in Aegea. Additionally, as part of our agreement with Aegea, on May 26, 2020, Tauriga issued to Aegea 5,000,000 unregistered common shares of Tauriga common stock.													As of March 31, 2021, the Company had invested $278,212 in Aegea for 69,553 shares, representing an ownership percentage of 1.03%.
Common stock shares issued, value		$ 69,552																									$ 69,553
Ownership interest	1.03%	2.04%																								1.03%	1.03%
Investment	$ 278,212																									$ 278,212	$ 278,212
Shares owned | shares		139,104
Number of common stock on sale transaction shares | shares															10,000,000
Master Services Agreement [Member]
Consulting fees				$ 67,500
Additional consulting fees					$ 85,000
E&M Distribution Agreement [Member]
Restricted common stock issued during period | shares																					1,000,000
Payment received from delivery of product																													$ 54,000
One time cash payment																					$ 125,000
South Florida Region Distribution Agreement [Member]
Restricted common stock issued during period | shares																				450,000
Cash stipend																				$ 10,000
Cash stipend paid																				$ 6,000
North Eastern United States Distribution Agreement [Member]
Restricted common stock issued during period | shares																			1,000,000
Go To Market Disctribution Agreement [Member] | Mr. Checkout [Member]
Commission description											Agreement enables the Company to launch its flagship brand Tauri-Gum™ through Mr. Checkout's network of independent direct store distributors that service approximately 150,000 stores and retail locations across the United States. These stores include well-known convenience stores, gas station marts and supermarket chains. Under the terms of this agreement, on July 7, 2020, the Company paid a one-time $5,000 retainer on commission against the first $100,000 in sales. Subsequent commissions shall be paid to Mr. Checkout during the first thirty (30) days of the subsequent quarter once retainer has been met and exceeded. Commission will not be paid until the retainer has been met. As of March 31, 2021, the Company has recognized no sales via this agreement.
Think BIG, LLC License Agreement [Member] | Think BIG, LLC [Member]
Terms of license agreement						The licensing arrangement permits for cross licensing, brand building, e-commerce customer acquisition efforts, retail customer acquisition efforts, enhanced social media presence, public relations & visibility strategies, as well as potential outreach to celebrities, and various other types of in-kind services in order to increase both Company revenue and customer acquisition efforts. The License will also allow for future joint development projects that will leverage the iconic "Frank White" brand and likeness/intellectual property (to which Think Big has the intellectual property rights). The Companies further agreed to a 50/50 gross profit split on sales of specially branded product, payable on or before the 15th day of each calendar month for the immediately preceding calendar month. In addition, the Company originally agreed to pay Think BIG, via a quarterly marketing fee for a period of twelve months in the amount $15,000 per quarter (for an aggregate total of $60,000), the first payment of which was paid by the Company within 10 days of the entry into the License. Subsequently, the parties agreed that the remaining payments would no longer be paid to Think BIG in exchange for the Company funding specially branded inventory printing and product as well as other marketing initiatives.
Professional Services Agreement [Member] | Each Brand Ambassador's [Member]
Agreement description																											As consideration for each Brand Ambassador's Services set forth under their respective PSAs, the Company agreed to issue each Brand Ambassador 1,500,000 restricted shares of the Company's common stock, upon execution of the PSA and PSA 2. These shares were issued on December 17,2020. In the event that the applicable PSA has not previously been terminated, following the one-year anniversary of the Effective Date, an additional 1,500,000 restricted shares of Company's common stock shall be issued to each Brand Ambassador, subject to the satisfaction of the terms of such additional services and/or criteria to be mutually agreed upon by the parties to the PSA and/or the PSA 2, as the case may be. In total, all shares issued and to be issued had a value of $183,600 that will be recognized over the term of the contract.
Restricted common stock issued during period | shares																											1,500,000
Number of restricted shares issued during the period, value																											$ 183,600
Stock Up Express Agreement [Member]
Agreement description			The Company entered into a distribution agreement with Connecticut based Stock Up Express, a division of Bozzuto's Inc., a distributor that generates more than $3 Billion in annual sales. The agreement shall remain in effect for a period of two (2) years, with automatic renewal for additional successive one (1) year terms. Under terms of this distribution agreement, Stock Up Express will market and resell the Company's flagship brand, Tauri-Gum™, to its customer base of wholesale and retail customers in the mainland United States. The two companies will jointly market Tauri-Gum™ to Stock Up Express' customer base. The Agreement allows for modification of product offerings, and the Company expects to offer additional product items over the course of calendar year 2021. Either party may terminate this Agreement for convenience by giving a sixty (60) day written notice to the other party or either party has the right to terminate this agreement if the other party breaches or is in default of any obligation hereunder, including the failure to make any payment when due, which default is incapable of cure or which, being capable of cure, has not been cured within thirty (30) days after receipt of written notice from the non-defaulting party or within such additional cure period as the non-defaulting party may authorize in writing.
Investment Agreement [Member] | Tangier's Global, LLC [Member]
Number of common stock shares issued | shares																											13,910,000
Common stock shares issued, value																											$ 400,514
Number of common stock on sale transaction shares | shares																76,000,000	76,000,000
Sale of stock, value of shares issued on transaction																$ 5,000,000	$ 5,000,000
Volume weighted average price, discount																	88.00%
Investment Agreement [Member] | Tangier's Global, LLC [Member] | Minimum [Member]
Amount of shares to sell on a closing date																	$ 5,000
Investment Agreement [Member] | Tangier's Global, LLC [Member] | Maximum [Member]
Amount of shares to sell on a closing date																	$ 350,000
Placement Agreement [Member] | KushCo Holdings, Inc [Member]
Agreement description										The Company and KushCo Holdings, Inc., a Nevada corporation ("KushCo"), entered into a Product Placement Membership Agreement (the "Placement Agreement"). Under the terms of the Placement Agreement, KushCo will provide placement services of the Company's Tauri-Gum™ product line(s), and will assist with retail activation, product incubation, branding and marketing solutions, and sales management services. As compensation for providing such services and placement of the Company's products, when KushCo or one of its affiliates consummates a purchase, distribution or sale of products (either directly or through third parties), KushCo will be paid a fee equal to 10% of the total gross sales for such transaction(s) (the "Placement Fee"). The Placement Fee shall be earned as of the date of the respective transaction and shall be paid in cash by the Company on a monthly basis and no later than the last calendar day of each calendar month. The Placement Agreement has a term of two (2) years, unless earlier terminated upon sixty (60) days notice to the Company, as provided under the KushCo Agreement.
Debt Conversion Agreement [Member] | Honeywood LLC [Member]
Debt conversion																								$ 170,000
Debt Conversion Agreement [Member] | Honeywood LLC [Member] | Written Off [Member]
Debt conversion																								$ 199,119
Debt Conversion Agreement [Member] | Honeywood LLC [Member] | Ownership [Member]
Ownership interest																								5.00%
Transfer Agreement [Member] | Open Therapeutics [Member]
Percentage of membership interest sold																														80.00%
Percentage of unexercised portion of warrant to purchase of shares terminated and cancel during the period																														80.00%
Percentage of net profit generated																														20.00%
Transfer Agreement [Member] | Open Therapeutics [Member]
Restricted common stock issued during period | shares																						500,000
Equity Line Financing Agreement [Member] | Tangier's Global, LLC [Member]
Number of common stock on sale transaction shares | shares																	76,000,000
Sale of stock, value of shares issued on transaction																	$ 5,000,000
Sale of stock, description																	The Company entered into a $5,000,000 equity line financing agreement with Tangiers, as well as a registration right agreement related thereto. The financing is over a maximum of 36 months. Pursuant to the Registration Rights Agreement, a maximum of 76,000,000 shares of our common stock, par value $.00001 per share that we may sell to Tangiers from time to time will be registered by us on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended, for this financing. As a result of the Company's Collaboration Agreement with Aegea, whereby seventy percent (70%) of the Net Proceeds from the sale of the initial 10,000,000 shares of stock of Tauriga using the ELOC were transferred to and invested in Aegea for the purchase of common stock of Aegea. Additionally, the Company has excluded 4,000,000 shares under this agreement to cover liabilities and expenses related to the establishment and maintenance of this agreement.
Investment Agreement and Registration Rights Agreement [Member] | Tangier's Global, LLC [Member]
Number of common stock shares issued | shares																											3,910,000
Common stock shares issued, value																											$ 4,000,000

XML

Summary of Significant Accounting Policies (Details Narrative)		12 Months Ended
	Jun. 29, 2018	Mar. 31, 2021 USD ($) Integer	Mar. 31, 2020 USD ($)
Number of segments | Integer		2
Variable annual fee, percentage	0.07
Sales revenue		$ 285,319	$ 234,389
Accounts receivable		32,227	42,580
Allowance for doubtful accounts		93,550
Refund to customers		100
Cash FDIC insured amount		250,000
Cash		49,826	5,348
Cash equivalents
Loss on the impairment on investments		244,706
Inventory asset		201,372	128,711
Receivable on funds paid for inventory		423,200
Fulfilment services		106,519	42,050
Research and development costs		$ 273,385	$ 6,923
Maximum [Member]
Ownership interest percentage		20.00%

XML

Summary of Significant Accounting Policies - Schedule of Segment Information (Details) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues	$ 285,319	$ 234,389
Cost of goods sold	162,627	180,154
Gross profit	122,692	54,235
General and administrative	2,857,220	1,855,229
Research and development	273,385	6,923
Selling and fulfillment expense	379,824
Operating Loss	(3,389,474)	(2,039,010)
Total assets	2,488,703	643,462
Total liabilities	1,217,456	$ 951,659
Tauri-gum [Member]
Revenues	285,319
Cost of goods sold	(162,627)
Gross profit	122,692
General and administrative	2,778,282
Research and development	50,885
Selling and fulfillment expense	379,824
Operating Loss	(2,761,045)
Total assets	2,288,263
Total liabilities	1,076,038
Pharma [Member]
Revenues
Cost of goods sold
Gross profit
General and administrative	80,675
Research and development	222,500
Selling and fulfillment expense
Operating Loss	(303,175)
Total assets	200,440
Total liabilities	141,418
Adjustments, Eliminations and Unallocated items [Member]
Revenues
Cost of goods sold
Gross profit
General and administrative
Research and development
Selling and fulfillment expense
Operating Loss
Total assets
Total liabilities

XML

Summary of Significant Accounting Policies - Schedule of Shipping Expense (Details) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Accounting Policies [Abstract]
Shipping revenue	$ 6,240	$ 24,438
Shipping expense	(24,693)	(31,114)
Net shipping expense	$ (18,453)	$ (6,706)

XML

Revenue (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Allowance for doubtful account			$ 93,550
Sales Revenue [Member] | Product Concentration Risk [Member] | E-Commerce Channel [Member]
Concentration risk percentage	82.00%	14.70%

XML

Revenue - Schedule of Disaggregation Revenue (Details) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues	$ 285,319	$ 234,389
Distributor [Member]
Revenues		62,441
E-Commerce [Member]
Revenues	233,995	34,439
Wholesale [Member]
Revenues	$ 51,324	$ 137,509

XML

Inventory (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Prepayments on deposits	$ 423,200
Tauri-GumTM [Member]
Deposits		$ 96,688

XML

Inventory - Schedule of Inventory (Details) - USD ($)		Mar. 31, 2021	Mar. 31, 2020
Total Inventory		$ 201,372	$ 128,711
Tauri-GumTM [Member]
Total Inventory		173,207	120,480
Tauri-GummiesTM [Member]
Total Inventory		22,829	4,029
Collagen/Omega-3 Gummies [Member]
Total Inventory	[1]		2,425
Other [Member]
Total Inventory	[2]	$ 5,336	$ 1,776

[1] This segment of inventory is stock that was purchased in conjunction with Resale Agreement with OG Laboratories, LLC.

[2] Other inventory consists of holiday pouches sold as a bundled of Tauri-GumTM, other CBD products and skin care.

XML

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Purchase of office furniture	$ 8,722
Furniture useful life	60 months
Disposal of obsolete computers, office furniture and other equipment	$ 55,942
Depreciation expense	$ 1,425	$ 913

XML

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Less: accumulated depreciation	$ (1,642)	$ (56,160)
Net	$ 12,063	13,478
Property and equipment estimated life	60 months
Computers, Office Furniture and Other Equipment [Member]
Property and equipment gross	$ 24,789	$ 69,638
Computers, Office Furniture and Other Equipment [Member] | Minimum [Member]
Property and equipment estimated life	3 years
Computers, Office Furniture and Other Equipment [Member] | Maximum [Member]
Property and equipment estimated life	5 years

XML

Leasehold Improvements (Details Narrative)	12 Months Ended
	Mar. 31, 2021 USD ($)
Property and equipment estimated life	60 months
Leasehold Improvements [Member]
Leasehold improvements	$ 5,000
Property and equipment estimated life	48 months

XML

Leasehold Improvements - Schedule of Leasehold Improvements (Details) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Less: amortization	$ (1,642)	$ (56,160)
Net	$ 12,063	$ 13,478
Property and equipment estimated life	60 months
Leasehold Improvements [Member]
Wappingers Falls office signage and sales display	$ 5,000
Less: amortization	(313)
Net	$ 4,688
Property and equipment estimated life	48 months

XML

Operating Lease (Details Narrative)							12 Months Ended
	Jan. 06, 2021 USD ($)	Oct. 31, 2020 USD ($)	Sep. 01, 2019 USD ($)	Jun. 11, 2019 USD ($)	Jun. 11, 2019 EUR (€)	Dec. 02, 2017 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)	Apr. 02, 2019 USD ($)
Right of use asset							$ 64,301	$ 22,090		$ 7,492
Lease liability							64,526	22,824		7,895
Lease expense							11,087	13,233
Gain (loss) on termination of lease							836
Unamortized lease right of use asset							64,301
Lease Agreements [Member]
Right of use asset	$ 67,938
Lease liability	$ 67,938
Lease term	2 years
Lease expiration date	Jan. 31, 2023
Security deposit	$ 1,600
Lease one [Member]
Gain (loss) on termination of lease		$ 750
First year term [Member]
Lease income	19,200
Lease income per month	1,600
Option term [Member]
Lease income	21,000
Lease income per month	$ 1,750
Operating lease, option to extend description	The Company has the option to one two-year extension.
Lease two [Member]
Gain (loss) on termination of lease		$ 86
New York [Member]
Right of use asset			$ 26,093			$ 7,492
Lease liability			$ 26,093
Debt discount rate			8.98%
Lease term			2 years			2 years
Lease expense						$ 1,010	8,062	$ 6,322
Lease expiration date			Nov. 30, 2021
Unamortized lease right of use asset
Spain [Member]
Lease liability
Lease term				2 years
Lease expiration date				Sep. 30, 2021	Sep. 30, 2021
Unamortized lease right of use asset
Lease, description				Monthly rent payments was approximately $201 per month (based on the contractual rate of €178 multiplied by the exchange rate of 1.13 on the day the lease agreement was entered into). In accordance with ASC 842 - Leases, effective June 11, 2019, the Company will record additional net lease right of use asset and a lease liability at present value of approximately $4,574, respectively as a result of this lease. The lease will be initially recorded using an exchange rate of 1.13. Any fluctuations in the currency rate were recorded as gain or loss on currency translation.	Monthly rent payments was approximately $201 per month (based on the contractual rate of €178 multiplied by the exchange rate of 1.13 on the day the lease agreement was entered into). In accordance with ASC 842 - Leases, effective June 11, 2019, the Company will record additional net lease right of use asset and a lease liability at present value of approximately $4,574, respectively as a result of this lease. The lease will be initially recorded using an exchange rate of 1.13. Any fluctuations in the currency rate were recorded as gain or loss on currency translation.
Monthly rent payments				$ 201
Spain [Member] | Euro [Member]
Monthly rent payments | €					€ 178
ASU No. 2016-02 [Member]
Right of use asset										7,492
Lease liability										$ 7,895
Debt discount rate										8.00%
ASU No. 2016-02 [Member] | Spain [Member]
Right of use asset				4,574
Lease liability				$ 4,574

XML

Operating Lease - Schedule of Operating Lease Cost (Details) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Leases [Abstract]
Amortization of right of lease asset	$ 10,311	$ 13,233
Lease interest cost	2,324	1,666
Total Lease cost	$ 12,635	$ 14,899

XML

Operating Lease - Schedule of Maturity of Operating Lease Liability (Details)	Mar. 31, 2021 USD ($)
Leases [Abstract]
2022	$ 14,426
2023	16,201
2024	18,990
2025	14,910
Total lease payments	$ 64,527

XML

Operating Lease - Schedule of Right of Use Asset and Operating Lease Liability (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020	Apr. 02, 2019
Leases [Abstract]
Right of Use (ROU) asset	$ 64,301	$ 22,090	$ 7,492
Operating lease liability: Current	14,426	13,891
Operating lease liability: Non-Current	50,100	8,933
Total	$ 64,526	$ 22,824	$ 7,895

XML

Notes Payable (Details Narrative) - USD ($)					12 Months Ended
	Mar. 05, 2021	Nov. 18, 2020	Oct. 22, 2020	Oct. 05, 2020	Mar. 31, 2021	Mar. 31, 2020
Number of restricted stock, value					$ 35,000
Conversion of convertible debt, amount					253,868	$ 218,460
Accrued interest					14,722	39,384
Interest expense					$ 902,228	$ 1,093,071
Convertible Notes [Member]
Number of shares issued from common stock for conversion of debt, shares					93,197,109	21,295,495
Conversion of convertible debt, amount					$ 1,588,926	$ 467,500
Accrued interest					$ 111,749	$ 28,762
Average conversion price per share					$ 0.01825	$ 0.0233
Jefferson Street Capital LLC [Member]
Number of restricted stock, shares			1,250,000
Number of restricted stock, value			$ 40,000
Shares issued, price per share			$ 0.032
Accrued interest					$ 3,218
Jefferson Street Capital LLC [Member] | Inventory Financing Promissory Note [Member]
Debt instrument, face amount				$ 135,000
Moody Capital Solutions, Inc [Member] | Securities Purchase Agreement [Member]
Debt instrument, maturity date				Oct. 05, 2021
Original issue of discount				$ 10,000
Due diligence fee				$ 3,000
Debt instrument, interest rate during period				10.00%
Debt instrument, interest rate effective rate description				Any amount of principal or interest on the note which is not paid when due shall bear interest at the rate of eighteen percent (18%) per annum from the due date thereof until the same is paid or converted in accordance with the terms of the note.
Debt instrument, frequency of periodic payment description				The repayment of this note shall be in seven equal cash monthly installments beginning on April 5, 2021 and ending on October 5, 2021, for an aggregate amount of $148,500
Repayment of debt				$ 148,500
Debt conversion, description				In the event of a default of the note, noteholder shall have the right to convert all or any part of the outstanding and unpaid amounts into fully paid and non-assessable shares of Common Stock; provided, however, that in no event shall the holder be entitled to convert any portion of the note in excess of that portion of the note upon the conversion of which would result in beneficial ownership by noteholder and its affiliates of more than 4.99% of the outstanding shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and Regulations 13D-G thereunder. The beneficial ownership limitations noted above may not be waived by noteholder. The conversion price shall equal (subject to customary adjustments for stock splits, stock dividends or rights offerings, recapitalization, reclassifications, extraordinary distributions and similar events) 75% multiplied by the market price, which is defined to mean the lowest one day volume weighted average price of our Common Stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date.
Debt discount rate				At any time after October 5, 2020, if in the case that the Company's Common Stock is not deliverable by DWAC for any reason, an additional 10% discount will apply for all future conversions under all notes. If in the case that the Company's Common Stock is "chilled" for deposit into the DTC system and only eligible for clearing deposit, an additional 15% discount shall apply for all future conversions under the Note while the "chill" is in effect; (ii) if both the events noted in (i) above were to occur, an additional cumulative 25% discount shall apply; (iii) if the Company ceases to be a reporting company pursuant to the 1934 Act or if the Note cannot be converted into free trading shares after one hundred eighty-one (181) days from the issuance date, an additional 15% discount will be attributed to the conversion price; if the Company ceases to be a reporting company under the 1934 Act,
Non-cash repayment of debt				21,000,000
SE Holdings, LLC [Member]
Accrued interest					$ 7,008
SE Holdings, LLC [Member] | Promissory Note [Member]
Debt instrument, face amount		$ 110,000
Debt instrument, maturity date		Sep. 11, 2021
Original issue of discount		$ 10,000
Debt instrument, interest rate during period		12.00%
Debt instrument, interest rate effective rate description		Any amount of principal or interest on the note which is not paid when due shall bear interest at the rate of twenty four percent per annum from the due date thereof until the same is paid or converted in accordance with the terms of the note.
Repayment of debt		$ 22,500
Debt conversion, description		Principal payments shall be made in five (5) installments, each in the amount of US$22,500.00 commencing one the fifth monthly anniversary following the issue date and continuing thereafter each thirty (30) days for five (5) months (assuming no defaults or partial or complete conversions of our Common Stock as a form of repayment). This note may not be converted by SE into shares of our Common Stock unless we default in our monthly repayment obligation pursuant to the cash repayment schedule noted above. In the event of a default of the note, SE shall have the right to convert all or any part of the outstanding and unpaid amount of the note into fully paid and non-assessable shares of Common Stock at the lowest market price for the preceding five trading days; provided, however, that in no event shall SE be entitled to convert any portion of the note in excess of that portion of the note upon the conversion of which would result in beneficial ownership by SE and its affiliates of more than 4.99% of the outstanding shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934
GS Partners Capital, LLC [Member] | Non Convertible Redeemable Note [Member]
Debt instrument, face amount	$ 273,000
Debt instrument, maturity date	Dec. 05, 2021
Original issue of discount	$ 5,000
Debt instrument, interest rate during period	6.00%
Debt instrument, interest rate effective rate description	This note may be prepaid without penalty, provided that an event of default has not occurred. Upon an event of default, interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law.
Accrued interest	$ 1,167

XML

Notes Payable - Schedule of Convertible Notes (Details) - USD ($)		Mar. 31, 2021	Mar. 31, 2020
Total notes payable and convertible notes			$ 1,067,550
Less - note discounts			(482,416)
Less - current portion of these notes		(504,819)	(585,134)
Total notes payable and convertible notes, net discounts
GS Capital Partners LLC - Mar 2019 [Member]
Total notes payable and convertible notes	[1]		175,000
GS Capital Partners LLC - Jun 2019 [Member]
Total notes payable and convertible notes	[2]		60,000
Odyssey Funding, LLC - Sep 2019 [Member]
Total notes payable and convertible notes	[3]		80,000
BHP Capital NY Inc. - Oct 2019 [Member]
Total notes payable and convertible notes	[4]		55,000
Tangiers Global, LLC - Nov 2019 [Member]
Total notes payable and convertible notes	[5]		137,500
Odyssey Funding, LLC - Dec 2019 [Member]
Total notes payable and convertible notes	[6]		100,000
Jefferson Street Capital LLC - Dec 2019 [Member]
Total notes payable and convertible notes	[7]		55,000
BHP Capital NY Inc. - Jan 2020 [Member]
Total notes payable and convertible notes	[8]		44,000
ADAR Alef, LLC - Jan 2020 [Member]
Total notes payable and convertible notes	[9]		44,000
GS Capital LLC - Jan 2020 [Member]
Total notes payable and convertible notes	[10]		110,000
Tangiers Global, LLC - Feb 2020 [Member]
Total notes payable and convertible notes	[11]		65,000
Crown Bridge Partners, LLC - Feb 2020 [Member]
Total notes payable and convertible notes	[12]		55,000
ADAR Alef, LLC - Mar 2020 [Member]
Total notes payable and convertible notes	[13]		44,000
Tangiers Global, LLC - Mar 2020 [Member]
Total notes payable and convertible notes	[14]		43,050
GS Capital Partners, LLC - Apr 2020 [Member]
Total notes payable and convertible notes	[15]
ADAR Alef, LLC - Apr - 2020 [Member]
Total notes payable and convertible notes	[16]
Tangiers Global, LLC - May 2020 [Member]
Total notes payable and convertible notes	[17]
First Fire Investments - May 2020 [Member]
Total notes payable and convertible notes	[18]
GS Capital LLC - Jun 2020 [Member]
Total notes payable and convertible notes	[19]
Tangiers Global, LLC - Jun 2020 [Member]
Total notes payable and convertible notes	[20]
Tangiers Global, LLC - Dec 2020 [Member]
Total notes payable and convertible notes	[21]

[1] On March 14, 2019, the Company entered into a 12-month $300,000 principal face value 8.0% convertible debenture with GS Capital, with a maturity date of March 13, 2020. The GS Capital Note carried a $20,000 original issue discount (OID) and, as such, the initial net proceeds to the Company was $280,000. In connection with this agreement, the Company was obligated to issue 750,000 commitment shares having a value of $142,500 ($0.19 per share) which is reflected as interest expense in the Company's consolidated statement of operations during the year ended March 31, 2019. These shares were issued on June 20, 2019. The Holder was entitled, at its option, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock at a price for each share of Common Stock equal to 68% of the lowest daily VWAP of the Common Stock as reported on the National Quotations Bureau OTC Markets exchange for the fifteen (15) prior trading days. Due to the discount to market conversion, a beneficial conversion feature was recorded on this note as a discount to the note in the amount of the full-face value of the note which will be amortized over the life of the note. This amortization will be reflected as interest cost ratably over the term of the note. Also, in conjunction with this note, the 213,334 five-year cashless warrants, associated with the June 27, 2017, $80,000 5% one-year note were fully cancelled. As of March 31, 2021, the noteholder fully converted the $300,000 of principal and $26,009 of accrued interest into 14,473,254 shares of the Company's common stock ($0.0225 per share). Upon conversion, the balance of the share reserve was returned to treasury.

[2] On June 21, 2019, the Company entered into a one year 8% $60,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note had a maturity date of June 21, 2020 and carried a $5,000 original issue discount (such that $55,000 was funded to the Company on June 21, 2019). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company's common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 2,650,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the "Share Reserve") and maintain a 2.5 times reserve for the amount then outstanding. On June 3, 2020, the noteholder converted the entire $60,000 of principal and $4,937 of accrued interest into 3,162,115 shares of common stock ($0.0205 per share) and the balance of the reserved shares were returned to the treasury.

[3] On September 13, 2019, the Company entered into a one year 8% $100,000 Convertible Note with Odyssey Funding, LLC ("Investor") pursuant to the terms of a Securities Purchase Agreement (the "Odyssey Note"). The Odyssey Note has a maturity date of September 13, 2020 and carried a $5,000 original issue discount (such that $95,000 was funded to the Company at closing). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the Odyssey Note then outstanding into shares of the Company's common stock at a price for each share of common stock equal to 64% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the Odyssey Note, the Company issued irrevocable transfer agent instructions reserving 22,727,000 shares (the "Share Reserve") of its Common Stock for conversions under this Note. As of March 31, 2021, the full principal of $100,000 and accrued interest in the amount of $4,443 as well as $500 in fees were converted into 5,543,332 shares of common stock ($0.0188 per share). Upon conversion, all shares remaining in the Share Reserve were cancelled and returned to the treasury.

[4] On October 17, 2019, the Company entered into a Convertible Promissory Note ("BHP Note"), bearing an interest rate of 10% per annum, pursuant to a Securities Purchase Agreement with BHP Capital NY, Inc. dated October 7, 2019. The BHP Note had a maturity date of July 3, 2020 and carried a $5,000 original issue discount (such that $50,000 was funded to the Company on October 8, 2019). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the BHP Note then outstanding into shares of the Company's common stock at a price for each share of common stock equal to 65% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Holder was entitled to deduct $500 from the conversion amount in each Notice of Conversion to cover Holder's deposit fees associated with each Notice of Conversion. The Borrower was required at all times to have authorized and reserved three times the number of shares that would be issuable upon full conversion of the Note (assuming that the 4.99% limitation is not exceeded) in effect, initially 7,000,000 shares. On October 16, 2019, the Company issued 250,000 commitment shares to noteholder, BHP Capital NY, Inc. pursuant to the BHP Note. The shares had a value of $9,750 ($0.039 per share) which was recorded as interest expense on the Company's consolidated balance sheet. As of March 31, 2021, the noteholder converted the full principal of $55,000, accrued interest in the amount of $2,795 as well as $500 in fees into 3,060,931shares of common stock ($0.0191 per share). Upon conversion, all shares remaining in the Share Reserve were cancelled and returned to the treasury.

[5] On November 7, 2019, the Company effectuated a nine-month convertible promissory note with Tangiers Global, LLC (the "Tangiers Note"). The Company received funds in the amount of $125,000 after reduction of the Original Issue Discount of $12,500. The $137,500 face value note matured on August 5, 2020 and bears and interest rate of 10%, guaranteed. The Note holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the Tangiers Note then outstanding into shares of the Company's common stock at a price for each share of common stock equal to 66% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty (20) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Holder may not engage in any "shorting" or "hedging" transaction(s) in the Common Stock of the Company prior to conversion. In connection with the Tangiers Note, the Company issued irrevocable transfer agent instructions reserving 35,000,000 shares (the "Share Reserve") of its Common Stock for conversions under this Note, which Share Reserve has since been reduced as a result of conversions and other transactions between the parties. As of March 31, 2021, Tangiers fully converted all outstanding principal of $137,500 and accrued interest of $13,750 under this note. Interest on this note was guaranteed and prorated over the term of the note. Note principal and interest totaling $151,250 converted into 8,839,041 shares (average of $0.017112 per share). As a result, this note is fully repaid and retired and no further obligations or remuneration is due and owing thereunder, and any remaining shares of common stock in the Share Reserve were returned to treasury.

[6] On December 18, 2019, the Company entered into a one year 8% $100,000 Convertible Note with Odyssey Capital, LLC ("Odyssey") pursuant to the terms of a Securities Purchase Agreement (the "Odyssey Note"). The Odyssey Note has a maturity date of December 18, 2020 and carried a $5,000 original issue discount (such that $95,000 was funded to the Company at closing). The Investor was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the Odyssey Note then outstanding into shares of the Company's common stock at a price for each share of common stock equal to 64% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the Odyssey Note, the Company issued irrevocable transfer agent instructions reserving 22,084,000 shares (the "Share Reserve") of its Common Stock for conversions under this Odyssey Note. As of March 31, 2021, the Company fully paid and retired this note including accrued interest $4,252 and a prepayment penalty in the amount of $45,748. Upon full conversion of this note, any shares remaining in the Share Reserve were returned to treasury.

[7] On December 26, 2019, the Company entered into a one year 10% $55,000 Convertible Note with Jefferson Street Capital LLC ("Jefferson Street") pursuant to the terms of a Securities Purchase Agreement (the "Jefferson Street Note"). The Jefferson Street Note had a maturity date of December 26, 2020 and carried a $5,000 original issue discount (such that $50,000 was funded to the Company at closing). The Investor was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the Jefferson Street Note then outstanding into shares of the Company's common stock at a price for each share of common stock equal to 65% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen (15) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Commencing on the date which is 180 days following the date of this Jefferson Street Note and ending on the later of: (i) the Maturity Date and (ii) the date of payment of the Default Amount, this Jefferson Street Note may be converted by Jefferson Street in whole or in part at any time from time to time after the Issue Date as noted in the Jefferson Street Note. In connection with the Jefferson Street Note, the Company was required at all times to have authorized and reserved six times the number of common shares that would be issuable upon full conversion of the Jefferson Street Note in effect, initially reserved at 20,000,000 common shares (the "Share Reserve") of its Common Stock for conversions under this Jefferson Street Note. Upon full conversion of this note, remaining in the Share Reserve were cancelled. As of March 31, 2021, the noteholder converted the full principal of $55,000 plus accrued interest of $2,750 and $1,000 in fees for 3,095,362 shares of common stock ($0.01898 per share). Upon full conversion of this note, any shares remaining in the Share Reserve were returned to treasury.

[8] On January 3, 2020, the Company entered into a one-year 2% $44,000 Convertible Promissory Note with BHP Capital NY Inc. ("BHP Capital") pursuant to the terms of a Securities Purchase Agreement (the "BHP Capital Note"). The BHP Capital Note has a maturity date of January 3, 2021 and carries a $4,000 original issue discount (such that $40,000 was funded to the Company at closing). Subsequent to this note funding, BHP exercised a most favored nations clause increasing this notes interest rate to 8%, based on subsequent notes issued by the Company. BHP had the right from time to time, and at any time after closing, to convert all or any amount of the principal face amount of the BHP Capital Note then outstanding into shares of the Company's common stock at a price for each share of common stock equal to 65% of the lowest one-day volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty (20) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the BHP Capital Note, the Company issued irrevocable transfer agent instructions pursuant to which the Company is required at all times to have reserved three times the number of shares that would be issuable upon full conversion of the Note (assuming that the 4.99% beneficial ownership limitation is not in effect) (based on the respective Conversion Price of the Note in effect from time to time, initially 14,100,000 shares of its Common Stock (the "Share Reserve") for conversions under this BHP Capital Note. As of March 31, 2021, the noteholder fully converted the full principal of $44,000 plus accrued interest of $2,290 and $1,000 fees for 3,095,362 common shares ($0.01512 per shares). Upon full conversion of this note, any shares remaining in the Share Reserve were returned to treasury.

[9] On January 15, 2020, the Company entered into security purchase agreement with Adar Alef, LLC whereby the Company issued an 8% convertible redeemable note in the principal amount of $44,000. The note was funded with net proceeds of $37,800 after the deduction of $4,000 for OID and $2,200 in legal fees. The note has a maturity date of January 15, 2021. The face value amount plus accrued interest under the note are convertible into shares of the Company's common stock at a price for each share of common stock equal to 65% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the 20 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. The Company established an initial reserve of 6,296,000 shares of its common stock and at all times reserve a minimum of 4 times the amount of shares required if the note were to fully convert. As of March 31, 2021, the noteholder converted the full principal of $44,000 plus accrued interest of $2,750 and $1,000 in fees for 3,095,362 shares of common stock ($0.01898 per share). The full share reserve was released upon satisfaction of the note and returned to treasury.

[10] On January 17, 2020, the Company entered into a one year 8% $110,000 Convertible Note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement. The GS Capital Note had a maturity date of January 21, 2021 and carried a $10,000 original issue discount (such that $100,000 was funded to the Company on January 21, 2020). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company's common stock at a price for each share of common stock equal to 65% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty (20) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 5,150,000 shares of its Common Stock for conversions under this Note (the "Share Reserve") within 5 days from the date of execution and maintained a 2.5 times reserve for the amount then outstanding. Upon full conversion or repayment of this Note, all remaining shares in the Share Reserve were cancelled. Pursuant to this note, the Company issued to the noteholder 400,000 shares of its restricted common stock as debt commitment shares valued at $20,960 ($0.0524 per share). As of March 31, 2021, the noteholder converted the full principal of $110,000 plus accrued interest of $4,388 for 6,045,769 shares of common stock ($0.01898 per share). Upon full conversion of this note, any shares remaining in the Share Reserve were returned to treasury.

[11] On February 7, 2020, the Company effectuated a six-month convertible promissory note with Tangiers Global, LLC (the "Tangiers Note"). The Company received funds in the amount of $60,000 after reduction of the Original Issue Discount of $5,000. The $65,000 face value note matured on August 6, 2020 and bore an interest rate of 2%, guaranteed. This note had a fixed conversion price of $0.03 per share. The Company established an initial reserve of 7,000,000 shares of its common stock and has agreed to reserve a multiple of shares to fully convert under the terms of this note. The Note was retired after the Maturity Date, therefore was subject to the terms hereof and restrictions and limitations contained herein, the Holder had the right, at the Holder's sole option, to convert in whole or in part the outstanding and unpaid principal amount under this note into shares of common stock at the "Variable Conversion Price" which was equal to the lower of: (a) the Fixed Conversion Price or (b) 65% of the lowest volume weighted average price of the Company's Common Stock during the 20 consecutive trading days prior to the date on which holder elected to convert all or part of the note. Accrued interest in the amount of $1,300 has been recognized on this note as of March 31, 2021. As of March 31, 2021, the noteholder converted the full principal of $65,000 plus accrued interest of $1,300 for 4,444,891 shares of common stock ($0.014916 per share). Upon full conversion of this note, any shares remaining in the Share Reserve were returned to treasury.

[12] Effective February 11, 2020 the Company entered into a one-year 10% convertible promissory note with Crown Bridge Partners, LLC ("Crown"), having a face value of $55,000. The Company received funds in the amount of $50,000 on February 23, 2020, after reduction of the Original Issue Discount of $5,000. The $55,000 face value note had a maturity date of February 11, 2021. Crown had the right at any time to convert all or any part of the outstanding and unpaid principal amount and accrued and unpaid interest of this note into fully paid and non-assessable shares of common stock. The "Conversion Amount", with respect to any conversion of this note, the sum of (1) the principal amount of this note to be converted in such conversion plus (2) at Crown's option, accrued and unpaid interest, if any, on such principal amount at the interest rates provided in this note to the conversion date, plus (3) at Crown's option, default interest, if any. The conversion price shall be the lesser of (i) 65% multiplied by the lowest volume weighted average price on the OTCQB, or applicable trading market during the previous twenty (20) trading day period ending on the latest complete trading day prior to the date of this note or (ii) the variable conversion price which meant 65% multiplied by lowest intraday trading price of any market makers for the common stock during the twenty (20) trading day period ending on the last complete trading day prior to the conversion date. The Company agreed that during the period the conversion right exists, the Company will reserve from its authorized and unissued common stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of common stock upon the full conversion of this note. The Company was required at all times to have authorized and reserved six times the number of shares that is actually issuable upon full conversion of the note. The Company, on February 24, 2020, issued 250,000 debt commitment shares in conjunction with this note. The commitment shares had a value of $13,500 ($0.054 per share). The Company, on August 25, 2020 agreed issue 125,000 additional make-whole shares valued at $4,438 ($0.0355). As of March 31, 2021, the noteholder converted $8,543 on note principal including $1,500 of interest for 500,000 shares $0.020085. On January 5, 2021, the Company and the noteholder agreed to fully settle and retire this note for the amount of $75,0000. Along with $46,458 of note principal and $4,053 of accrued interest a prepayment penalty of $24,438 was recorded as a loss on conversion of debt. Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

[13] On March 17, 2020, the Company entered into security purchase agreement with Adar Alef, LLC whereby the Company issued an 8% convertible redeemable note in the principal amount of $44,000. The note was funded with net proceeds of $37,800, after the deduction of $4,000 of Original Issue Discount and $2,200 in legal fees. The note had a maturity date of March 17, 2021. The face value amount plus accrued interest under the note are convertible into shares of the Company's common stock at a price for each share of common stock equal to 65% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market for the 20 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. The Company established an initial reserve of 7,584,500 shares of its common stock and at all times reserved a minimum of 4 times the amount of shares required if the note were to fully convert. As of March 31, 2021, the noteholder converted $44,000 of note principal and accrued interest of $1,989 for 2,600,620 ($ 0.017684 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

[14] On March 23, 2020, the Company effectuated a six-month convertible promissory note with Tangiers Global, LLC. The Company received funds in the amount of $41,000 after reduction $2,050 of Original Issue Discount. The $43,050 face value note matured on September 23, 2020 and bore an interest rate of 5%, guaranteed. This note had a fixed conversion price of $0.03 per share. The Company agreed that it would, at all times, reserve and keep available for Tangiers, out of its authorized and unissued Common Stock a multiple of the number of shares of Common Stock issuable upon the full conversion of this note. Since this note was not converted as of the maturity date, Tangiers had the right, at its sole option, to convert in whole or in part the outstanding and unpaid Principal Amount under this Note into shares of Common Stock at the Variable Conversion Price which was equal to the lower of: (a) the Fixed Conversion Price or (b) 65% of the lowest volume weighted average price of the Company's Common Stock during the 20 consecutive Trading Days prior to the date on which Tangiers elects to convert all or part of the Note. As of March 31, 2021, the note holder converted $43,050 in note principal and $2,153 of accrued interest for 2,826,923 shares ($0.01599 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

[15] On April 17, 2020, the Company entered into a one-year 8% $55,000 convertible note with GS Capital Partners, LLC pursuant to the terms of a Securities Purchase Agreement ("GS Note"). The GS Note had a maturity date of April 17, 2021 and carried a $5,000 Original Issue Discount (such that $50,000 was funded to the Company on April 17, 2020). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company's common stock at a price for each share of common stock equal to 65% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty (20) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 5,717,000 shares of its common Stock for conversions under this and agreed to maintain a 2.5 times reserve for the amount then outstanding. The Company issued to the noteholder 150,000 shares of its restricted common stock as debt commitment shares valued at $5,000 ($0.03 per share). As of March 31, 2021, this noteholder converted note principal of $55,000 and accrued interest of $2,662 for 4,650,335 shares ($0.01408 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

[16] On April 30, 2020, the Company entered into securities purchase agreement with Adar Alef, LLC whereby the Company issued an 8% convertible redeemable note in the principal amount of $44,000. The note was funded with net proceeds of $37,800, after the deduction of $4,000 for Original Issue Discount and $2,200 in legal fees. The note has a maturity date of April 30, 2021. The face value amount plus accrued interest under the note was convertible into shares of the Company's common stock at a price for each share of common stock equal to 65% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the 20 prior trading days including the day upon which a notice of conversion was received by the Company or its transfer agent. The Company established an initial reserve of 7,736,000 shares of its common stock and at all times reserve a minimum of 4 times the amount of shares required if the note were to fully convert. As of March 31, 2021, the noteholder converted note principal of $44,000 and accrued interest $1,975 for 3,701,000 shares ($0.01242 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

[17] On May 8, 2020, the Company effectuated a six-month fixed convertible promissory note with Tangiers Global, LLC with a total face value of $102,500 containing an Original Issue Discount of $2,500. On May 8, 2020 and June 10, 2020, the Company received funds, on each date, in the amount of $50,000 and recognized Original Issue Discount of $1,250. This note matured on November 8, 2020 and bore an interest rate of 5%, guaranteed. This note has a fixed conversion price of $0.03 per share. The Company agreed that it would, at all times, reserve and keep available for Tangiers, out of its authorized and unissued Common Stock a multiple of the number of shares of Common Stock as were issuable upon the full conversion of this note. Since the note was not retired on or before the maturity date, it was subject to the terms hereof and restrictions and limitations contained herein, Tangiers had the right, at the its sole option, to convert in whole or in part the outstanding and unpaid principal amount under this note into shares of Common Stock at the variable conversion price which shall be equal to the lower of: (a) the fixed conversion price or (b) 70% of the lowest volume weighted average price of the Company's Common Stock during the 15 consecutive trading days prior to the date on which Tangiers elects to convert all or part of the note. As of March 31, 2021, the noteholder converted note principal of $102,500 and accrued interest $5,125 for 5,823,864 shares ($0.01848 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

[18] On May 18, 2020, the Company entered into a Securities Purchase Agreement with Firstfire Global Opportunities Fund, LLC ("Firstfire") pursuant to a convertible promissory note in the principal amount of $88,333, having an Original Issue Discount in the amount of $8,833. On May 24, 2020, the Company received funds in the amount of $75,000 after the deduction of legal fees in the amount of $4,500. This note bore an annual interest rate of 8%. The per share conversion price into which principal amount and interest under this note was convertible into shares of Common Stock hereunder equal to 65% multiplied by the average of the two (2) lowest volume weighted average prices of the common stock during the fifteen (15) consecutive trading day period immediately preceding the date of the respective conversion. The borrower agreed that at all times until the note is satisfied in full, the borrower will reserve from its authorized and unissued Common Stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of a number of conversion shares equal to the greater of: (a) 8,500,000 shares of Common Stock or (b) the sum of the number of Conversion Shares issuable upon the full conversion of this Note multiplied by (ii) three and a half (3.5). The Company issued to the noteholder 375,000 shares of its restricted common stock as debt commitment shares valued at $12,075 ($0.0322 per share). As of March 31, 2021, the noteholder converted note principal of $88,333 and accrued interest $3,501 for 6,020,000 shares ($0.015255 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

[19] On June 4, 2020, the Company entered into a one-year 8% $33,000 convertible note with GS Capital Partners, LLC (the "GS Note") pursuant to the terms of a Securities Purchase Agreement. The GS Note had a maturity date of June 4, 2021 and carried $3,000 of original issue discount (such that $30,000 was funded to the Company on or about June 4, 2020). The holder was entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company's common stock at a price for each share of common stock equal to 65% of the lowest daily volume weighted average price of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty (20) prior trading days including the day upon which a notice of conversion was received by the Company or its transfer agent. Accrued but unpaid interest was subject to conversion. In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 3,678,000 shares of its Common Stock for conversions under this note and maintained a 2.5 times reserve for the amount then outstanding. The Company issued to the noteholder 90,000 shares of its restricted common stock as debt commitment shares valued at $3,105 ($0.0345 per share). As of March 31, 2021, the noteholder converted note principal of $33,000 and accrued interest $1,807 for 2,369,458 shares ($0.01469 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

[20] On June 24, 2020, the Company effectuated a six-month fixed convertible promissory note with Tangiers Global, LLC with a total face value of $210,000 containing Original Issue Discount of $10,000. On June 26, 2020, the Company received proceeds of $200,000, net Original Issue Discount of $10,000. This note matured on December 24, 2020 and bore an interest rate of 8%, guaranteed. This note has a fixed conversion price of $0.03 per share. Since the note was not retired on or before the maturity date, then at any time and from time to time after the maturity date, and subject to the terms hereof and restrictions and limitations contained herein, Tangiers had the right, at the Tangiers's sole option, to convert in whole or in part the outstanding and unpaid principal amount under this note into shares of Common Stock at the variable conversion price which was equal to the lower of: (a) the fixed conversion price or (b) 70% of the lowest volume weighted average price of the Company's Common Stock during the 15 consecutive trading days prior to the date on which Tangiers elected to convert all or part of the note. During January 2021, the noteholder converted $210,000 of note principal and accrued interest $16,800 for 12,221,861 shares ($0.01856 per share). Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

[21] On December 21, 2020, the Company effectuated a $210,000 six-month fixed convertible promissory note with Tangiers Global, LLC containing Original Issue Discount of $10,000. This note had a mature date of June 22, 2021 with an interest rate of 8%, guaranteed. This note had a fixed conversion price of $0.03 per share. If the Note was not retired on or before the maturity date, then at any time and from time to time after the maturity date, and subject to the terms hereof and restrictions and limitations contained herein, the Tangiers had the right, at the Tangiers' sole option, to convert in whole or in part the outstanding and unpaid principal amount under this note into shares of common stock at the variable conversion price which was equal to the lower of: (a) the Fixed Conversion Price or (b) 70% of the lowest volume weighted average price of the Company's common stock during the 15 consecutive trading days prior to the date on which Tangiers elected to convert all or part of the note. During March 2021, the noteholder converted $135,000 of note principal and accrued interest $16,800 for 5,060,000 shares ($0.03 per share). The Company paid $75,000 cash to convert the remaining note principal. Upon full conversion of this note, any shares remaining in the share reserve were returned to treasury.

XML

Notes Payable - Schedule of Convertible Notes (Details) (Parenthetical)																														1 Months Ended		12 Months Ended
	Mar. 31, 2021 USD ($) $ / shares shares	Jan. 05, 2021 USD ($)	Dec. 21, 2020 USD ($) TradingDays $ / shares	Aug. 25, 2020 USD ($) $ / shares shares	Jun. 26, 2020 USD ($) TradingDays $ / shares	Jun. 10, 2020 USD ($)	Jun. 04, 2020 USD ($) TradingDays $ / shares shares	Jun. 03, 2020 USD ($) $ / shares shares	May 24, 2020 USD ($) TradingDays $ / shares shares	May 08, 2020 USD ($) TradingDays $ / shares	Apr. 30, 2020 USD ($) TradingDays shares	Apr. 17, 2020 USD ($) TradingDays $ / shares shares	Mar. 23, 2020 USD ($) TradingDays $ / shares	Mar. 17, 2020 USD ($) TradingDays shares	Feb. 24, 2020 USD ($) $ / shares shares	Feb. 11, 2020 USD ($) TradingDays	Feb. 07, 2020 USD ($) TradingDays $ / shares shares	Jan. 17, 2020 USD ($) TradingDays $ / shares shares	Jan. 15, 2020 USD ($) TradingDays shares	Jan. 03, 2020 USD ($) TradingDays shares	Dec. 26, 2019 USD ($) TradingDays shares	Dec. 18, 2019 USD ($) TradingDays shares	Nov. 07, 2019 USD ($) TradingDays shares	Oct. 17, 2019 USD ($) TradingDays shares	Oct. 16, 2019 USD ($) $ / shares shares	Sep. 13, 2019 USD ($) TradingDays shares	Jun. 21, 2019 USD ($) TradingDays shares	Mar. 14, 2019 USD ($) TradingDays $ / shares shares	Jun. 27, 2017 USD ($) shares	Mar. 31, 2021 USD ($) $ / shares shares	Jan. 31, 2021 USD ($) $ / shares shares	Mar. 31, 2021 USD ($) $ / shares shares	Mar. 31, 2020 USD ($)	Jun. 24, 2020 USD ($)	May 18, 2020 USD ($)	Jan. 21, 2020 USD ($)	Oct. 08, 2019 USD ($)
Proceeds from notes payable																																$ 482,000	$ 971,100
Common stock shares issued, value																																1,587,212	143,420
Conversion of convertible debt, amount																																253,868	218,460
Accrued interest	$ 14,722																													$ 14,722		14,722	39,384
Legal fees																																17,700	24,900
Settlement of note payable																																$ 221,457	$ 27,500
Securities Purchase Agreement [Member]
Warrant term	7 years																													7 years		7 years	3 years
GS Capital Note [Member] | Securities Purchase Agreement [Member] | Noteholders [Member]
Shares issued price per share | $ / shares								$ 0.0205
Conversion of convertible debt, amount								$ 60,000
Conversion of convertible debt, accrued interest								$ 4,937
Conversion of convertible debt, shares | shares								3,162,115
BHP Note [Member] | Securities Purchase Agreement [Member]
Shares issued price per share | $ / shares	$ 0.01512																													$ 0.01512		$ 0.01512
Conversion of convertible debt, amount																																$ 44,000
Conversion of convertible debt, accrued interest																																$ 2,290
Conversion of convertible debt, shares | shares																																3,095,362
Fee amount	$ 1,000																													$ 1,000		$ 1,000
GS Capital Partners, LLC [Member] | Convertible Note [Member] | Securities Purchase Agreement [Member]
Debt principal amount																		$ 110,000									$ 60,000
Debt instrument, interest rate																		8.00%									8.00%
Debt maturity date																		Jan. 21, 2021									Jun. 21, 2020
Original issue of discount																		$ 10,000									$ 5,000
Shares issued price per share | $ / shares	$ 0.01898																													$ 0.01898		$ 0.01898
Percentage of share price multiplied by the lowest closing price																		65.00%									66.00%
Trading days | TradingDays																		20									15
Conversion of convertible debt, amount																																$ 110,000
Conversion of convertible debt, accrued interest																																$ 4,388
Conversion of convertible debt, shares | shares																																6,045,769
Funded amount																											$ 55,000									$ 100,000
Debt conversion, description																		In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 5,150,000 shares of its Common Stock for conversions under this Note (the "Share Reserve") within 5 days from the date of execution and maintained a 2.5 times reserve for the amount then outstanding. Upon full conversion or repayment of this Note, all remaining shares in the Share Reserve were cancelled.									In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 2,650,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the "Share Reserve") and maintain a 2.5 times reserve for the amount then outstanding.
Shares reserve | shares																		5,150,000									2,650,000
GS Capital Partners, LLC [Member] | Convertible Note [Member] | Securities Purchase Agreement [Member] | Restricted Common Stock [Member]
Shares issued price per share | $ / shares																		$ 0.0524
Conversion of convertible debt, amount																		$ 20,960
Conversion of convertible debt, shares | shares																		400,000
GS Capital Partners, LLC [Member] | Convertible Promissory Note [Member]
Debt principal amount												$ 55,000
Debt instrument, interest rate												8.00%
Debt maturity date												Apr. 17, 2021
Original issue of discount												$ 5,000
Shares issued price per share | $ / shares	0.01408																													0.01408		$ 0.01408
Percentage of share price multiplied by the lowest closing price												65.00%
Trading days | TradingDays												20
Conversion of convertible debt, amount																																$ 55,000
Conversion of convertible debt, accrued interest																																$ 2,662
Conversion of convertible debt, shares | shares																																4,650,335
Funded amount												$ 50,000
Debt conversion, description												In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 5,717,000 shares of its common Stock for conversions under this and agreed to maintain a 2.5 times reserve for the amount then outstanding.
Shares reserve | shares												5,717,000
GS Capital Partners, LLC [Member] | Convertible Promissory Note [Member] | Restricted Common Stock [Member]
Number of common stock shares issued | shares												150,000
Common stock shares issued, value												$ 5,000
Shares issued price per share | $ / shares												$ 0.03
GS Capital Partners, LLC [Member] | Convertible Promissory Note [Member] | Securities Purchase Agreement [Member]
Debt principal amount							$ 33,000
Debt instrument, interest rate							8.00%
Debt maturity date							Jun. 04, 2021
Original issue of discount							$ 3,000
Shares issued price per share | $ / shares	0.01469																													0.01469		$ 0.01469
Percentage of share price multiplied by the lowest closing price							65.00%
Trading days | TradingDays							20
Conversion of convertible debt, amount																																$ 33,000
Conversion of convertible debt, accrued interest																																$ 1,807
Conversion of convertible debt, shares | shares																																2,369,458
Funded amount							$ 30,000
Debt conversion, description							In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 3,678,000 shares of its Common Stock for conversions under this note and maintained a 2.5 times reserve for the amount then outstanding.
Shares reserve | shares							3,678,000
GS Capital Partners, LLC [Member] | Convertible Promissory Note [Member] | Securities Purchase Agreement [Member] | Restricted Common Stock [Member]
Number of common stock shares issued | shares							90,000
Common stock shares issued, value							$ 3,105
Shares issued price per share | $ / shares							$ 0.0345
Odyssey Funding, LLC [Member] | Odyssey Note [Member] | Securities Purchase Agreement [Member]
Debt principal amount																										$ 100,000
Debt instrument, interest rate																										8.00%
Debt maturity date																										Sep. 13, 2020
Original issue of discount																										$ 5,000
Shares issued price per share | $ / shares	$ 0.0188																													$ 0.0188		$ 0.0188
Percentage of share price multiplied by the lowest closing price																										64.00%
Trading days | TradingDays																										15
Conversion of convertible debt, amount																																$ 100,000
Conversion of convertible debt, accrued interest																																$ 4,443
Conversion of convertible debt, shares | shares																																5,543,332
Funded amount																										$ 95,000
Debt conversion, description																										In connection with the Odyssey Note, the Company issued irrevocable transfer agent instructions reserving 22,727,000 shares (the "Share Reserve") of its Common Stock for conversions under this Note.
Shares reserve | shares																										22,727,000
Fee amount	$ 500																													$ 500		$ 500
BHP Capital NY Inc [Member] | BHP Note [Member] | Securities Purchase Agreement [Member]
Debt principal amount																				$ 44,000
Debt instrument, interest rate																				2.00%				10.00%
Debt maturity date																				Jan. 03, 2021				Jul. 03, 2020
Original issue of discount																				$ 4,000				$ 5,000
Number of common stock shares issued | shares																									250,000
Common stock shares issued, value																									$ 9,750
Shares issued price per share | $ / shares	$ 0.0191																								$ 0.039					$ 0.0191		$ 0.0191
Percentage of share price multiplied by the lowest closing price																				65.00%				65.00%
Trading days | TradingDays																				20				15
Conversion of convertible debt, amount																								$ 500								$ 55,000
Conversion of convertible debt, accrued interest																																$ 2,795
Conversion of convertible debt, shares | shares																								7,000,000								3,060,931
Funded amount																				$ 40,000																	$ 50,000
Debt conversion, description																				In connection with the BHP Capital Note, the Company issued irrevocable transfer agent instructions pursuant to which the Company is required at all times to have reserved three times the number of shares that would be issuable upon full conversion of the Note (assuming that the 4.99% beneficial ownership limitation is not in effect) (based on the respective Conversion Price of the Note in effect from time to time, initially 14,100,000 shares of its Common Stock (the "Share Reserve") for conversions under this BHP Capital Note.				The Borrower was required at all times to have authorized and reserved three times the number of shares that would be issuable upon full conversion of the Note (assuming that the 4.99% limitation is not exceeded) in effect, initially 7,000,000 shares.
Shares reserve | shares																				14,100,000				7,000,000
Fee amount	$ 500																													$ 500		$ 500
Tangier's Global, LLC [Member]
Number of common stock shares issued | shares																																13,910,000
Shares issued price per share | $ / shares	$ 0.01848																													$ 0.01848		$ 0.01848
Conversion of convertible debt, amount																																$ 102,500
Conversion of convertible debt, accrued interest																																$ 5,125
Conversion of convertible debt, shares | shares																																5,823,864
Tangier's Global, LLC [Member] | Tangier's Note [Member]
Debt principal amount																	$ 65,000
Debt instrument, interest rate																	2.00%
Debt maturity date																	Aug. 06, 2020
Original issue of discount																	$ 5,000
Proceeds from notes payable																	$ 60,000
Shares issued price per share | $ / shares	$ 0.014916																													$ 0.014916		$ 0.014916
Percentage of share price multiplied by the lowest closing price																	65.00%
Trading days | TradingDays																	20
Conversion of convertible debt, amount																																$ 65,000
Conversion of convertible debt, accrued interest																																$ 1,300
Conversion of convertible debt, shares | shares																																4,444,891
Debt conversion, description																	The Company established an initial reserve of 7,000,000 shares of its common stock and has agreed to reserve a multiple of shares to fully convert under the terms of this note.
Shares reserve | shares																	7,000,000
Conversion price | $ / shares
Accrued interest	$ 1,300																													$ 1,300		$ 1,300
Tangier's Global, LLC [Member] | Tangier's Note [Member] | Securities Purchase Agreement [Member]
Debt principal amount																							$ 137,500
Debt instrument, interest rate																							10.00%
Debt maturity date																							Aug. 05, 2020
Original issue of discount																							$ 12,500
Proceeds from notes payable																							$ 125,000
Percentage of share price multiplied by the lowest closing price																							66.00%
Trading days | TradingDays																							20
Conversion of convertible debt, amount	137,500
Conversion of convertible debt, accrued interest	13,750
Shares reserve | shares																							35,000,000
Note principal and interest	$ 151,250
Number of shares issued | shares	8,839,041
Conversion price | $ / shares	$ 0.017112																													$ 0.017112		$ 0.017112
Tangier's Global, LLC [Member] | Convertible Promissory Note [Member]
Debt principal amount			$ 210,000							$ 102,500			$ 43,050																					$ 210,000
Debt instrument, interest rate			8.00%		8.00%					5.00%			5.00%
Debt maturity date			Jun. 22, 2021		Dec. 24, 2020					Nov. 08, 2020			Sep. 23, 2020
Original issue of discount			$ 10,000		$ 10,000	$ 1,250				$ 2,500			$ 2,050																					$ 10,000
Proceeds from notes payable					$ 200,000	$ 50,000				$ 50,000			$ 41,000
Shares issued price per share | $ / shares	0.01599		$ 0.03		$ 0.03																									0.01599		$ 0.01599
Percentage of share price multiplied by the lowest closing price			70.00%		70.00%					70.00%			65.00%
Trading days | TradingDays			15		15					15			20
Conversion of convertible debt, amount																																$ 43,050
Conversion of convertible debt, accrued interest																																$ 2,153
Conversion of convertible debt, shares | shares																																2,826,923
Debt conversion, description										Since the note was not retired on or before the maturity date, it was subject to the terms hereof and restrictions and limitations contained herein, Tangiers had the right, at the its sole option, to convert in whole or in part the outstanding and unpaid principal amount under this note into shares of Common Stock at the variable conversion price which shall be equal to the lower of: (a) the fixed conversion price or (b) 70% of the lowest volume weighted average price of the Company's Common Stock during the 15 consecutive trading days prior to the date on which Tangiers elects to convert all or part of the note.
Conversion price | $ / shares										$ 0.03
Tangier's Global, LLC [Member] | Convertible Promissory Note [Member]
Shares issued price per share | $ / shares	$ 0.03																													$ 0.03	$ 0.01856	$ 0.03
Conversion of convertible debt, amount																														$ 135,000	$ 210,000
Conversion of convertible debt, accrued interest																														$ 16,800	$ 16,800
Conversion of convertible debt, shares | shares																														5,060,000	12,221,861
Settlement of note payable																																$ 75,000
Odyssey Capital, LLC [Member] | Odyssey Note [Member] | Securities Purchase Agreement [Member]
Debt principal amount																						$ 100,000
Debt instrument, interest rate																						8.00%
Debt maturity date																						Dec. 18, 2020
Original issue of discount																						$ 5,000
Percentage of share price multiplied by the lowest closing price																						64.00%
Trading days | TradingDays																						15
Funded amount																						$ 95,000
Debt conversion, description																						In connection with the Odyssey Note, the Company issued irrevocable transfer agent instructions reserving 22,084,000 shares (the "Share Reserve") of its Common Stock for conversions under this Odyssey Note.
Shares reserve | shares																						22,084,000
Accrued interest	$ 4,252																													$ 4,252		4,252
Prepayment penalty	$ 45,748																													$ 45,748		$ 45,748
Jefferson Street Capital, LLC [Member] | Jefferson Street [Member] | Securities Purchase Agreement [Member]
Debt principal amount																					$ 55,000
Debt instrument, interest rate																					10.00%
Debt maturity date																					Dec. 26, 2020
Original issue of discount																					$ 5,000
Shares issued price per share | $ / shares	$ 0.01898																													$ 0.01898		$ 0.01898
Percentage of share price multiplied by the lowest closing price																					65.00%
Trading days | TradingDays																					15
Conversion of convertible debt, amount																																$ 55,000
Conversion of convertible debt, accrued interest																																$ 2,750
Conversion of convertible debt, shares | shares																																3,095,362
Funded amount																					$ 50,000
Debt conversion, description																					In connection with the Jefferson Street Note, the Company was required at all times to have authorized and reserved six times the number of common shares that would be issuable upon full conversion of the Jefferson Street Note in effect, initially reserved at 20,000,000 common shares (the "Share Reserve") of its Common Stock for conversions under this Jefferson Street Note.
Shares reserve | shares																					20,000,000
Fee amount	$ 1,000																													$ 1,000		$ 1,000
Adar Alef, LLC [Member] | Convertible Redeemable Note [Member] | Securities Purchase Agreement [Member]
Debt principal amount																			$ 44,000
Debt instrument, interest rate																			8.00%
Debt maturity date																			Jan. 15, 2021
Original issue of discount																			$ 4,000
Proceeds from notes payable																			$ 37,800
Shares issued price per share | $ / shares	$ 0.01898																													$ 0.01898		$ 0.01898
Percentage of share price multiplied by the lowest closing price																			65.00%
Trading days | TradingDays																			20
Conversion of convertible debt, amount																																$ 44,000
Conversion of convertible debt, accrued interest																																$ 2,750
Conversion of convertible debt, shares | shares																																3,095,362
Debt conversion, description																			The Company established an initial reserve of 6,296,000 shares of its common stock and at all times reserve a minimum of 4 times the amount of shares required if the note were to fully convert
Shares reserve | shares																			6,296,000
Fee amount	$ 1,000																													$ 1,000		$ 1,000
Legal fees																			$ 2,200
Adar Alef, LLC [Member] | Convertible Promissory Note [Member]
Debt principal amount											$ 44,000
Debt instrument, interest rate											8.00%
Debt maturity date											Apr. 30, 2021
Original issue of discount											$ 4,000
Proceeds from notes payable											$ 37,800
Shares issued price per share | $ / shares	$ 0.01242																													$ 0.01242		$ 0.01242
Percentage of share price multiplied by the lowest closing price											65.00%
Trading days | TradingDays											20
Conversion of convertible debt, amount																																$ 44,000
Conversion of convertible debt, accrued interest																																$ 1,975
Conversion of convertible debt, shares | shares																																3,701,000
Debt conversion, description											The Company established an initial reserve of 7,736,000 shares of its common stock and at all times reserve a minimum of 4 times the amount of shares required if the note were to fully convert.
Shares reserve | shares											7,736,000
Legal fees											$ 2,200
Adar Alef, LLC [Member] | Convertible Promissory Note [Member] | Securities Purchase Agreement [Member]
Debt principal amount														$ 44,000
Debt instrument, interest rate														8.00%
Debt maturity date														Mar. 17, 2021
Original issue of discount														$ 4,000
Shares issued price per share | $ / shares	0.017684																													0.017684		$ 0.017684
Percentage of share price multiplied by the lowest closing price														65.00%
Trading days | TradingDays														20
Conversion of convertible debt, amount																																$ 44,000
Conversion of convertible debt, accrued interest																																$ 1,989
Conversion of convertible debt, shares | shares																																2,600,620
Funded amount														$ 37,800
Debt conversion, description														The Company established an initial reserve of 7,584,500 shares of its common stock and at all times reserved a minimum of 4 times the amount of shares required if the note were to fully convert.
Shares reserve | shares														7,584,500
Legal fees														$ 2,200
Crown Bridge Partners, LLC [Member] | Convertible Promissory Note [Member]
Debt principal amount		$ 46,458														$ 55,000
Debt instrument, interest rate																10.00%
Debt maturity date																Feb. 11, 2021
Original issue of discount																$ 5,000
Proceeds from notes payable																$ 50,000
Shares issued price per share | $ / shares	0.020085			$ 0.0355											$ 0.054															0.020085		$ 0.020085
Percentage of share price multiplied by the lowest closing price																65.00%
Trading days | TradingDays																20
Conversion of convertible debt, amount				$ 4,438											$ 13,500																	$ 8,543
Conversion of convertible debt, accrued interest																																$ 1,500
Conversion of convertible debt, shares | shares				125,000											250,000																	500,000
Debt conversion, description																(1) the principal amount of this note to be converted in such conversion plus (2) at Crown's option, accrued and unpaid interest, if any, on such principal amount at the interest rates provided in this note to the conversion date, plus (3) at Crown's option, default interest, if any. The conversion price shall be the lesser of (i) 65% multiplied by the lowest volume weighted average price on the OTCQB, or applicable trading market during the previous twenty (20) trading day period ending on the latest complete trading day prior to the date of this note or (ii) the variable conversion price which meant 65% multiplied by lowest intraday trading price of any market makers for the common stock during the twenty (20) trading day period ending on the last complete trading day prior to the conversion date.
Accrued interest		4,053
Prepayment penalty		24,438
Settlement of note payable		$ 750,000
Firstfire Global Opportunities Fund, LLC [Member] | Convertible Promissory Note [Member] | Securities Purchase Agreement [Member]
Debt principal amount																																			$ 88,333
Debt instrument, interest rate																																			8.00%
Original issue of discount																																			$ 8,833
Proceeds from notes payable									$ 75,000
Number of common stock shares issued | shares									8,500,000
Shares issued price per share | $ / shares	0.015255																													0.015255		$ 0.015255
Percentage of share price multiplied by the lowest closing price									65.00%
Trading days | TradingDays									15
Conversion of convertible debt, amount																																$ 88,333
Conversion of convertible debt, accrued interest																																$ 3,501
Conversion of convertible debt, shares | shares																																6,020,000
Legal fees									$ 4,500
Firstfire Global Opportunities Fund, LLC [Member] | Convertible Promissory Note [Member] | Securities Purchase Agreement [Member] | Restricted Common Stock [Member]
Number of common stock shares issued | shares									375,000
Common stock shares issued, value									$ 12,075
Shares issued price per share | $ / shares									$ 0.0322
Convertible Debenture [Member]
Shares issued price per share | $ / shares	$ 0.0225																													$ 0.0225		$ 0.0225
Conversion of convertible debt, amount																																$ 300,000
Conversion of convertible debt, accrued interest																																$ 26,009
Conversion of convertible debt, shares | shares																																14,473,254
Convertible Debenture [Member] | GS Capital Partners, LLC [Member]
Debt principal amount																												$ 300,000
Debt instrument, interest rate																												8.00%	5.00%
Debt maturity date																												Mar. 13, 2020
Original issue of discount																												$ 20,000
Proceeds from notes payable																												$ 280,000
Number of common stock shares issued | shares																												750,000
Common stock shares issued, value																												$ 142,500
Shares issued price per share | $ / shares																												$ 0.19
Percentage of share price multiplied by the lowest closing price																												68.00%
Trading days | TradingDays																												15
Cashless warrants | shares																													213,334
Warrant term																													5 years
Debt principal amount cancelled																													$ 80,000

XML

Related Parties (Details Narrative) - Chief Executive Officer [Member] - USD ($)	Dec. 26, 2019	Jul. 22, 2019
Deposit	$ 50,159
Convertible Note [Member] | Securities Purchase Agreement [Member] | Jefferson Street Capital, LLC [Member]
Debt instrument, interest rate		10.00%
Debt principal amount		$ 55,000

XML

Stockholders' Equity (Deficit) (Details Narrative) - USD ($)							12 Months Ended
	Jul. 10, 2020	Apr. 03, 2020	Mar. 27, 2020	Mar. 05, 2020	Jan. 21, 2020	Feb. 01, 2012	Mar. 31, 2021	Mar. 31, 2020	Jun. 28, 2021
Common stock authorized							400,000,000	400,000,000
Common stock, shares issued							275,858,714		283,496,214
Common stock, shares outstanding							275,858,714	107,039,107	283,496,214
Proceeds from common stock							$ 1,665,211	$ 244,420
Common stock shares issued, value							1,587,212	143,420
Number of common stock shares issued for service, value
Share-based compensation expense							$ 1,019,814	$ 569,636
Current Executive [Member]
Options to purchase common shares						66,667
Former Executive [Member]
Options to purchase common shares						66,667
Two Executives [Member]
Options to purchase common shares						133,334
Fiscal Year 2020 [Member]
Number of shares issued from common stock for conversion of debt, shares								21,295,495
Number of shares issued from common stock for conversion of debt								$ 467,500
Accrued interest								$ 28,762
Number of common stock shares issued for service								7,100,000
Number of common stock shares issued for debt commitment								2,350,000
Number of common stock issued for debt commitment								$ 218,460
Beneficial conversion feature								$ 569,636
Fiscal Year 2020 [Member] | Vice President [Member]
Number of common stock shares issued								250,000
Fiscal Year 2021 [Member]
Shares issued price per share							$ 0.01825
Number of shares issued from common stock for conversion of debt, shares							93,197,109
Number of shares issued from common stock for conversion of debt							$ 1,588,926
Accrued interest							$ 111,749
Number of common stock shares issued for service							7,687,500
Number of common stock shares issued for debt commitment							5,740,000
Number of common stock issued for debt commitment							$ 253,869
Beneficial conversion feature							$ 208,806
Fiscal Year 2021 [Member] | Two Director [Member]
Number of common stock shares issued							2,500,000
Shares issued price per share								$ 0.092
Fiscal Year 2021 [Member] | Chief Executive Officer [Member]
Shares issued price per share	$ 0.05
Shares purchased during period	700,000
Shares purchased during period, value	$ 35,000
Minimum [Member] | Fiscal Year 2020 [Member]
Shares issued price per share								0.01412
Stock issued during period, per share								0.039
Minimum [Member] | Fiscal Year 2021 [Member]
Shares issued price per share							$ 0.0306
Stock issued during period, per share							0.028
Maximum [Member] | Fiscal Year 2020 [Member]
Shares issued price per share								0.04725
Stock issued during period, per share								0.19
Maximum [Member] | Fiscal Year 2021 [Member]
Shares issued price per share							0.050
Stock issued during period, per share							$ 0.09
Tangier's Global, LLC [Member]
Number of common stock shares issued							13,910,000
Proceeds from common stock							$ 400,514
Shares issued price per share							$ 0.01848
Tangier's Global, LLC [Member] | Fiscal Year 2021 [Member]
Number of common stock shares issued							13,910,000
Common stock shares issued, value							$ 369,482
Tangier's Global, LLC [Member] | Minimum [Member] | Fiscal Year 2021 [Member]
Shares issued price per share							$ 0.02614
Tangier's Global, LLC [Member] | Maximum [Member] | Fiscal Year 2021 [Member]
Shares issued price per share							$ 0.03344
Open Therapeutics [Member] | Minimum [Member] | Fiscal Year 2020 [Member]
Shares issued price per share								0.08
Open Therapeutics [Member] | Maximum [Member] | Fiscal Year 2020 [Member]
Shares issued price per share								$ 0.2092
Aegea Biotechnologies Inc [Member] | Unregistered Common Stock [Member]
Number of common stock shares issued		5,000,000
Common stock shares issued, value		$ 155,000
Shares issued price per share		$ 0.031
Investment Agreement [Member] | Tangier's Global, LLC [Member]
Sale of stock, value of shares issued on transaction				$ 5,000,000	$ 5,000,000
Number of common stock on sale transaction shares				76,000,000	76,000,000
Number of common stock shares issued							13,910,000
Common stock shares issued, value							$ 400,514
Distribution Agreements [Member] | Fiscal Year 2020 [Member]
Number of common stock shares issued								2,450,000
Common stock shares issued, value								$ 496,261
Stock Purchase Agreements [Member] | Fiscal Year 2020 [Member] | Accredited Investors [Member]
Number of common stock shares issued			200,000					5,470,286
Common stock shares issued, value			$ 5,000					$ 143,420
Shares issued price per share			$ 0.025
Stock Purchase Agreements [Member] | Fiscal Year 2021 [Member]
Shares issued for consideraiton							40,084,998
Shares issued for consideraiton, value							$ 1,587,214
Stock Purchase Agreements [Member] | Minimum [Member] | Fiscal Year 2020 [Member] | Accredited Investors [Member]
Shares issued price per share								$ 0.02
Stock Purchase Agreements [Member] | Minimum [Member] | Fiscal Year 2021 [Member]
Shares issued price per share							$ 0.024
Stock Purchase Agreements [Member] | Maximum [Member] | Fiscal Year 2020 [Member] | Accredited Investors [Member]
Shares issued price per share								$ 0.07
Stock Purchase Agreements [Member] | Maximum [Member] | Fiscal Year 2021 [Member]
Shares issued price per share							$ 0.09
Securities Purchase Agreement [Member]
Warrants shares awarded							72,226	488,011
Warrant term							7 years	3 years
Warrant exercise price per share							$ 1.50	$ 0.75

XML

Stockholders' Equity (Deficit) - Schedule of Warrants Activity (Details) - Warrants [Member] - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Shares, Outstanding, Beginning balance	722,265	1,210,276
Shares, Granted
Shares, Expired	(722,265)	(488,011)
Shares, Exercised
Shares, Cancelled
Shares, Outstanding and exercisable, Ending balance		722,265
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 1.19	$ 1.2
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Expired		0.75
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Outstanding and exercisable, Ending balance		$ 1.19
Average Remaining Contractual Term, Outstanding, Beginning	9 months 29 days	1 year 3 months 11 days
Average Remaining Contractual Term, Outstanding and exercisable, Ending		9 months 29 days
Aggregate Intrinsic Value, Outstanding Beginning
Aggregate Intrinsic Value, Outstanding and exercisable, Ending

XML

Stockholders' Equity (Deficit) - Schedule of Stock Options Activity (Details) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Equity [Abstract]
Shares, Outstanding, Beginning Balance	133,334	133,334
Shares, Granted
Shares, Expired
Shares, Exercised
Shares, Outstanding and Exercisable, Ending balance	133,334	133,334
Weighted Average Exercise Price, Outstanding, Beginning Balance	$ 7.50	$ 7.50
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Outstanding, Ending Balance	$ 7.50	$ 7.50
Weighted Average Remaining Contractual Term Outstanding, Beginning	1 year 10 months 6 days	2 years 10 months 6 days
Weighted Average Remaining Contractual Term Outstanding and Exercisable, Ending	10 months 6 days	1 year 10 months 6 days
Aggregate Intrinsic Value Outstanding, Beginning
Aggregate Intrinsic Value Outstanding and Exercisable, Ending

XML

Provision for Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Increase in valuation allowance	$ 657,752
Decrease in valuation allowance		$ 657,980
United States [Member]
Net operating loss carryforward	$ 21,700,000
Net operating loss carryforward, expiration year	2038

XML

Provision for Income Taxes - Schedule of Effective Income Tax Rate (Details)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Federal income taxes at statutory rate	21.00%	21.00%
State income taxes at statutory rate	0.00%	0.00%
Temporary differences	11.83%	2.42%
Permanent differences	0.03%	(0.87%)
Impact of Tax Reform Act	0.00%	0.00%
Change in valuation allowance	(32.86%)	(22.55%)
Totals	0.00%	0.00%

XML

Provision for Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Net operating losses before non-deductible items	$ 4,586,526	$ 4,269,938
Loss on disposal of fixed assets		613
Stock-based compensation	543,375	329,214
Unrealized gains (losses) on investments	164,666	(50,290)
Total deferred tax assets	5,294,567	4,599,765
Less: Valuation allowance	(5,294,567)	(4,599,765)
Net deferred tax assets

XML

Investments (Details Narrative) - USD ($)										1 Months Ended		12 Months Ended			13 Months Ended
	Jun. 25, 2021	May 18, 2021	Feb. 26, 2021	Feb. 18, 2021	Feb. 05, 2021	Dec. 08, 2020	Apr. 03, 2020	Oct. 31, 2018	Aug. 10, 2018	Mar. 31, 2021	Feb. 28, 2021	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019	Aug. 01, 2019	Mar. 02, 2021	Dec. 29, 2020	Dec. 11, 2019	Dec. 04, 2019
Common stock shares issued, value												$ 1,587,212	$ 143,420
Membership Unit Purchase Agreement [Member] | Paz Gum LLC [Member]
Investment amount					$ 50,000
Membership units owned percentage					5.00%
Subsequent Event [Member] | Warrant [Member]
Warrant term		5 years
Cost price of warrants		$ 1.50
Number of excerices warrant shares		180,000
Value of warrant exercise		$ 270,000
Restricted Warrant [Member]
Warrants strike price										$ 0.65		$ 0.65
Common Stock [Member]
Common stock shares issued, value												$ 401	54
Warrants [Member] | Subsequent Event [Member]
Warrants strike price		$ 1.50
Warrant term		5 years
Number of excerices warrant shares		180,000
Value of warrant exercise		$ 270,000
Sale of shares of stock	485,000
AYTU Bioscience [Member] | Common Stock [Member]
Warrants purchase of common shares										5,555		5,555
Warrants strike price										$ 10.80		$ 10.80
Warrants expired date										Mar. 06, 2023		Mar. 06, 2023
Reverse stock split						1 for 10 shares			1 for 20 reverse stock-split.
AYTU Bioscience [Member] | Warrant [Member]
Warrants strike price										$ 102.49		$ 102.49
VistaGen Therapeutics, Inc. (VTGN) [Member]
Common stock shares issued, value														$ 61,998
Sale of shares of stock										125,000	125,000				389,380
Price per share															$ 1.33
VistaGen Therapeutics, Inc. (VTGN) [Member] | Restricted Warrant [Member]
Warrants purchase of common shares																		250,000
Warrants strike price																		$ 0.50
Warrant term																		3 years
Cost price of warrants																		$ 0.15
Warrants purchase of common shares, value																		$ 37,500
VistaGen Therapeutics, Inc. (VTGN) [Member] | Common Stock [Member]
Warrants purchase of common shares										320,000		320,000
Warrants strike price										$ 1.50		$ 1.50
Warrants expired date										Dec. 13, 2022		Dec. 13, 2022
Warrants description												The Company still holds 320,000 total warrants at a strike price of $1.50 per share.
Investment share sold				220,000
Investment shares owned				710,000
Price per share				$ 2.96
VistaGen Therapeutics, Inc. (VTGN) [Member] | Warrant [Member]
Warrants strike price										$ 0.50		$ 0.50
VistaGen Therapeutics, Inc. (VTGN) [Member] | Common Stock One [Member]
Warrants purchase of common shares										230,000		230,000
Warrants strike price										$ 0.44		$ 0.44
Warrants expired date										Feb. 28, 2022		Feb. 28, 2022
VistaGen Therapeutics, Inc. (VTGN) [Member] | Warrants [Member]
Warrants strike price																	$ 0.50		$ 0.50
Warrants purchase of common shares, value																	$ 230,000
SciSparc Ltd [Member]
Cost investments																$ 88,375
Cost investments, shares																12,500
SciSparc Ltd [Member] | Private Placement [Member]
Warrants purchase of common shares																1,152,628
Warrants strike price																$ 7.07
Warrants purchase of common shares, value																$ 8,150,000
SciSparc Ltd [Member] | Private Placement [Member] | Series A Warrants [Member]
Warrants strike price																$ 7.07
SciSparc Ltd [Member] | Private Placement [Member] | Series B Warrants [Member]
Warrants strike price																$ 10.60
SciSparc Ltd [Member] | Private Placement [Member] | Pre-Funded Warrant [Member]
Warrants purchase of common shares																278,744
Warrants strike price																$ 0.001
Aegea Biotechnologies Inc [Member]
Investment amount			$ 139,104
Ownership interest percentage			2.04%
Acquired additional shares			69,552
Acquired additional information , description			On February 26, 2021, as part of a settlement agreement concluding the Collaboration Agreement, the Company acquired an additional 69,552 common shares of Aegea, increasing the Company’s total holdings to 139,104 Aegea shares (representing a 2.04% stake in Aegea as of March 31, 2021).
Aegea Biotechnologies Inc [Member] | Collaboration Agreement [Member]
Investment amount										$ 278,212		$ 278,212
Common stock shares issued, value			$ 69,552									69,553
Invested percentage							70.00%
Sale of shares of stock							10,000,000
Price per share							$ 4.00
Sale of units							10,000,000
Pre- money valuation amount							$ 25,000,000
Impairment loss												$ 139,106
Ownership interest percentage			2.04%							1.03%		1.03%
Kudzoo, Inc [Member]
Pre- money valuation amount													10,200,000
Kudzoo, Inc [Member] | Ownership [Member]
Investment amount													$ 105,600
Ownership interest percentage										1.41%		1.41%	0.20%
Serendipity Brands LLC [Member]
Pre- money valuation amount								$ 14,000,000
Serendipity Brands LLC [Member] | Ownership [Member]
Investment amount								$ 35,000
Ownership interest percentage								0.24%

XML

Investments - Schedule of Investment in Trading Securities (Details) - USD ($)		12 Months Ended
		Mar. 31, 2021		Mar. 31, 2020		Mar. 31, 2019	Mar. 31, 2018
Investment of cost at beginning				$ 317,500
Investment of purchases
Investment of sales proceeds				40,000
Investment of cost at end				287,500
Investment of fair value				101,200
Investment of realized gain (loss)
Investment of unrealized gain (loss)	[1]			(186,300)
VistaGen Therapeutics, Inc. (VTGN) [Member]
Investment of cost at beginning		$ 287,500	[2]	287,500	[2]		$ 490,117
Investment of purchases	[2]	277,500
Investment of sales proceeds	[2]	302,827
Investment of cost at end		408,750	[2]	287,500	[2]	$ 287,500
Investment of fair value		1,246,050	[2]	101,200	[2]		$ 306,207
Investment of realized gain (loss)	[2]	146,577
Investment of unrealized gain (loss)	[2]	$ 837,300	[1]	(186,300)
Basanite Inc. (BASA) [Member]
Investment of cost at beginning	[3]			30,000
Investment of purchases	[3]
Investment of sales proceeds	[3]			40,000
Investment of cost at end	[3]
Investment of fair value	[3]
Investment of realized gain (loss)	[3]			10,000
Investment of unrealized gain (loss)	[3]

[1] This amount represents the cumulative unrealized loss as of March 31, 2021 and March 31, 2020.

[2] On December 11, 2017 the Company invested $480,000 in the common stock of VistaGen Therapeutics, Inc. (VTGN). The Company purchased 320,000 common shares along with 320,000 five-year warrants with a strike price of $1.50. On March 26, 2018, the Company purchased an additional 10,000 common shares. The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company's investment in VTGN has a cost of $490,117, unrealized loss of $183,910 and a fair value of $306,207 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 59,380 shares of VTGN for $61,998 (average price per share of $1.04 per share) in the open market. During the period of June 22, 2018 through August 1, 2018, the Company sold 389,380 shares of VTGN for $517,485 ($1.33 per share) for a realized loss of $34,630. The Company also purchased in a direct offering 230,000 restricted common shares directly from VTGN during the year ended March 31, 2019 for a cost of $287,500. On December 11, 2019, the Company purchased 250,000 three-year restricted warrant at a cost of $0.15 each (total value of $37,500). As of March 31, 2021, the Company has recognized an unrealized gain on these shares in the amount of $59,110, compared to an unrealized loss of $74,301 for the nine months ended December 31, 2019 in VTGN. As December 31, 2019, these shares were on deposit held with a broker. On December 29, 2020, the Company exercised 480,000 of its $0.50 warrants in VTGN. The new cost basis for these warrant shares is the $0.50 paid to covert each warrant in to shares (230,000 shares) as well as an addition $0.15 per share on the purchased options (250,000) shares. During February and March 2021, the Company sold 125,000 shares of VTGN for proceeds of $302,827. The Company recognized a gain on the sale of these shares of $146,577.

[3] On July 5, 2018, the Company purchased 100,000 shares of Basanite Industries Inc. (BASA) (formerly Paymeon, Inc. (PAYM)) for $12,998 ($0.13 per share) in the open market. During July 2018 the Company sold the 100,000 shares for $10,821 ($0.11 per share) for a realized loss of $2,177. On July 9, 2018, the Company purchased 400,000 restricted common shares directly from the Company for $30,000 ($0.075 per share). During the year ended March 31, 2020, the Company sold its 400,000 shares for $40,000 ($0.10 per share) recognizing a profit of $10,000.

XML

Investments - Schedule of Investment in Trading Securities (Details) (Parenthetical) - USD ($)					1 Months Ended				9 Months Ended	12 Months Ended						13 Months Ended
	Jul. 09, 2018	Jul. 05, 2018	Mar. 26, 2018	Dec. 11, 2017	Mar. 31, 2021		Feb. 28, 2021	Jul. 31, 2018	Dec. 31, 2019	Mar. 31, 2021		Mar. 31, 2020		Mar. 31, 2019	Mar. 31, 2018	Aug. 01, 2019	Dec. 29, 2020	Dec. 11, 2019	Dec. 04, 2019
Investment cost												$ 317,500
Investment unrealized gain (loss)										$ 1,023,600		(219,200)
Fair value of investment												101,200
Common stock shares issued, value										1,587,212		143,420
Investment realized gain (loss)										$ 146,577		10,000
Investment of cost net												287,500
Restricted Warrant [Member]
Warrants strike price					$ 0.65					$ 0.65
VistaGen Therapeutics, Inc. (VTGN) [Member]
Investment cost					$ 287,500	[1]				$ 287,500	[1]	287,500	[1]		$ 490,117
Number of common stock shares issued														59,380
Investment unrealized gain (loss)															183,910
Fair value of investment					$ 1,246,050	[1]				1,246,050	[1]	101,200	[1]		$ 306,207
Common stock shares issued, value														$ 61,998
Share issued price per share														$ 1.04
Number of common stock sold shares					125,000		125,000									389,380
Proceeds from investment					$ 302,827		$ 302,827									$ 517,485
Sale of stock price per share																$ 1.33
Investment realized gain (loss)																$ 34,630
Number of restricted stock, shares														230,000
Investment of cost net					408,750	[1]				408,750	[1]	$ 287,500	[1]	$ 287,500
Unrealized gain										$ 59,110
Unrealized loss									$ 74,301
Gain on sale of investments					$ 146,577
VistaGen Therapeutics, Inc. (VTGN) [Member] | Warrants [Member]
Warrants purchase of common shares																	480,000
Warrants strike price																	$ 0.50		$ 0.50
Warrants purchase of common shares, value																	$ 230,000
VistaGen Therapeutics, Inc. (VTGN) [Member] | Warrants [Member]
Warrants strike price																	$ 0.15
Warrants purchase of common shares, value																	$ 250,000
VistaGen Therapeutics, Inc. (VTGN) [Member] | Restricted Warrant [Member]
Warrants purchase of common shares																		250,000
Warrant term																		3 years
Warrants strike price																		$ 0.50
Cost price of warrants																		$ 0.15
Warrants purchase of common shares, value																		$ 37,500
VistaGen Therapeutics, Inc. (VTGN) [Member] | Common Stock [Member]
Investment cost				$ 480,000
Number of common stock shares issued				320,000
Warrants purchase of common shares				320,000
Warrant term				5 years
Warrants strike price				$ 1.50
Additional number of common stock purchased			10,000
Basanite Industries Inc. (BASA) [Member]
Number of common stock shares issued		100,000
Common stock shares issued, value		$ 12,998
Share issued price per share		$ 0.13
Number of common stock sold shares								100,000
Proceeds from investment								$ 10,821
Sale of stock price per share								$ 0.11
Investment realized gain (loss)								$ 2,177
Basanite Industries Inc. (BASA) [Member] | Restricted Common Stock [Member]
Number of common stock shares issued	400,000
Common stock shares issued, value	$ 30,000
Share issued price per share	$ 0.075
Number of common stock sold shares												400,000
Sale of stock price per share												$ 0.10
Investment realized gain (loss)												$ 10,000
Sale of stock value												$ 40,000

[1] On December 11, 2017 the Company invested $480,000 in the common stock of VistaGen Therapeutics, Inc. (VTGN). The Company purchased 320,000 common shares along with 320,000 five-year warrants with a strike price of $1.50. On March 26, 2018, the Company purchased an additional 10,000 common shares. The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company's investment in VTGN has a cost of $490,117, unrealized loss of $183,910 and a fair value of $306,207 at March 31, 2018. During the year ended March 31, 2019, the Company purchased 59,380 shares of VTGN for $61,998 (average price per share of $1.04 per share) in the open market. During the period of June 22, 2018 through August 1, 2018, the Company sold 389,380 shares of VTGN for $517,485 ($1.33 per share) for a realized loss of $34,630. The Company also purchased in a direct offering 230,000 restricted common shares directly from VTGN during the year ended March 31, 2019 for a cost of $287,500. On December 11, 2019, the Company purchased 250,000 three-year restricted warrant at a cost of $0.15 each (total value of $37,500). As of March 31, 2021, the Company has recognized an unrealized gain on these shares in the amount of $59,110, compared to an unrealized loss of $74,301 for the nine months ended December 31, 2019 in VTGN. As December 31, 2019, these shares were on deposit held with a broker. On December 29, 2020, the Company exercised 480,000 of its $0.50 warrants in VTGN. The new cost basis for these warrant shares is the $0.50 paid to covert each warrant in to shares (230,000 shares) as well as an addition $0.15 per share on the purchased options (250,000) shares. During February and March 2021, the Company sold 125,000 shares of VTGN for proceeds of $302,827. The Company recognized a gain on the sale of these shares of $146,577.

XML

Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Investment-trading securities	$ 1,246,050	$ 101,200
Kudzoo [Member]
Cost method investments		106,600
Serendipity Brands [Member]
Cost method investments	35,000	35,000
Aegea Biotechnologies Inc [Member]
Cost method investments	139,106
Level 1 [Member]
Investment-trading securities	1,246,050	101,200
Level 1 [Member] | Kudzoo [Member]
Cost method investments
Level 1 [Member] | Serendipity Brands [Member]
Cost method investments
Level 1 [Member] | Aegea Biotechnologies Inc [Member]
Cost method investments
Level 2 [Member]
Investment-trading securities
Level 2 [Member] | Kudzoo [Member]
Cost method investments
Level 2 [Member] | Serendipity Brands [Member]
Cost method investments
Level 2 [Member] | Aegea Biotechnologies Inc [Member]
Cost method investments
Level 3 [Member]
Investment-trading securities
Level 3 [Member] | Kudzoo [Member]
Cost method investments		105,600
Level 3 [Member] | Serendipity Brands [Member]
Cost method investments	35,000	$ 35,000
Level 3 [Member] | Aegea Biotechnologies Inc [Member]
Cost method investments	$ 139,106

XML

Concentrations (Details Narrative)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Sales Revenue [Member] | Supplier Concentration Risk [Member] | Supplier [Member]
Concentration of risk percentage	71.00%	100.00%

XML

Subsequent Events (Details Narrative) - USD ($)										3 Months Ended	12 Months Ended
	Jun. 25, 2021	Jun. 14, 2021	May 18, 2021	Apr. 30, 2021	Apr. 05, 2021	Dec. 21, 2020	Jun. 26, 2020	May 08, 2020	Mar. 23, 2020	Jun. 24, 2021	Mar. 31, 2021	Mar. 31, 2020	Apr. 14, 2021	Jun. 24, 2020	Jun. 10, 2020
Proceeds from issuance of common stock											$ 1,665,211	$ 244,420
Number of shares authorized											400,000,000	400,000,000
Share par value											$ 0.00001	$ 0.00001
Common stock shares issued, value											$ 1,587,212	$ 143,420
Number of restricted stock, value											$ 35,000
Tangier's Global, LLC [Member]
Number of common stock shares issued											13,910,000
Proceeds from issuance of common stock											$ 400,514
Shares issued price per share											$ 0.01848
Tangier's Global, LLC [Member] | Convertible Promissory Note [Member]
Shares issued price per share						$ 0.03	$ 0.03				$ 0.01599
Principal amount						$ 210,000		$ 102,500	$ 43,050					$ 210,000
Original issue of discount						$ 10,000	$ 10,000	$ 2,500	$ 2,050					$ 10,000	$ 1,250
Debt instrument, maturity date						Jun. 22, 2021	Dec. 24, 2020	Nov. 08, 2020	Sep. 23, 2020
Conversion price per shares								$ 0.03
Securities Purchase Agreement [Member]
Warrant term											7 years	3 years
Cost price of warrants											$ 1.50	$ 0.75
Subsequent Event [Member] | NFTauriga Corp [Member]
Number of shares authorized													100
Share par value													$ 0.00001
Subsequent Event [Member] | Tangier's Global, LLC [Member] | Convertible Promissory Note [Member]
Principal amount					$ 525,000
Original issue of discount					$ 25,000
Debt instrument, maturity date					Oct. 05, 2021
Debt instrument, interest rate during period					8.00%
Conversion price per shares					$ 0.075
Debt instrument, interest rate effective rate					(i) if within the first 90 days of the issuance date, then for an amount equal to 110% of the unpaid principal amount so paid of this Note along with any interest that has accrued during that period, and (ii) if after the 91st day, but by the 180th day of the issuance date, then for an amount equal to 120%. After 180 days from the effective date, the Company may not pay this note in cash, in whole or in part without prior written consent by Holder. The Company covenants that it will at all times reserve out of its authorized and unissued Common Stock the number of shares of Common Stock as shall be issuable upon the conversion of this note. Tangiers may not engage in any "shorting" or "hedging" transaction(s) in the Common Stock of the Company prior to conversion. The note contains a number of additional covenants and other provisions, including default or penalty clauses, cross-default, restrictions on note proceeds, maintain exchange and SEC requirements, delivery of shares, reservation of share requirements and other such provisions, each as set forth in more detail in the note and SPA. If an Event of Default occurs, the outstanding Principal Amount of this Note owing in respect thereof through the date of acceleration, shall become, at the Tangiers's election, immediately due and payable in cash at the "Mandatory Default Amount". The Mandatory Default Amount means 20% of the outstanding Principal Amount of this Note will be automatically added to the Principal Sum of the Note and tack back to the Effective Date for purposes of Rule 144. Commencing 5 days after the occurrence of any Event of Default that results in the eventual acceleration of this Note, this Note shall accrue additional interest, at a rate equal to the lesser of 18% per annum or the maximum rate permitted under applicable law.
Subsequent Event [Member] | Warrants [Member]
Number of excerices warrant shares			180,000
Warrant term			5 years
Value of warrant exercise			$ 270,000
Cost price of warrants			$ 1.50
Number of common stock sold shares	485,000
Proceeds from investment	$ 1,153,645
Subsequent Event [Member] | Restricted Common Stock [Member]
Number of restricted stock, shares										1,800,000
Subsequent Event [Member] | Restricted Common Stock [Member] | Investor [Member]
Number of common stock shares issued										2,300,000
Proceeds from issuance of common stock										$ 174,000
Shares issued price per share										$ 0.0757
Subsequent Event [Member] | Restricted Common Stock [Member] | Investor [Member] | Private Placement [Member]
Number of common stock shares issued										2,500,000
Shares issued price per share										$ 0.04
Proceeds from issuance of private placement										$ 100,000
Subsequent Event [Member] | Restricted Stock [Member] | Tangier's Global, LLC [Member] | Convertible Promissory Note [Member]
Number of restricted stock, shares					1,000,000
Shares issued price per share					$ 0.0129
Number of restricted stock, value					$ 129,000
Subsequent Event [Member] | Consulting Agreement [Member]
Number of common stock shares issued										5,737,500
Subsequent Event [Member] | Strategic Marketing and Consulting Agreement [Member] | Restricted Common Stock [Member] | Mayer & Associates [Member]
Number of common stock shares issued		3,500,000
Common stock shares issued, value		$ 150,000
Agreement description		Under this agreement the Company will pay $150,000 along with the issuance of 3,500,000 shares of restricted common shares of Company stock. Half of the cash payment ($75,000) was paid upon execution of the agreement and the other half will be paid 90 days later. Upon execution, the Company shall issue 2,200,000 of the above-mentioned shares. The remaining 1,300,000 above-mentioned shares will be issued 90 days after this contract was executed. Mayer and Associate will provide the Company with opportunities relating to the world of professional sports, with respect to its products and product lines. This includes but is not limited to: introductions to professional sports leagues, celebrity (professional athletes) influencers/brand ambassadors/brand liaison(s), research and development opportunities, hosting of small periodic events for the Company and a diversified group of high-profile contacts and relationships, use social media exposure, podcasts backing of various elements from professional sports as well as assist the Company in advising of potential merger partners and developing corporate partnering relationships. If explicitly authorized by the Company's board, exactly180 days after execution of this Agreement, a final $75,000 payment is permitted to be rendered under this agreement.
Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Partners Capital, LLC [Member] | Non Convertible Redeemable Note [Member]
Principal amount				$ 313,000
Original issue of discount				$ 23,000
Debt instrument, maturity date				Jun. 01, 2022
Debt instrument, interest rate during period				8.00%
Debt instrument, interest rate effective rate				Interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law.